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SYNTHETIC LETHALITY OF CDK INHIBTION AND DOXORUBICIN IN TRIPLENEGATIVE BREAST CANCER REQUIRES P53 INACTIVATION
Natalie A. Jabbour-Leung, B.A.
Advisory Professor: Khandan Keyomarsi, Ph.D.
Triple-negative breast cancer (TNBC) is an aggressive malignancy in which the
tumors lack expression of estrogen receptor, progesterone receptor and HER2. As such,
TNBC patients cannot benefit from clinically available targeted therapies and must rely on
chemotherapy and surgery for treatment. While initially responding well to chemotherapy,
TNBC patients are at increased risk of developing distant metastasis and have decreased
overall survival compared to non-TNBC patients. A majority of TNBC tumors carry p53
mutations, enabling them to bypass the G1 checkpoint and complete the cell cycle even in
the presence of DNA damage. Therefore, we hypothesized that TNBC cells are sensitive
to cell cycle targeted combination therapy, which leaves non-transformed cells
unharmed. Our findings demonstrate that sequential administration of the pan-CDK
inhibitor roscovitine prior to doxorubicin treatment is synthetic lethal explicitly in TNBC cells.
Furthermore, this novel combination therapy is well tolerated and efficacious, significantly
reducing tumor volume and increasing overall survival compared to single drug treatment
arms in a pre-clinical model system. Mechanistic studies found that combination treatment
arrested TNBC cells in the G2/M cell cycle phase, where cells rely on homologous
recombination for repair of DNA double strand breaks. Notably, combination treatment
increased DNA double strand breaks, while simultaneously reducing recruitment of
homologous recombination proteins. Examination of isogenic immortalized human
mammary epithelial cells and isogenic tumor cell lines found that abolishment of the p53
pathway is required for combination-induced cytotoxicity; making mutated p53 a putative
predictor of response to therapy. Consequently, p53 wildtype non-transformed cells are
able to avoid cell death by arresting in G1. By exploiting the specific biological and
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molecular characteristics of TNBC tumors, this innovative therapy has the potential to
greatly impact the treatment and care of TNBC patients.
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CHAPTER 1: INTRODUCTION
1.1 EPIDIEMOLGOY AND RISK FACTORS OF BREAST CANCER
Although the rate of cancer mortality has decreased 20% over the past two decades,
it is expected that over half a million people will die from cancer in the United States in the
year 2015 [1]. Second only to lung cancer, breast cancer kills over 40,000 women each year
[1, 2]. While 1 in 8 women will develop breast cancer in their lifetime [2], there are many
reproductive, dietary and hereditary factors that can contribute to the risk of developing
breast cancer.
Non-hereditary factors
Several reproductive factors affect the development of breast cancer. Early onset of
menarche increases the risk of breast cancer [3, 4]. Moreover, beginning menstruation at or
after the age of 15 reduces the risk by 23% compared to women who began menstruating at
age 12. Since early menarche coincides with regular menstrual cycles, girls who begin
menstruating early are exposed to hormones that may have a causative effect on breast
cancer at an earlier age. Additionally, women with early menarche have increased estrogen
levels. Similarly, longer exposure to the premenopausal hormone estrogen, due to later
onset of menopause, leads to increased risk of breast cancer [3]. Furthermore, presence of
circulating oestrogens and androgens are correlated with increased breast cancer risk in
premenopausal women [5]. Bilateral oophorectomies are associated with lower risk of
breast cancer compared to natural menopause at the same age. This may be due to the
more dramatic decrease in estrogen hormone levels associated with an oophorectomy [3].
The age of a woman’s first full-term pregnancy can influence her risk for breast
cancer [3]. Pregnancy initially causes a transient increased risk of developing breast cancer
for up to 15 years [6-8]. However, in the long-term, childbearing has a protective effect
specifically against hormone receptor-positive breast cancer, but has no effect on hormone
receptor-negative breast cancer [9]. While it is currently unknown why pregnancy causes a
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temporary increase in risk, there are four main hypotheses as to why parity has long-term
protective effect: (1) differentiation of breast epithelial cells, causing them to become less
prone to transformation (2) changes in responsiveness of breast epithelial cells to estrogen
(3) changes in hormone profile, especially the pregnancy hormones estrogen, progesterone,
the lactogenic hormone PRL and placental lactogen (4) possible effects of pregnancy
hormones on stem cells [6]. Pregnancies that occur before the age 20 cause a 50%
reduction in the risk of developing breast cancer, with the first full-term pregnancy continuing
to have a protective effect until the age of 35 [6, 10]. However, women who begin having
children later in life (over 35) are subject to increased risk of developing breast cancer [11].
This may be because the increased risk that is associated with pregnancy persists for 30-50
years post-partum [12]. The age of subsequent pregnancies has little to no effect on risk
development [13]. Therefore, while age of first pregnancy affects risk of developing breast
cancer, further studies are needed to fully understand the link between parity and breast
cancer.
The same protective effect of parity is observed in rodents. Exposure to pregnancy
hormones estrogen and progesterone reduced incidence of carcinogen-induced mammary
tumors, and had a protective effect in the p53-null mammary transplant model and the
MMTV-Her2 transgenic mouse model [14]. Additionally, studies showed that the basal and
progenitor cells of parous mice upregulated differentiation genes while reducing the
Wnt/Notch signaling ratio compared to virgin mice. This alteration in signaling led to
decreased proliferation potential [15].
In addition to age of pregnancy, other factors associated with childbearing can affect
the risk of developing breast cancer. Increased parity of seven or more children decreases
the risk of developing breast cancer [16]. Also, a multi-center case control study performed
by the Cancer and Steroid Hormone group, compared 4599 women between the ages of 2055 with confirmed breast cancer to 4536 control women and found that women who
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breastfed for over 25 months had a 33% less risk of developing breast cancer compared to
women who never breastfed [16]. While it was previously hypothesized that offspring birth
size could affect breast cancer mortality, a population-based cohort study found no
correlation between child birth size and premenopausal breast cancer mortality or tumor
features [17].
Weight and obesity can impact the risk of developing breast cancer. Body mass
index (BMI) is often used to define obesity (BMI >30) [18]. Although high BMI is usually
associated with increased disease risk, there is an inverse relationship between weight and
risk of developing breast cancer in premenopausal women [18]. However, a four year
prospective study that included a cohort of 121,964 female registered nurses ages 30-55
demonstrated that while lean women are subjected to increased risk of breast cancer, their
tumors tend to be non-metastatic, low-grade tumors [19]. In contrast, overweight or obese
postmenopausal women have increased risk of developing breast cancer, with a relative risk
of 1.26 [18]. Relative risk is defined as the proportion of an adverse outcome in the
intervention group divided by the proportion of adverse outcome in the control group; a
relative risk over 1 means that the treatment group is at a higher risk of the poor outcome
[20]. Several hypotheses have been proposed as to why obesity increases the risk of breast
cancer in postmenopausal women. Adipose tissue is the primary site of estrogen synthesis,
where aromatase catalyzes androgens to estrogen. Aromatase levels have a direct
relationship with BMI, with a higher BMI increasing exposure to estrogen and estrogen
receptor (ER) activation [21, 22]. Moreover, metabolic disease, in which higher amounts of
insulin are released into the blood stream due to unabsorbed glucose, can cause activation
of IGF-1, a mitogenic factor [21]. Obese women also have increased risk of dying from
breast cancer. A prospective study that included participants from the Cancer Prevention
Study II followed 495,477 women over a 16-year period demonstrated that grade II
overweight women (BMI 35-39.9) had a relative risk of 1.41 and obese women (BMI >40)
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had a relative risk of 2.12 of dying from breast cancer compared to lean (BMI 18.5-24.9)
women with a relative risk of 1 [21, 23]. Moreover, obese breast cancer patients exhibited
higher risk of developing lymph node metastasis, a poor prognostic maker, compared to
non-obese breast cancer patients [18]. These findings suggest that the level of obesity
directly correlates to risk of dying from breast cancer and aggressive disease. Unfortunately,
weight loss upon diagnosis does not appear to benefit the survival of obese women with
breast cancer [24].
Hereditary factors
Although most breast cancers are sporadic, 5-7% of breast cancers are due to germ
line mutations in either of the breast cancer susceptibility genes BRCA1 or BRCA2.
Inheriting just one mutated copy of either gene results in hereditary breast and ovarian
cancer (HBOC) syndrome [25]. Women who carry mutations in either gene have a lifetime
risk of 60 to 85 percent of developing breast cancer [26]. More specifically, BRCA1
mutation carriers were found to have 65% and 39% risk of developing breast and ovarian
cancer by age 70, respectively. BRCA2 mutation carriers had a 45% and 11% risk of
developing breast and ovarian cancer, respectively. It was found that while the risk for
BRCA1 mutation carriers decreased with age, the same trend was not observed in BRCA2
mutation carriers [27]. Also, women with HBOC are more likely to be diagnosed with
aggressive high grade, triple-negative tumors at an early age [25, 28]. The Ashkenazi
Jewish population have a high incidence of about 2% of three specific mutations: BRCA1
185delAG, BRCA1 5382insC, and BRCA2 6174delT [29].
Both proteins participate in the DNA double strand break (DSB) repair pathway
homologous recombination (HR) and maintain genomic stability, but have separate
functions [30]. During HR, BRCA1 acts upstream of BRCA2 by recruiting other HR proteins
to the site of DNA DSB damage and facilitating strand resection. In response to DNA
damage, the BRCA1-BARD1 complex can also induce transcription of p21, activating the
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G1/S checkpoint, and also has a lesser defined role during the G2/M checkpoint [25].
BRCA2 binds to the HR protein Rad51, mediating its recruitment to the site of the DNA DSB
[31]. Without either BRCA1 or BRCA2, cells are forced to undergo a more error-prone form
of DNA DSB called non-homologous end joining (NHEJ), potentially increasing genomic
instability [25].
Mutation carriers for the PALB2 gene, which also participates in DNA repair, also
have an increased risk of developing breast cancer. PALB2 interacts with both BRCA1 and
BRCA2. At 50 years of age, PALB2 mutation carriers have a 14% likelihood of developing
breast cancer, which increases to 35% by age 70 [32]. The association of mutations in
PALB2 and other DNA repair proteins and their role in cancer will be discussed in
proceeding sections.
1.2 CELL CYCLE
A detailed understanding of normal cell function is required before examining the
causes and deregulated pathways associated with cancer. In order to grow and divide, cells
must successfully progress through the cell cycle. During the cell cycle, cells must transition
through a highly regulated series of orchestrated events that is managed by cyclins, their
cyclin dependent kinase (CDK) counterparts and CDK inhibitors (CKIs), leading to the
generation of daughter cells (Figure 1, Table 1) [33]. There are two stages of the cell cycle:
(1) interphase, which occurs between cell divisions and where DNA is synthesized, and (2)
mitosis (M), where the cell divides [34]. If the cell is not undergoing DNA synthesis and
division, it can become quiescent and enter a G0 stage [35]. Interphase is composed of gap
1 (G1), DNA synthesis (S) and gap 2 (G2) (Figure 1). Within interphase there are three
checkpoints, including G1/S, intra-S and G2/M, which ensure that the DNA is accurately
replicated and separated [36]. There are 20 CDKs and four classes of cyclins, including D,
E, A and B that form complexes with the CDKs [33]. Cyclin expression oscillates through
the cell cycle depending on which CDK activity is needed (Table 1). The CKI INK4 family

5

includes p16 INK4A, p15 INK4B, p18 INK4C and p19 INK4D, which can selectively inhibit
CDK4 and CDK6 activity [37]]. The CKI Cip/Kip family includes p21Cip1/Waf1/Sdi1, p27Kip1 and
p57Kip2 and can selectively inhibit CDK2 and CDK1 activity [33].

Figure 1: Regulation of the cell cycle. The cell can enter quiescence (G0), or complete
G1, S, G2 and M to generate two identical daughter cells. Specific CDK/cyclin activity is
required per cell cycle phase. CKIs provide quality control checkpoints to ensure that cells
replicate and divide accurately.
ccurately. The transcription factor p53 activates p21 transcription upon
cellular stress. During transition through G1, CDK phosphorylation of Rb will release
transcription
anscription factor E2F to activate S phase genes. Phosphatases
tases CDC25A/B/C remove
inhibitory phosphate groups. Kinases Wee1 and Myt add inhibitory phosphate groups to
CDK1 upon DNA damage detection.
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Table 1. CDK-cyclin complex that regulate the cell cycle
CDK-cyclin
Peak
Substrates
complex
Activity
CDK4/CDK6-cyclin D

G1

Rb protein family
Rb protein family

CDK2-cyclin E

G1/S

p27
Histone 1
NPAT
Rb protein family
Unbound Cdc6
DNA polymerase α/δ
DNA polymerase d

CDK2-cyclin A

S

PCNA
MCM4, 6, 7
Histone 1
CDC45

CDK1-cyclin A

G2/M

Rb protein family
CDC25C

CDK1-cyclin B

CDK7-cyclin H

M

All

Histone1/Histone 3
Nuclear lamins
Kinesin-related
motors (ex. Eg5)
Microtubule-binding
proteins (eg.
stathmin)
Condensins
Golgi matrix
components
APC E3 ligase
CDK-cyclin
complexes

Adapted from: [33, 38-40]
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Function
Inhibit Rb and release E2F
transcription factors
Maintains Rb
phosphorylation, required for
G1-S transition
Signal for degradation
Chromosome condensation
Initiate histone gene
transcription
Maintains Rb inhibition
Inhibit re-replication
Initiate replication
Elongation
Links CDK2 to DNA
replication substrates
Inhibit helicase activity
Chromosome condensation
Initiate DNA replication, DNA
unwinding
Required for G2 to M
transition
Positive feedback loop
required for continued CDK1
activation
Chromosome condensation
Nuclear envelope breakdown
Centrosome separation
Spindle assembly

Chromosome condensation
Golgi fragmentation
Activate anaphase
CAK, activate CDKs

Mitogenic signaling can stimulate quiescent cells to exit GO and enter G1. Mitogenic
signaling, including growth factors that can activate the Ras/Raf/Mek pathway, is only
required to progress through the first two-thirds of G1 [41, 42]. A major regulator of G1, the
retinoblastoma (Rb) protein family consists of Rb, p107 and p130. Together they are known
as pocket proteins, due to their conserved binding pocket domain that binds E2F and other
oncoproteins [41]. Rb is a tumor suppressor and serves as the molecular determinant of
whether the cell will pass through the G1/S transition, known as the restriction point [41].
Once the cell has passed through the restriction point, mitogenic signaling is no longer
required as the cell is then committed to completing G1 and transitioning through S phase
[43]. Passage through the restriction point occurs 2-3 hours prior to S phase [44]. Rb is
maintained in a hypophosphorylated state to inhibit inaccurate progression through G1 [45].
The hypophosphorylated form of Rb binds to the transactivation domains of E2F
transcription factor family members, inhibiting their activity. Rb can also inhibit transcription
of S phase genes by binding to histone deacetylase (HDAC) [45]. Furthermore, the Rb/E2F
complex can act as a transcription repressor complex by binding to the promoters of E2F
regulated genes [46]. Upon mitogenic signaling, Ras will activate cyclin D transcription and
CDK4 and CDK6 are released from CKI INK4 proteins, allowing them to bind to D-type
cyclins (D1, D2 and D3). The CDK4/CDK6- cyclin D complex is shuttled to the nucleus
where they are phosphorylated by a CDK activating kinase (CAK). CAK is composed of the
CDK7/cyclin H complex (Table 1). Upon CAK activation, the cyclin D-CDK4/CDK6 complex
can phosphorylate Rb, forcing it to release the E2F family of transcription factors [37, 41,
47]. E2F target genes include cyclin E- and cyclin-A type cyclins [33]. Cyclin DCDK4/CDK6 complexes can also bind to Cip/Kip inhibitors, separating them from CDK2 [37].
As the cell progresses through G1, E-type and A-type cyclins are synthesized, with their
expression climaxing at the G1/S transition. Cyclin E and cyclin A will associate with CDK2,
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further phosphorylating Rb and initiating S phase. Rb has 16 CDK phosphorylation sites
[38], where complexes CDK2-cyclin A, CDK1-cyclin A and CDK1-cyclin B1 maintain Rb
phosphorylation at specific sites as the cell transitions through the cell cycle [37].
Due to the complexity of DNA synthesis and the vast amount of genetic information
that must be replicated, there are an array of errors that can occur during S-phase.
Moreover, the cell can be assaulted by genotoxic stress such as ionizing or UV radiation
outside of S-phase. Fortunately, the cell has developed three checkpoints, including the
G1/S, intra-S and G2/M, to ensure its DNA has been accurately duplicated prior to dividing
[36]. While these checkpoints act only at certain times, the proteins used to detect and
repair the DNA damage overlap. The detection and repair of DNA damage will be
discussed in proceeding sections.
The replication or the G1/S checkpoint prevents progression through S-phase when
there is a stalled replication fork due to lack of deoxyribonucleotides, inhibition of the DNA
polymerases or the replication fork encountering a damaged piece of DNA [48]. The
phosphotyrosine phosphatases CDC25A, CDC25B and CDC25C promote the G1/S
transition when they are in their active, unphosphorylated state (Figure 1) [36].
Unphosphorylated CDC25A is an activator of CDK2 and removes inhibitory phospho-groups
from CDK2 [49]. Upon detection of DNA damage, either ataxia telangiectasia (ATM) for
DNA DSBs or Rad3 related (ATR) for DNA single strand breaks (SSBs) activate Chk2 or
Chk1 via phosphorylation, respectively. ATM and ATR are phosphoinositide 3-kinase
related kinases (PIKKs). Once activated, Chk1 or Chk2 will inhibit CDK2 activation by
phosphorylating CDC25A, causing it to be exported from the nucleus and undergo ubiquitinmediated proteolytic degradation, inducing a G1 arrest [36]. Activated Chk1 and Chk2 will
also phosphorylate downstream proteins that can lead to cell apoptosis (p53), transcription
of DNA repair genes (BRCA1, E2F1) and chromatin remodeling (Tlk 1/2) [50].
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The tumor suppressor protein p53 can also initiate a G1 arrest. Upon detection of
DNA damage, ATM/Chk2 or ATR/Chk1 act together to phosphorylate and stabilize p53
through BRCA1 [36]. BRCA1 forms a complex with BRCA1-associated RING domain
protein 1 (BARD1), which must be phosphorylated by either ATM or ATR to aid in the
phosphorylation and activation of p53 [51]. p53 has several phosphorylation sites, including
serines 15 and 20. Phosphorylation of p53 disassociates it from its negative regulators
MDM2 and MDM4, stabilizing its expression [52]. Stabilized p53 activates transcription of
p21, which will inhibit CDK2 activity [36]. Activation of the G1 checkpoint should allow the
cell to repair any DNA damage prior to progressing into S-phase.
Once the cell transitions through the restriction point, the entire cell genome must be
truthfully replicated during S-phase. Preceding S phase, DNA replication begins with the
assembly of the pre-replicative complex (pre-RC) on the replication origins of genomic DNA.
The first six proteins that bind form a complex called the origin recognition complex (ORC).
While multiple replication sites are bound at the same time throughout the genome, not all
will initiate DNA replication, with some serving as back up origins. After ORC has been
assembled, Cdc6 and Cdt1 are recruited to the origination site, followed by the binding of
Mcm2-Mcm7, which serve as a helicase complex that unwinds the DNA [53].
As cells transition into S-phase, CDK2-cyclin A and Dbf4 dependent kinase activity
are required for the transition of the pre-RCs to replication forks [33, 53, 54]. At this point,
helicase activity unwinds the DNA, the DNA single strands are stabilized and DNA
polymerases are loaded onto the DNA. CDK2 phosphorylates Cdc45, allowing it to bind to
the Mcm2-7 complex, which is required for DNA unwinding and for binding of the DNA
polymerase [53, 54]. The resulting single strands of DNA are stabilized by replication protein
A (RPA) binding [55]. Three types of polymerases (pol), including DNA pol α, DNA pol δ
and DNA pol ε, participate in the elongation of the newly synthesized DNA. The proliferating
cell nuclear antigen (PCNA) protein serves as a clamp for DNA pol δ and ε, linking the
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polymerase to the DNA template [56]. Since DNA can only by synthesized 5’ to 3’, there is
a leading strand and a lagging strand. The leading strand is synthesized continuously, while
the lagging strand is synthesized in discontinued Okazaki fragments, with the gaps later
filled and ligated together. DNA pol α synthesizes RNA primers for the leading and lagging
strands, acting as template for the other polymerases. DNA pol α is the only polymerase that
that can begin DNA synthesis without primers. DNA pol δ is required for synthesis of both
strands [57].
Genotoxic stress can also occur during DNA replication, activating the intra-s-phase
checkpoint [48]. This checkpoint acts to temporarily inhibit the firing of DNA origins of
replication [49]. Two main pathways work to initiate the intra-S-phase checkpoint upon DNA
damage. Similar to the G1 checkpoint, one pathway relies on inhibition and degradation of
CDC25A. When activation of ATM/ATR pathway causes CDC25A degradation, CDK2
activity is inhibited, preventing the loading of CDC45 onto the chromatin. Since CDC45 is
required for the recruitment of DNA polymerase α, inhibition of CDC25A and CDK2 prevents
the firing of new origins [49]. The second pathway acts through ATM-Chk2 to phosphorylate
proteins NBS1 and SMC1 to both detect DNA damage and initiate arrest [36, 49].
Before cells can pass through mitosis and divide into two daughter cells, they must
pass the G2/M checkpoint. This checkpoint is activated in the event that remnants of DNA
damage that were not repaired in G1 or S are detected or DNA damage occurs during G2
[49]. CDK1, the major regulator of mitosis, is inhibited if the cell detects DNA damage
through either the ATM/Chk2 or ATR/Chk1 pathways. Wee1 and Myt1 add inhibitory
phospho-groups on CDK1 at tyrosine 15 and tyrosine 14, respectively, with CDC25 family
removing these phospho-groups to activate CDK1 [58, 59]. If DNA damage is detected,
phosphatase CDC25 is inhibited via the ATM/ATR pathways, inhibiting CDK1 activity [59].
The kinase p38 can also inhibit CDK1 activity by sequestering and inhibiting CDC25A.
Expression of p53 is required for the maintenance of the G2 checkpoint [49].
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The p53 transcriptional targets, p21, GADD45 and 14-3-3σ, act to inhibit CDK1
activity. CDK1 is inhibited by p21 directly, while 14-3-3σ sequesters CDC25 to the
cytoplasm, preventing it from activating CDK1. GADD45 separates cyclin B1 from CDK1,
also inhibiting CDK1 activity. On its own, p53 can suppress cyclinB1 and CDC2 (CDK1)
transcription [58].
During G2, in which the cells continue to grow and make proteins in preparation for
mitosis, the CDK1-cyclin B1 complex is exported from the nucleus to the cytoplasm.
However as cells begin to transition into mitosis, CDK1 or polo like kinase 1 (Plk1)
phosphorylate cyclin B1, preventing the complex from being exported. This allows the
CDK1-cyclin B1 complex to aggregate in the nucleus and induce mitosis [60]. In addition to
CDC25B and CDC25C phosphatase activity, CAK activates and phosphorylates CDK1 at
threonine 161 [58]. The five phases of mitosis are prophase, prometaphase, metaphase,
anaphase and telophase followed by cytokinesis [39]. The CDK1-cyclin A complex is active
during prophase and will facilitate chromatin DNA coiling tightly into two sister chromatids,
which requires several post-translational modifications to histones [39, 61]. Also, the
centrosomes, which will later pull the sister chromatids apart, migrate to opposite poles.
CDK1-cyclin B1 activity is required for the recruitment of motor proteins that will participate
in the separation of the two centrosomes. The centrosomes will then begin to organize and
nucleate microtubule and promote spindle formation. Also, the CDK1-cyclin B1 complex
will facilitate nuclear envelope break down by phosphorylating the nuclear lamin that would
otherwise stabilize the nuclear envelope. During prometaphase, the microtubules will attach
to the kinetochores located at the centromeres of the sister chromatids. During kinetochore
attachment, the cells will proceed to metaphase, where the chromosomes will align at the
metaphase plate [39]. The spindle assembly checkpoint prevents entry into anaphase and
activation of the anaphase-promoting complex (APC) until there is bipolar attachment of
mitotic spindle to each sister chromatid and tension is created between the sisters. As the
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cells approach anaphase, where the sister chromatids are separated and pulled towards
opposite poles of the cell, APC activity increases. The APC, a multisubunit E3 ubiquitinprotein ligase, is responsible for adding ubiquitin chains to its substrates, targeting them for
degradation. The APC has two activators, including Cdc20 and Cdh1, which have differing
substrates. APCCdc20 targets both securin, the inhibitor of separase, and cyclin B for
degradation [61]. After metaphase, CDK activity is no longer required, and the degradation
of cyclin B due to APC Cdc20 ubiquitination turns off CDK activity [60, 61]. Also during
anaphase, certain CDK1-cyclin A/cyclin B1 substrates must be dephosphorylated. The CDK
substrate separase, which is responsible for cleaving the cohesin complex that holds the
two sister chromatids together, is dephosphorylated and activated. Additionally, inner
centromere protein, the regulatory subunit of Aurora B, must be dephosphorylated to allow
Aurora B to migrate to the spindle midzone and encourage spindle stability. APCCdh1
ubiquinates Cdc20 and Plk1 in late anaphase and Aurora kinases A and B in late telophase
[61]. As the sister chromatids are pulled apart, the spindle poles separate further. When
the chromosomes have reached the poles, telophase is initiated, which includes nuclear
envelope reformation and chromosome decondensation [39].
Cytokinesis, or the division of the cytoplasm, is the final step in formation of the two
daughter cells. Ingression of the cleavage furrow, the site at the cell equator where the
parent cell will contract, begins in telophase. The spindle midzone, or the area of
overlapping centrosomal microtubules, will indicate where the cleavage furrow will form.
The small GTPase Rho localizes at and contributes to the cleavage furrow by managing
actin, myosin II and other actin binding proteins. Kinases Aurora B and Plk1 are required
for RhoA recruitment and activity at the cleavage furrow [62]. The microtubules will relay
spatial signals to the cytoskeleton at the cell membrane, or the cell cortex [63]. As
cytokinesis progresses, the gathering of actin and myosin II at the cell equator pulls together
like “purse strings” at the cleavage furrow to form a contractile ring [62]. Once the cleavage
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furrow has completely ingressed, an intracellular bridge with a microtubule midbody forms
between the two daughter cells [63]. The proteins KIF14 and Citron kinase promote
abscission of the two daughter cells followed by membrane fusion [62].
1.3 DEREGULATION OF THE CELL CYCLE IN CANCER
One of the hallmarks of cancer is evasion of anti-proliferation signals. As previously
described, normal cells have the ability to arrest or undergo apoptosis if there is damaged
DNA. However, tumor cells develop the ability to evade cell cycle checkpoints and continue
to replicate through several mechanisms, including increased expression of cyclin/CDK
complexes and mutated CKIs (Table 2) [64]. The avoidance of any of the three checkpoints
(G1/S, inrtra-S or G2/M) can lead to chromosomal and genomic instability, contributing to
tumor progression. Additionally, tumor cells can undergo unscheduled proliferation, in which
they will enter the cell cycle without receiving mitogenic signals [65]. This section will
discuss the mechanisms that allow tumor cells to proliferate continuously.
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Table 2. Failure in cell cycle regulation and cancer
Gene/
Mutation/
Cancer Association
Protein
Defect
HNSCC, NSCLC, endometrial, melanoma, breast and
CCND1
Amplification
pancreatic cancer
HNSCC, NSCLC, endometrial, melanoma, breast,
Overexpression
pancreatic and colorectal cancer
Cyclin D1
Increased nuclear
Lymphoma and prostate cancer
localization
CCNE1
Amplification
NSCLC, lymphoma, breast and ovarian cancer
Protein truncation/
Breast and ovarian cancer
Cyclin E
cytoplasmic
localization
Increased nuclear
Breast and oseophageal cancer
localization
Cyclin B1
Breast, colon, prostate, oral, lung and oseophageal
Overexpression
cancer
Polymorphism
Familial melanoma
CDK4
R24C
Sporadic melanoma, glioblastoma, osteosarcoma,
CDK4
Amplification
breast and cervical cancer
Cdc2
Amplification
Colon cancer
CDK2
Amplification
Colon cancer
Deletion, point
NSCLC, glioma, T-cell ALL, mesothiloma, bilary tract,
p16INKA
mutation,
pancreatic and bladder cancer
hypermethylation
p14ARF
Deletions
Breast, brain and lung cancer
Point and missense
Li-Fraumeni syndrome, colon, breast, lung, brain,
mutations
pancreas and stomach cancer
p53
Viral HPV E6 protein Cervical cancer
Leukemia, lymphoma, sarcoma, glioma and breast
Mdm2
Amplification
cancer
Mutation, loss of
Retinoblastoma, NSCLC
function
Rb
Viral HPV E7
Squamous cell carcinoma and cervical cancer
oncoprotein
Missense, nonsense (Ataxia-telangiectasia) Thymic lymphoma, leukemia &
ATM
and truncations
breast cancer
Truncation or
Stomach, breast, endometrial
ATR
missense mutations
CHK1
Frameshift mutation
Colorectal, gastric, endometrial & small cell lung cancer
Truncation or
Li-Fraumeni syndrome, breast, bladder, colon, ovary,
CHK2
missense mutation
prostate and lung cancer
AURKA
Amplification
Breast, colorectal and bladder cancer
Adapted from: [37, 65-69]
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CDK-cyclin complexes are often deregulated in cancer. In melanoma, CDK4 often
has an R24C mutation that inhibits binding of CKIs, while a variety of cancers have CDK4
and CDK6 gene amplification. Increased CDK4/CDK6 activity can cause
hyperphosphorylation of Rb, allowing tumor cells to bypass the G1 checkpoint [37, 65].
Cancers such as leukemia, lymphoma, gastric, colorectal, lung, kidney and breast can have
overexpression of cyclin D1 via gene amplification, rearrangement or translocation [37]. This
will also increase activity of CDK4/CDK6. Mouse mammary tumorgenesis induced by
oncogenes Ras and Neu requires cyclin D1 expression, and up to 70% of breast cancers
show overexpression of cyclin D1 [66, 70]. While E-type and A-type cyclins are often
overexpressed and increase activity of CDK2, the CDK2 gene is not typically mutated in
cancer [37, 65]. Additionally, about 6% of cancers have lost function of the F-box and WD
repeat domain 7 (FBXW7) protein, which when present ubiquitinates cyclin E and signals for
proteasome degradation. However, lack of FBXW7 causes stabilization of cyclin E
expression in the nucleus. Aberrant enrichment of nuclear cyclin E can cause chromosomal
instability and deregulate the loading of DNA licensing proteins onto the ORCs [71, 72].
CDK1 can have augmented activity in cancers including, breast, colon, lung and prostate,
due to overexpression of cyclin B1.
CDK-cyclin complexes can also be mislocalized. Mislocalization of CDK-cyclin
complexes at inappropriate times in the cell cycle can cause early or continuous
phosphorylation of substrates. Under normal conditions, cyclin D1 is exported to the
cytoplasm at the start of S-phase due to glycogen synthase kinase 3β (GSK3β)
phosphorylation, which reveals a nuclear export signal. However, a proportion of prostate
and lymphoma tumor cells show increased cyclin D1 nuclear localization. Increased cyclin
D-1 nuclear localization has been attributed to GSK3β inhibition by increased KRAS or PI3K
activity, mutations in the cyclin D1 GSK3β phosphorylation site and mutations in the cyclin-

16

D1 ubiquitination domain. Consequences of cyclin D1 mislocalization include increased
CDK4 activity, chromosome instability and aneuploidy due to DNA re-replication [71]. Cyclin
E can be post-translationally cleaved by the serine protease neutrophil elastase to generate
oncogenic forms of cyclin E called low molecular weight cyclin E (LMW-E) [73]. Due to a
lack of nuclear localization signal, LMW-E is primarily observed in the cytoplasm and has not
been detected in normal tissue [74-76]. LMW-E has increased binding affinity to CDK2, is
resistant to CDK inhibition by CKIs, causes aneuploidy and accelerates entrance and exit
from mitosis, leading to failed cytokinesis and multinucleated cells [77-79]. LMW-E also
correlates with poor prognosis in breast and ovarian cancer [80, 81]. Additionally, cyclin B1
can have aberrant localization. During G2/M, cyclin B1 translocates to the nucleus just prior
to nuclear envelope breakdown to bind to CDK1. However, cyclin B1 is detected in the
nuclei in a high proportion of tumor cells, suggesting early entry into the nucleus. Aberrant
localization of cyclin B1 in the nucleus is a poor prognostic marker for breast and
oesophageal cancer [71].
Tumor cells can bypass checkpoints by silencing or downregulating CKIs and other
endogenous cell cycle inhibitors. The p16 gene is often subjected to deletion or epigenetic
silencing via hypermethylation of its promoter in many cancers, including pancreatic,
melanoma, lung, breast and colorectal [35, 67, 82]. Rb can also be mutated or deleted.
Inhibition of the Rb pathways generally only requires one “hit,” with manipulations of cyclin
D/CDK4, p16 loss or Rb loss being mutually exclusive. To induce cell cycle arrest or cell
death, cells with a deregulated Rb pathway may compensate with increased activity of p53.
Upstream of p53, ATR can have truncation or missense mutations in stomach, breast and
endometrial cancers, inhibiting activation of the DNA damage checkpoint. Additionally, DNA
damage checkpoint proteins Chk1 and Chk2 can be deleted or mutated, leading to
increased genomic instability and oncogenesis [37].
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Over 50% of cancers carry p53 gene mutations, a major regulator of cell cycle arrest
and apoptosis [67]. Most p53 mutations are missense mutations. Some mutations will
cause loss of wild-type function or can generate dominant-negative mutants that inhibit wildtype p53 protein [83]. The transactivation capacity of p53 is often lost in cancers such as
colon, breast, lung, brain, pancreas and stomach due to alterations in its DNA binding
domain [83, 84]. Tumor cells can also inhibit p53 by increasing expression of proteins that
inhibit its activity, such as MDM2. Under normal conditions, MDM2 binds to p53 to inhibit its
transactivation domain, exporting it from the nucleus for degradation and serves as a p53
ubiquitin ligase [85]. Concordantly, the mdm2 gene is often amplified in sarcomas and
gliomas [86, 87]. Also, deletions in the p14ARF gene, a negative regulator of MDM2, can be
found in breast, brain and lung cancers [84]. Viral oncoproteins such as hepatitis B virus X
protein and human papilloma virus E6 proteins can bind and inhibit p53 function [88, 89].
Not all p53 mutations are inactivating, with some mutations causing gain of function (GOF)
oncogenic activity. GOF Mutant p53 typically has a longer half-life than wildtype p53 and
can have changes at the transactivation domain that, while still retaining its DNA binding
ability, may cause it to recognize different sequences [90, 91]. Mutant p53 has been shown
to affect expression of genes such as c-myc, cyclin D3, epidermal growth factor receptor
(EGFR) and others [91]. GOF Mutant p53 can bind to some of the same transcription factors
as the wildtype, including E2F1, but alter or increase their activity to promote oncogenicity
[90, 92]. Similar to wildtype p53, GOF mutant p53 can also interact with the transcription
factor NF-Y. However upon DNA damage, the mutant p53/NF-Y complex activates
transcription of genes such as cyclin A, cyclin B2, CDK1 and cdc25C. This is the opposite
response of the wildtype p53/NF-Y complex after DNA damage [93]. These examples
demonstrate how loss of function and gain of function p53 mutations have a large impact on
tumor cells and cell-cycle regulation.
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1.4 DNA DAMAGE REPAIR PATWAYS
To protect the genome, the cell has developed several mechanisms to detect,
remove and repair DNA damage (Table 3). The cell can incur DNA damage from
endogenous sources such as stalled replication forks during DNA replication or exogenous
sources such as UV radiation, ionizing radiation or DNA damage agents (i.e.
chemotherapeutics). In response to DNA damage, a normal cell will arrest and attempt to
repair the damage. If repair is impossible, the cell will undergo cell death [49, 50]. The DNA
damage and repair pathway includes damage detectors, signal transducers and
downstream effectors [94].
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DSB

SSB

Table 3. DNA Damage and Repair
Damaging
Agent

ROS, adducts, IR and
alkylating agents

Altered base

ROS, UV radiation,
chemical carcinogens

Intra-strand
crosslink (bulky
adducts)

Replication Error

Base mismatch,
insertions,
deletions

Replication error, IR,
chemical agents

DSB

Replication error,
ROS, chemical
agents, alkylating
agents

DSB

Lipid peroxidation,
chemotherapeutics:
derivatives of nitrogen
mustards & platinumbased
Adapted from: [36, 95-97]
ICL

Lesion

ICL
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Repair
Pathway

Crucial
Proteins
DNA glycosylase, APE1
endonuclease, PARP,
DNA polymerase β,
BER
DNA polymerase ε,
Ligase3, XRCC1,
PCNA, FEN1
XPC, XPA, RPA, TFIIH
centrin1, XPG, PCNA,
NER
EXRCC1-XPF, DNA
polymerase δ/ ε, RPA,
RFC, CSA, CSB, ligase
MSH2, MSH3, MSH6,
MLH1-PMS2, EXO1,
MMR
RPA, PCNA, DNA
polymerase δ, RFC,
ligase
Ku70, Ku86, DNA-PKcs,
Artemis nuclease, DNA
NHEJ
polymerase-µ, DNA
ligase IV, XRCC4
Mre11 nuclease, CtIP,
Exo1, BLM, DNA2,
CDK1, BRCA1, BRCA2
HR
RPA, RAD51, RAD52,
RAD54, PALB2, DNA
polymerase
(NER and HR proteins)
NER, HR, or
FANCM, FA core
Fanconi
complex, FAPP24,
Anemia
FANCD2, FANCI, BTR
Pathway
complex

1.4A SINGLE STRAND BREAKS
Before the cell can repair DNA damage, it must be able detect it and arrest cell cycle
progression. The stalling of DNA polymerases during S phase, reactive oxidative species
(ROS) and UV radiation can all generate SSBs [36, 48]. During SSB recognition, the single
strand DNA will become coated by RPA, recruiting ATR and its regulatory subunit ATRinteracting protein (ATRIP). RPA will also recruit Rad17, which will load the ring structure
complex 9-1-1, consisting of Rad9, Hus 1 and Rad1. ATR will phosphorylate Rad17 and
911. ATR will also phosphorylate topoisomerase II binding protein 1 (TopBP1), which is
required for ATR activation and Chk1 checkpoint activation [36, 48, 98].
The type of DNA damage determines the mechanism of repair. The three types of
repair for SSBs are base excision repair (BER), nucleotide excision repair (NER) and
mismatch repair (MMR). Cells rely on BER in response to an aberrant base, ROS,
chemicals that bind to DNA (adducts), ionizing radiation, and failure in topoisomerase I
activity or alkylating agents. A glycosylase enzyme usually recognizes the damaged base
and, combined with the endonuclease APE1, facilitates base removal [36, 95]. The type of
glycosylase used is dependent upon the substrate that needs to be excised. For example,
the uracil DNA glcosylase is required to excise aberrant inclusion of uracil into the DNA,
whereas DNA glycosylase SMUG1 excises uracil and oxidized pyrimidines [99]. This causes
a gap in the strand that is “cleaned” by poly (ADP-ribose) polymerase (PARP) and
polynucleotide kinase to hasten repair [99]. PARP transfers ADP-ribose to form polymer
chains. A single nucleotide gap is filled using short-patch repair, while wider gaps require
long-patch repair. DNA synthesis that occurs during repair is called repair synthesis. Shortpatch repair relies on DNA pol β to add the required nucleotide, followed by ligation by the
Ligase3/XRCC1 complex [36]. XRCC1 also serves as a scaffold to recruit other SSB repair
proteins. Long-patch repair requires DNA pol β, DNA poly ε and PCNA for repair synthesis.
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PCNA helps recruit the endonuclease FEN-1, which is required to remove the 5’ blocking
group that is displaced as a flap. Finally, ligase 1 seals the DNA backbone [99].
NER serves to repair bulkier DNA damage caused by UV radiation (thymidine
dimers), ROS and chemical carcinogens that interrupt the double helix structure [36, 95].
During NER, an oligonucleotide fragment of 25-30 nucleotides is excised [100]. NER acts
through two pathways: global-genome NER and transcription-coupled NER (TCNER) [95].
During global genome NER, several proteins, including XPC, XPA and RPA, must first
recognize the damaged DNA. XPC is in a complex with HHRAD23A (or HHRAD23B) and
centrin2. HHRAD23A may not be required for NER, but aids in NER efficiency, while
centrin2 stabilizes binding between HHRAD23A and XPC. Following XPC binding, XPA and
RPA bind to the damaged area. Due to the extent of damage, some of the double helix
unwinds, facilitating RPA binding to a single strand. Following damage recognition, the sixsubunit complex called core transcription factor IIH (TFIIH), which is part of the RNA
polymerase II transcription systems, binds to the damaged site. TFIIH is comprised of two
DNA helicases (XPB and XPD), which unwind the DNA. The unwinding of the DNA creates
a bubble. The proteins p62, p44, p34 and p52 also make up TFIIH and promote bubble
formation. Bubble development creates junctions between the unraveled single strand and
the remaining helix, which are crucial for accurate excision of the damaged bases. The 3’
end of the damaged DNA is cut by XPG, and the 5’ end is cut by the EXRCC1-XPF
heterodimer. Similar to BER, repair synthesis requires PCNA along with DNA polymerase δ
or ε, RPA and replication factor C (RFC), followed by ligase activity to seal the DNA with
covalent bonds [100]. The mechanism of TCNER, or NER that occurs during transcription,
is not as defined as global-genome NER. Since XPC knockout mice can still perform
TCNER, is it is suggested that damaged bases are recognized due to stalled RNA
polymerase II activity. The proteins CSA and CSB are required for TCNER, however, their
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exact function is unknown. The events of TCNER following damage recognition require
TFIIH and are thought to be very similar to global NER [100].
MMR, an intricate process, occurs in response to mismatched bases and insertion or
deletion loops formed by DNA replication errors [95]. Mismatched bases are due to DNA
polymerase errors that are not detected during proofreading, while insertion/deletion loops
(IDL) are due to heteroduplex DNA formation. Heteroduplexes form when two homologous
strands from different sources, such as a primer and a template, anneal incorrectly [96].
MMR was first studied in E. coli, where the MutS homodimer was discovered as the error
detector. In mammalian cells, the MutS homologs (MSH) MSH2, MSH3 and MSH6 have
been found to participate in MMR. The heterodimer MSH2-MSH6 (MutSα) binds and repairs
base mismatches and IDLs that are 1-2 nucleotides long, while heterodimer MSH2-MSH3
(MutSβ) repairs base mismatches and IDLs greater than two bases. MutSα and MutSβ
interact with the DNA as sliding clamps and can work together [96, 101]. Following binding,
MutSα or MutSβ recruits the heterodimer MLH1-PMS2 (MutLα), forming a ternary structure.
ATP-hydrolysis causes a conformational change in the MutSα- MutLα complex, allowing it to
slide either upsteam or downstream from the damage site. If they slide upstream, they will
meet with and displace RFC to allow binding of exonuclease 1 (EXO1) at the 5’ end. EXO1
is activated by MutSα and will excise and degrade the damaged strand from 5’ to 3’, leaving
a single strand gap that is stabilized by RPA. Following mismatch removal, MutLα inhibits
EXO1. PCNA allows binding of DNA polymerase δ, which synthesizes the new strand,
followed by DNA ligase I mediated ligation [96]. In the event that a MutSα- MutLα complex
slide downstream towards the 3’ terminus, it will meet a PCNA molecule bound at the 3’ end
of the strand break. EXO1 is also recruited here, degrading the damaged strand. RFC at
the 5’ end blocks degradation away from the mismatch site in the 5’ to 3’ direction. Similar
to the 5’ terminus, EXO1 inactivation is followed by RPA binding, DNA pol δ repair synthesis
and DNA ligase I sealing with covalent bonds [96].
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1.4B DOUBLE STRAND BREAKS
DNA damage due to collapsed replication forks, ionizing radiation, ROS, alkylating
agents and chemotherapeutics can generate DNA DSBs. The two methods to repair DNA
DSBs are non-homolgous end joining (NHEJ) and homologous recombination (HR). NHEJ
is considered an imperfect, error-prone method of repair since it seals the gaps created by
DSB, with a few nucleotides at each end are lost [102]. HR, on the other hand, provides
error-free repair because it uses a sister chromatid as a template to fill the gap [103]. Since
HR requires a sister chromatid, it is only performed during late S, G2 and M, when a sister
chromatid is available [104]. NHEJ can occur during any phase of the cell-cycle [95].
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Figure 2. Schematic of DNA DSB repair through NHEJ or HR. In response to
DNA double strand breaks, the MRN complex will identify the break and recruit ATM. ATM
will phosphorylate CHK2 and H2AX, activating the cell
cell-cycle
cycle checkpoint and inducing
recruitment of DNA repair foci, respectively. NHEJ can occur at any point
oint of the cell cycle.
However, HR is limited to late S, G2 and M because it requires CDK
CDK-mediated
mediated end
resection.
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In order for repair to occur, the cell-cycle checkpoint must be activated [105]. The
Rad50/ meiotic recombination 11 (Mre11)/ Nijmegen Breakage Syndrome 1 (NBS1) or MRN
complex detects and processes DNA DSBs to create single strand DNA (Figure 2) [36, 98,
105]. MRN also serves as a sensor for ATM, with the C-terminal domain of Nbs-1 and the
HEAT repeats of ATM mediating the interaction between MRN and ATM [94]. Once
recruited to the DNA damage site, ATM will separate from its inactive, dimer form and
autophosphorylate itself at S1981, S367 and S1893 [98, 106, 107]. ATM has many
substrates, including p53, NBS1, BRCA1 and CHK2 [49, 50]. ATM phosphorylation of Chk2
will activate the cell-cycle checkpoint (Figure 2) [105].
Following MRN formation at the DSB and checkpoint activation by ATM, downstream
effectors will be activated to initiate repair. ATM will phosphorylate the C-terminus of histone
H2AX at S139 (γ-H2AX), which serves as a major signal of DNA DBS damage and as a
recruiter of downstream DNA repair proteins. H2AX can also be phosphorylated by ATR
and the DNA-dependent protein kinase catalytic subunit (DNA-PKcs). Following
phosphorylation, the BRCA-1 C-terminus (BRCT) region of the mediator damage checkpoint
protein (MDC1) will bind to γ-H2AX by directly binding to the phosphoepitope of H2AX at the
C-terminus, enhancing the γ-H2AX signal, and possibly continuing the interaction with ATM
[98, 108]. MDC1 also binds to NBS1 of the MRN complex, and is required for the interaction
between MRN and γ-H2AX. Moreover, MDC1 and γ-H2AX binding is required for the
recruitment of 53BP1, BRCA1, CHK2 and p53, which can also initiate cell arrest or
apoptosis [98, 109].
The first repair protein to bind the damage site during NHEJ is the doughnut-shaped
heterodimer Ku, composed of Ku70 and Ku86 [110]. Ku will then recruit and activate the
PIKK DNA-PKcs, forming the trimeric DNA-PK holoenzyme [95, 102, 104]. During NHEJ, it
is imperative that the two damaged ends are kept near each other, in a process called
synapsis, to be repaired. It is unclear how exactly this occurs, but it is believed that Ku and
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DNA-PKcs play a role [104]. A study using an intermolecular ligation assay reported that Ku
could stimulate DNA ligation by bridging the DNA ends while still making them DNA ligaseaccessible [111]. Many times the ends of the DNA will be ligated where they, by chance,
share 1-4 complementary nucleotides, referred to as microhomology. However,
microhomology is not required for end-joining. When microhomology occurs, extra
nucleotides beyond the area of microhomology must be trimmed [104]. Ku will also recruit
the nuclease Artemis, which is phosphorylated by DNA-PK [110]. Artemis combined with
DNA-PKcs, acts as an endonuclease at the 5’ and 3’ ends [104]. It is the deletion of these
nucleotides that can cause a loss of genetic information and an increase in genomic
instability [103]. Although polymerase activity is not required in many instances of NHEJ, it
has been suggested that the polymerase-µ may fill in some gaps during repair. Following
excision of the damaged ends, DNA-PK recruits the DNA Ligase IV/XRCC4 complex to
ligate together the blunt ends, completing the process (Figure 2) [104].
As previously stated, HR can only occur during late S, G2 and M phases [104]. To
repair DSBs through HR, end resection is performed to form single-stranded DNA. Mre11
nuclease activity combined with CtBP-interacting protein (CtIP) promotes DSB end
resection, followed by activity from EXO1, Bloom’s syndrome protein (BLM) and DNA2. CDK
activity is required for strand resection, as CtIP is phosphorylated by CDK1, limiting HR
strand resection to S and G2 (when CDK1 is active) [112, 113]. Ubiquination of CtIP by
BRCA1 may also play a role in activating it [114]. MRE11 nuclease activity will stimulate
RPA recruitment to coat the 3’ ends of the remaining single-stranded DNA. RPA can
promote checkpoint induction by binding to ATRIP and activating ATR [103, 115]. RPA
must then be replaced with the recombinase Rad51 with the aid of mediators, including
BRCA2. While both BRCA1 and BRCA2 have been shown to colocalize with Rad51,
BRCA2-Rad51 binding is required for accurate loading of RAD51 at the damage site and
completion of homologous recombination [116]. BRCA2 has a DNA binding domain that
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can bind both ssDNA and double stranded DNA (dsDNA) and 8 BRC repeats that bind to
Rad51 and manage Rad51 filament formation [117]. Rad52 also aids in Rad51 filament
formation [105]. Following phosphorylation by Chk2, BRCA1 interacts with Rad51 through
BRCA2 and PALB2 [118, 119]. After Rad51 binding, Rad51 and Rad54 enable the resected
end of the damaged strand to invade the homologous template, displacing the identical
strand and forming a displacement loop (D-loop). Rad51 is disassociated from the single
strand by the helicase Srs2 to allow for base complementation [102, 103]. Following D-loop
formation, the single strand is extended via DNA synthesis, with the homologous strand
serving as the template, causing a D-loop intermediate to form [103]. The intermediate form
can be resolved either through synthesis-dependent strand annealing (SDSA) or double
strand break repair (DSBR). During SDSA, the invading strand is displaced and re-anneals
to the single strand that it was originally bound to in a non-crossover event, allowing no
exchange of genetic information. DSBR can be resolved either via crossover or a noncrossover event. During DSBR, the invading strand can be captured at both the ends by the
damaged strand, forming Holliday junctions (HJs). Here the HJs can be resolved by either a
crossover or a non-crossover event (Figure 2) [120].
1.4C INTERSTRAND CROSSLINKS
Another form of DNA damage that can be lethal for a cell is interstrand crosslinks
(ICLs), which are irreversible covalent bonds between bases on opposite strands. ICLs are
very damaging because they inhibit the separation of the two DNA strands, which is
required for transcription and DNA replication. Chemotherapeutics that are derivatives of
nitrogen mustards, such as cycolophosphamide and melphalan, and platinum-based drugs,
such as cisplatin, are known to cause ICLs [97]. As a result, there is a risk of patients
treated with platinum-based drugs of developing a secondary cancer, especially leukemias
[121]. High-fat diets and alcoholism can cause lipid peroxidation that can lead to the
formation of ICLs [122, 123]. ICLs left unrepaired can lead to tumorgenesis, and people that
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carry germline mutations in the ICL repair pathway are prone to a rare syndrome called
Fanconi anemia (FA) [97]. While FA will be discussed in greater detail in proceeding
sections, FA cells have provided a source to elucidate ICL repair.
The mechanism of ICL repair is cell cycle dependent. If damage occurs during G1,
NER can resect some ICLs. If the ICL damage cannot be repaired via NER, it is carried on
into S phase. During S phase the replication fork will stall when it encounters the ICL
because the DNA will be unable to unwind [97]. The replication fork collapse can be
stabilized through HR, followed by unhooking of the ICL by nucleases MUS81 and EME1,
translesion synthesis and then completion through HR [97]. Alternatively, ICL is identified by
FANCM [124]. FANCM has an ERCC4 nuclease domain that binds to branched DNA and a
domain that interacts with the FA core complex. The FA core complex is composed of 7 FA
proteins, including FANCA, FANCB, FANCC, FANCE, FANCF, FANCG and FANCL.
Forming a heterodimer with FAAP24, which also has an ERCC4 domain, stabilizes FANCM.
FANCM-FAAP24 recruitment of the FA core complex to the site of damage is restricted to
cell cycle phases where replication is occurring [97, 124, 125]. The FA core complex
includes the ubiquitin ligase FANCL, which monoubiquinates FANCD2 and FANCI [126,
127]. It is believed that monoubiquination of FANCD2 and FANCI stabilizes their binding to
the ICL site. Following localization of FANCD2 and FANCI to the ICL site, repair and
checkpoint proteins such as RPA (activating ATR), BRCA1, BRCA2 and the Bloom’s
syndrome complex (BTR) proteins are recruited to the ICL site. BTR is comprised of
topoisomerase IIIα, RMI1, RMI2 and BLM, which are required for the resolution of Holliday
junctions. ICLs are then resolved through HR mediated by BRCA1 and BRCA2. Unresolved
ICLs can lead to cell death, allowing chemotherapeutics that induce ICL to be effective
against tumors [97].
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1.5 DEREGULATION OF DNA DAMAGE RESPONSE AND CANCER
To become malignant, cancer cells must acquire gene mutations to gain survival and
proliferative advantage while avoiding growth arrest or apoptotic signals [64]. Therefore,
germline or somatic mutations in DNA damage response (DDR) genes are known to
contribute to the development of cancer and impact the effectiveness of cancer treatment
(Table 4). Furthermore, epigenetic silencing of DDR genes occurs frequently in cancer.
Cells can compensate for the failure of one DNA repair pathway by upregulating another,
which can lead to chemotherapy and radiotherapy resistance [128]. The following section
will detail which DDR genes are mutated in cancer and how this can affect cancer therapy.
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Table 4. Failure in DDR and Cancer
Repair
Mutation/
Protein
Pathway
Defect

BER

APE1

XRCC1
PARP1

High expression

Polymorphism
R339Q
Polymorphism
V762A
XPA, XPC, XPE,
XPF & XPG

NER

XP
Proteins

XPC gene
methylation
SNPs in XPA &
XPC
SNPs in XPG (&
XRCC1)
SNPs

ERCC1

DSB repair

MMR

Gene methylation

Correlated to lung and bladder cancer
Associated with response of NSCLC to
platinum-based chemotherapy
Predictor of response to therapy in
lung cancer
Found in glioma, associated with
cisplatin sensitivity

Ref.

[129,
130]

[131]
[132]

[100]

[133]
[134,
135]
[136]
[137,
138]
[139]

MSH2,
MLH1 &
MSH6

Gene promoter
methylation

HNPCC (aka Lynch syndrome): early
onset (<45) of endometrial, gastric,
renal, ovarian and skin cancer.

[140]

NBS1

5 base pair
truncation

Nijmegen breakage syndrome
(autosomal recessive): early onset of
cancer, especially lymphoma (median
age 11)

[141]

Associated with ovarian cancer

[142]

Found in > 90% of colorectal cancers

[143]

Correlated to breast cancer

[144]

Point mutations
MRE11

Ku70
NHEJ

Contribution to
Cancer
Correlated with drug/radiotherapy
resistance in NSCLC & cervical
cancer. Poor prognosis in
osteosarcoma, medulloblastoma,
breast and head and neck cancer
Decreased efficacy in BER,
predisposed to cancer
Decreased activity, predisposed to
cancer
Xeroderma pigmentosum: UV
sensitivity and skin cancer, especially
squamous cell and basal cell
carcinoma
Correlated to worse outcome in
bladder cancer

Ku80
XRCC4&
Ligase
IV

Shortening of
poly(T)11 repeat,
aberrant splicing
Polymorphism
A46922G
Epigenetic
silencing
Gene promoter
methylation
SNPs

Correlated with colorectal, breast &
lung cancer
Found in > 30% of squamous cell
carcinoma
Associated with increased risk of
glioma
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[128]
[145]
[146]

HR

BRCA1
&
BRCA2

Rad50

ICL

PALB2

FANC
proteins

Increased risk of breast (> 70%) and
ovarian cancer (>40%) by age 70
Found in spontaneous breast, ovarian
& lung cancer
Increased risk of breast, ovarian,
Germline mutation
colorectal, esophageal, pancreatic,
of BRCA2
stomach and hematopoietic cancer
Frameshift
Found in >30% gastrointestinal
mutation, protein
cancers
truncation
Monoallelic
truncations,
Increased risk of breast cancer 2 – 4
germline
fold, correlated to pancreatic cancer
mutations
FANCA, FANCC,
FANCG, FANCF, High risk of AML (>50% by age 40),
FANCE, FANCB, HNSCC, oesophageal & gynecological
FANCD2, &
cancer
FANCI
Associated with neck squamous cell
Gene methylation
carcinomas, NSCLC, cervical &
of FANCF
ovarian cancer
Increased risk of early onset of
Biallelic mutation
childhood tumors, including Wilm’s
FANCD1
tumor & medulloblastoma (mortality by
(BRCA2)
5 yrs. of age)
Fanconi anaemia N: early onset of
FANCN (PALB2)
Wilm’s tumor & medulloblastoma

Germline mutation
of BRCA1
BRCA1 promoter
methylation
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[147]
[148]
[149]

[150]

[32]

[151]

[152154]
[155,
156]
[157]

Several members of the BER pathway are mutated in cancer. The R339Q mutation
in XRCC1 can decrease BER efficiency and can increase the risk of developing cancer
[131]. Furthermore, a variety of tumors have overexpression of the endonuclease APE1,
which can protect against radiotherapy and chemotherapeutics, making it a viable target
[129, 130].
Mutations in the XP proteins, including XPA, XPC, XPE, XPF and XPG, of the NER
pathway predispose people to the autosomal hereditary disease Xeroderma pigmentosum
(XP) [158]. Mutations in XP proteins cause defects in the NER pathway that leads to
sensitivity to UV radiation, leading to cell transformation, with the median age of onset for
skin cancer at 8 years old [100, 159]. Patients with XP most commonly have basal cell or
squamous cell carcinoma, but can also have melanoma, keratoacanthomas, angiomas and
sarcomas [100]. XP patients also have a higher incidence of non-skin cancer malignancies,
including brain tumors, leukemias and lung cancer [160, 161]. Accordingly, epigenetic
silencing via methylation and single nucleotide polymorphisms (SNPs) of XPC increases risk
of bladder cancer [162]. Also, SNPs in ERCC1 are associated with skin cancer and poor
prognosis in non-small cell lung cancer (NSCLC), further demonstrating the importance of a
functional NER pathway [161, 162].
Defects in the MMR pathway, due to promoter methylation of MLH1 or mutations in
MSH2 or MSH6, cause the development of autosomal dominant hereditary nonpolyposis
colorectal cancer (HNPCC), or Lynch syndrome. Lynch syndrome increases the risk of
developing colorectal, stomach, ovarian and endometrial cancer [140]. Moreover, defects in
the MMR pathway can cause resistance to the chemotherapeutic cisplatin, but are more
sensitive to other cross-linking agents [163-165].
The failure to detect DSBs due to a mutations or truncations in NBS1 causes
Nijmegen breakage syndrome. Nijmegen breakage syndrome is characterized by
immunodeficiency, ovarian dysgenesis and infertility, chromosome instability, sensitivity to
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radiation and high risk of developing cancer, especially lymphomas, at a very young age
[141]. Point mutations in Mre11, another member of the MRN complex, are associated with
hereditary breast and ovarian cancer [142]. Inactivated and mutated MRE11 is associated
with MMR-deficient cancers [143].
There are several mutated NHEJ proteins that contribute to cancer development.
SNPs in Ku70 and Ku80 are correlated with the development of breast cancer, while
epigenetic silencing of Ku80 correlates with lung cancer and squamous cell carcinoma [128,
145, 166]. SNPs in ligase IV and XRCC4 are associated with increased risk of developing
glioma [146]. Due to the importance of NHEJ to repair DSBs, DNA-PKc inhibitors are being
developed to radiosensitize cancer cells, particularly in B-cell chronic lymphocytic leukemia
[128].
Similar to NHEJ, members are of the HR pathway are often deregulated in tumors,
allowing them to maintain a higher level of genomic instability that is characteristic of cancer.
Germline mutations in the BRCA1 and BRCA2 genes are most frequently associated with
developing HBOC, but are also known to increase the risk of developing prostate,
pancreatic, melanoma and gastrointestinal tumors [147, 167, 168]. Moreover, even
sporadic breast and ovarian tumors have been shown to have BRCA1 silencing via
promoter methylation [148]. PARP inhibitors are being used to target BRCA-deficient
tumors. This is based on the premise that PARP inhibition prevents repair of SSBs,
generating DSBs and forcing cancer cells to rely on HR to resolve DNA breaks; BRCAmutated cells are HR-deficient causing them to undergo cell death [169, 170]. Moreover,
inhibiting HR can sensitize tumors to targeted therapy. For example, CDK inhibition can
reduce BRCA1 recruitment, sensitizing BRCA1 wildtype tumors to PARP inhibition [171].
Most recently, germline truncations, alternative splicing and deletion mutations in PALB2
were shown to increase the lifetime risk of developing breast cancer, especially in
premenopausal women [32]. Gastrointestinal cancers with microsatellite instability can carry
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frameshift mutations in Rad50 and BLM [150]. HR-defective cancers have been shown to
be sensitive to DSB-inducing agents [172]. Defective HR is paradoxical in that it allows
cancer cells to accumulate the gene mutations necessary for continued proliferation, while
providing drugable targets and sensitizing cancer cells to DNA damaging agents.
Failure in ICL repair due to gene mutations in the FA pathway is characteristic of
Fanconi anemia, a rare genetic disease that causes decreased fertility, congenital
abnormalities, bone marrow failure and increased risk of hematological and squamous cell
cancer [173]. FA is diagnosed via cytogenetic analysis in which lymphocytes are subjected
to ICL-inducing agents, such as platinum-based chemotherapeutics. FA-positive cells are
hypersensitive to ICL-inducing agents, showing increased chromosomal breaks [174]. A
majority of FA patients suffer from FANCA (65%), FANCC (15%) or FANCG (10%)
mutations. However, mutations have been found in a variety of FA pathway genes, including
FANCD2, FANCI and other HR genes [128]. Again, the high prevalence of cancer in
carriers of FA gene mutations emphasizes the importance of effective DNA repair pathways.
1.6 MOLECULAR SUBTYPES OF BREAST CANCER
Having detailed some of the major causes and deregulated pathways associated
with cancer, this section will describe the molecular characteristics of breast cancer and how
they impact treatment strategies. Breast cancer is a heterogeneous disease due to
differential gene expression, which affects treatment response and prognosis. Microarray
analysis was used to delineate five molecular breast cancer subtypes, including luminal A,
luminal B, human epidermal growth factor receptor 2 (HER2) positive, basal-like and normallike breast cancer (Table 5) [175, 176]. Additionally, a claudin-low subtype and seven
distinct subtypes within basal-like breast cancer have been identified [177, 178]. The
subtype of breast cancer determines how the tumor responds to targeted therapy or DNA
damage inducing treatments, including chemotherapy and radiotherapy. Molecular
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subtypes also present differently in the clinic [179]. This section will detail the characteristics
of all the molecular subtypes and new promising therapies entering the clinic.

Table 5. Molecular sub-types of breast cancer
Expression
Prevalence
Profile
(%)
Normal-like
Luminal A
Luminal B
HER2 positive
Basal-like

Claudin-low

Lo PARP1 and
Chk1, hi ALDH
ER+, PR+, HER2-,
lo ki67
ER+(low), PR+
(low), HER2+, hi
ki67
ER-, PR-, HER2+
ER-,PR-, HER2-,
CK 5/6, 14,17,
EGFR
Lo claudin 3,4,7,
occuldin, lo Ecadherin, hi
+
-/low
CD44 /CD24

Treatment
options

Prognosis

Undetermined

3-10

Good

24-39

Good

10-18

Poor

12-25

Poor

15

Poor

Chemotherapy,
surgery

Poor

Chemotherapy
(dependent upon
hormone/HER2
status)

12-14

Endocrine
therapy
Endocrine
therapy plus
chemotherapy
Trastuzumab,
lapatinib (plus
chemotherapy)

Adapted from: [175, 176, 178, 180-182], Lo = low, Hi = high, CK = cytokeratins
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1.6A NORMAL BREAST-LIKE CANCER
Up to 10% of breast cancers are diagnosed as normal breast-like tumors, which are
composed mostly of normal cells, including stromal cells, and show high expression of
genes found in adipose tissue [180, 183]. These tumors also have decreased expression of
proliferation genes compared to Luminal B, HER-2 and basal-like subtypes, while being
enriched for mesenchymal and extracellular matrix genes [184, 185]. Normal breast-like
tumors have low expression of PARP1 and Chk1, but have high expression of the stem cell
marker ALDH1. ALDH1 expression is also common in stromal cells [185]. Patients with
normal-breast like tumors show lower overall survival and recur sooner than patients with
the Luminal A subtype [180].
1.6B LUMINAL A
Luminal A breast cancer is more prevalent in post-menopausal women [181]. Both
luminal breast cancer sub-types are ER-positive. Immunohistochemistry (IHC) staining is
used to detect ER expression; as little as 1% of cells staining positive for ER qualifies the
tumor as ER positive [186]. The ligand estradiol binds to ER, activating ER to go to the
nucleus where it regulates gene expression [187, 188]. The luminal A subgroup is
characterized as being HER2 negative and progesterone receptor (PR) positive, with higher
ER expression and lower expression of the proliferation markers Ki-67 and PCNA than
luminal B tumors [189-192]. Luminal A tumors also have overexpression of GATA binding
protein 3, X-box binding protein 1, trefoil factor 3, hepatocyte nuclear factor 3α and estrogen
regulated LIV-1 [176, 180]. Luminal A tumors often present as histologically low-grade
tumors with good differentiation [191]. Also, a majority of grade 1 luminal A tumors show
genomic loss of chromosome 16q, which is correlated with good prognosis [190]. As a
result, patients with luminal A tumors have a lower probability of developing distant
metastasis, and have increased overall survival compared to patients diagnosed with other
subtypes [176].
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The treatment breast cancer patients receive is based on the disease stage and
pathological features, including receptor status and tumor grade. Patients with luminal A
breast cancer are often treated with endocrine therapy, including selective estrogen
response modulators (SERMs), such as tamoxifen and raloxifene, which can bind to ER and
inhibit its activity in cancer cells [193]. Treatment with tamoxifen is often combined with
breast conservation surgery, in which a lumpectomy is performed followed by radiotherapy.
As adjuvant therapy, 5 years of tamoxifen reduces risk of recurrence by 47% and death from
ER-positive breast cancer by 26% [194]. Tamoxifen and raloxifene are also effective as
preventive agents for women who are at high risk of developing invasive cancer.
Unfortunately, tamoxifen is associated with increased risk of developing endometrial cancer.
However, raloxifene is associated with lower rates of endometrial cancer and can equally
prevent the development of invasive cancer in high-risk patients [195]. While SERMs have
efficacy in both pre-menoposual and post-menopausal women, post-menopausal women
often receive aromastase inhibitors, including anastrozole, letrozole and exemestane [193].
As described previously, aromatase is an enzyme that converts androgen into estrogen [22].
A phase III clinical trial found that anastrozole extended time to progression (TTP) in postmenopausal women with metastatic breast cancer (MBC) to 11.1 months versus 5.6 months
with tamoxifen treatment [196]. Moreover, letrozole increased TTP to 41 weeks versus 26
weeks with tamoxifen treatment when used as a first line of therapy in post-menopausal
patients with advanced ER positive breast cancer [197]. Notably, the multi-center 10-year
Arimidex tamoxifen alone or in combination study found that while anastrozole significantly
improved disease-free survival (DFS) and time to recurrence compared to tamoxifen alone
or in combination, it did not significantly improve overall survival in post-menopausal women
with hormone positive breast cancer [198]. The efficacy of endocrine therapy as
neoadjuvant therapy, or therapy given prior to surgery, is still being studied, but initial
reports suggest improved response of letrozole or anastrozole compared to tamoxifen [193].
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The anti-ER agent fulvestrant is used as a second-line therapy in post-menopasual patients
with advanced ER-positive breast cancer, and is effective in tamoxifen refractory MBC
disease [199]. Overall, due to the development of endocrine therapy and a non-aggressive
disease, patients with luminal A breast cancer have a good prognosis and fare better than
patients with other sub-types.
1.6C LUMINAL B
Tumors classified as luminal B have decreased ER positivity, have little or no
expression of PR, are more likely to be HER2 positive (20% via IHC and mRNA) and have
higher expression of Ki-67 compared to luminal A tumors. Although high expression of Ki67 has been defined as greater than 13.5% positively stained cells, there have been
discrepancies in the scoring of Ki-67 via IHC, and the method is not standardized yet [189,
200, 201]. Microarray data shows increased gene expression of cyclin E, peroxiredoxin,
squalene epoxidase, gamma-glutamyl hydrolase and nuclease sensitive element binding
protein 1 are all specific to luminal B tumors [176, 180]. Also, about one third of luminal B
tumors carry TP53 mutations [202]. Luminal B tumors are distinguished from luminal A
tumors as being high grade and showing poor differentiation, with patients having increased
risk of recurrence and distant metastasis primarily to the bone and lung. Moreover, use of
the OncotypeDX, a diagnostic program that predicts outcome and optimal treatment based
on molecular characteristics of the tumors, often gives luminal B breast cancer a high
recurrence score (RS). The increased risk of metastasis and overall more aggressive
disease results in a decreased overall survival compared to patients with luminal A breast
cancer [183, 191, 193, 203].
Luminal B breast cancer patients are less responsive to endocrine therapy, and
benefit from the addition of chemotherapy for treatment [201]. Post-menopausal, ERpositive breast cancer patients with high RS were at greater risk of developing distant
recurrence when treated with endocrine therapies anastrozole, tamoxifen or in combination
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compared to patients with low or intermediate RS [204]. A clinical trial with node-negative,
ER-positive patients measuring the risk of distant recurrence in low, intermediate or high RS
patients who received tamoxifen or tamoxifen plus the chemotherapies cyclophosphamide,
methotrexate and fluorouracil (CMF) or MF found that only high RS patients saw a 28%
increase in distant recurrence free survival, versus only a 1.1% benefit in low RS patients
[205]. Moreover, a phase III trial with node-positive, ER-positive post-menopausal patients
found that 57% of patients that received cyclophosphamide, Adriamycin (doxorubicin) and
fluorouracil (CAF) prior to or concurrent with tamoxifen had DFS versus 48% of patients who
received tamoxifen alone during a 10-year follow-up [206]. While the CAF cocktail is
effective, a trial comparing CAF versus docetaxel, doxorubicin and cyclophosphamide (TAC)
found that 85.2% of patients with luminal B breast treated with TAC had 3 years of DFS
versus 79% treated with CAF [207, 208]. Therefore, patients with luminal B breast cancer
benefit from the combination of endocrine therapy and chemotherapy, but the
aggressiveness of the disease still calls for more efficient treatment strategies.
There are novel therapies being developed to treat luminal B breast cancer that
would target other pathways involved in proliferation and drug evasion. For example,
targeting the mTOR pathway in combination with letrozole has shown to be promising both
in neoadjuvant and metastatic settings [209, 210]. Combination of the mTOR inhibitor
everolimus with tamoxifen in patients with aromatase inhibitor pre-treated metastatic disease
increased progression free survival (PFS) by four months and increased overall survival
[211]. In a phase II trial, inhibition of fibroblast growth factor receptor (FGFR) in patients
with luminal metastatic disease that had amplification of FGR1, a known mechanism for
endocrine resistance, induced either a partial or stable response in patients [201]. Overall,
new treatment strategies that target pathways known to participate in endocrine resistance
appear to be promising for patients with luminal breast cancer.
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1.6C HER-2-POSITIVE BREAST CANCER
HER-2, or ERBB2, is a member of the epidermal growth factor (EGF) receptor
family, which is a subclass of the receptor tyrosine kinases superfamily. The fours receptors
within the EGF family are EGFR/ERBB1, ERBB2 (HER-2), ERBB3 and ERRB4, all of which
are transmembrane proteins with extracellular ligand binding domains and cytoplasmic
tyrosine kinase domains [212]. All of the EGF receptor family members, except HER-2,
have specific ligands that cause receptor activation. HER-2 has no soluble ligand, but is the
preferred partner to form heterodimers with other activated EGF receptors [213]. Receptor
activation leads to homodimer or heterodimer formation, followed by phosphorylation of the
cytoplasmic tail, which acts as docking site for other proteins to activate downstream
signaling [212]. Downstream pathways activated by HER-2 signaling include the mitogenactivated protein kinase (MAPK) pathway and the PI3K pathway [214, 215]. HER-2 can
also sequester the CDK inhibitor p27, preventing it from inhibiting CDK2 activity, promoting
proliferation [216].
HER-2 gene amplification and overexpression, detected through either fluorescence
in situ hybridization or IHC, occurs in 12 to 25 percent of breast cancers [183, 217]. HER-2
overexpression has also been detected in ovarian, gastric and salivary tumors [212, 218,
219]. The HER-2 pathway is constitutively active when HER-2 is overexpressed, as it can
form homodimers with itself [212]. Patients with HER-2 positive breast cancer have a poor
prognosis and decreased overall survival compared to non-HER-2 positive breast patients,
with a majority of tumors being poorly differentiated and high-grade [181, 218]. HER-2
positive breast cancer preferentially metastasizes to the liver, brain and bone [203].
However, targeted therapies have been developed to treat HER-2 positive breast
cancer. The recombinant, humanized monoclonal antibody trastuzumab (Herceptin) binds
to the extracellular domain of HER-2, inhibiting its activity and sequestering it away from
other EGF receptors [193]. Since, trastuzumab had an objective response rate (RR) of 35%
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in HER-2 overexpressing MBC patients, it was initially only approved as a single agent
[220]. However, subsequent trials evaluated the combination of trastuzumab with an
anthracycline (either doxorubicin or epirubicin) and cyclophosphamide or paclitaxel (in
patients who had previously received anthracycline chemotherapy) in HER-2-positive MBC
patients. When comparing trastuzumab plus chemotherapy versus chemotherapy alone,
time to disease progression increased to 7.4 months versus 4.6 months, with median
survival increasing to 25.1 months versus 20.3 months. Unfortunately, 27% of patients who
received an anthracycline with trastuzumab had cardiac dysfunction [221]. As a result,
trastuzumab is only used in combination with non-anthracycline chemotherapies [193].
Moreover, trastuzumab has been approved to be included in adjuvant therapy in patients
with localized breast cancer, due to a 52% decrease in risk of disease recurrence and
91.4% overall survival compared to 86.6% of the control group with a 24 month follow-up
[222]. The small molecule inhibitor lapatinib binds to and inhibits the tyrosine kinase domain
of EGFR and HER-2 [193]. The addition of lapatinib to capectiabine versus capecitabine
alone increased time to progression to 8.4 months versus 4.4 months in HER-2 positive
MBC patients who previously received anthracyclines, taxanes and trastuzumab [223]. A
randomized, open-label phase III trial examined lapatinib alone, trastuzumab alone, or in
combination in HER-2 positive breast cancer patients, and found that 51.3% of combination
treated patients had pathological complete response (pCR) versus only 29.5% of
trastuzumab treated patients [224]. Inhibition of EGFR alone via gefitinib, or in combination
with trastuzumab, has not been effective in breast cancer patients [193]. While HER-2
positive breast cancer is an aggressive disease, these patients can benefit from targeted
therapy as single agents or in combination with chemotherapy.
1.6D BASAL-LIKE BREAST CANCER
About 15% of breast cancers are classified as the aggressive subtype basal-like
breast cancer (BLBC). Forty percent of BLBC patients are premenopausal African American
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women [181]. BLBC is characterized through gene-expression profiling as having
expression of high-molecular weight basal cytokeratin (CK) 5/6, CK14 and CK17 and
expression of EGFR, with 15-35% of BLBC tumors having EGFR gene amplification.
Frequently, BLBC is ER and PR negative and HER-2 negative/low and have high Ki-67
expression by IHC, characteristics that overlap with triple-negative breast cancer (TNBC)
[225, 226]. However, since not all BLBC are hormone receptor and HER-2 negative, BLBC
is not synonymous with the clinical diagnosis of TNBC [226]. Up to 82% BLBC have been
found to have TP53 gene mutations [180]. The similarities between sporadic BLBC and
breast cancer due to germline mutations in BRCA1 have become increasingly recognized.
A majority of BRCA1 mutation breast cancers are also negative for hormone receptors and
HER-2 and carry TP53 mutations [28, 227]. BRCA1 mRNA has been found to be lower in
BLBC sporadic tumors compared to non-BLBC sporadic tumors [228]. Moreover, both
BRCA1 tumors and sporadic BLBC tumors present as high-grade tumors that have high
expression of EGFR, Skp2 and cyclin E and low expression of cyclin D1 and p27 expression
[28, 229]. Therefore, women carrying BRCA1 mutations who are at high risk of developing
breast cancer are more likely to develop BLBC.
Patients with BLBC have a poor prognosis, with decreased overall survival and
decreased relapse-free survival, especially during the initial 3-5 years after diagnosis,
compared to the other subtypes [180, 230]. Unlike non-BLBC tumors, BLBC preferentially
metastasizes to the brain and lung, with patients dying within 5-8 years of diagnosis [203,
226]. Moreover, the basal-like phenotype predicts aggressive disease and low survival after
the development of metastasis [231].
Since BLBC tumors can be ER, HER-2 low or triple-negative, BLBC status does not
currently denote a specific type of treatment regimen. Therefore, patients with ER-positive
or HER-2 positive BLBC tumors receive endocrine therapy and trastuzumab, respectively.
However, most BLBC tumors are triple-negative, which cannot benefit from currently
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available targeted therapies, and only receive chemotherapy [226]. Treatment of TNBC will
be discussed in greater detail in the following section. Therefore, BLBC is an aggressive
disease with high risk of recurrence, and the therapies used to treat this subtype are based
on hormonal and HER-2 status.
1.6E CLAUDIN-LOW BREAST CANCER
The claudin-low subtype is a more recently identified subtype using gene-expression
analysis of human breast tumors and murine mammary tumors from transgenic mouse
models [178]. Claudin-low tumors have low expression of the tight junction proteins claudin
3,4,7 and occuldin and the epithelial marker E-cadherin. Claudin-low tumors share some
characteristics of basal-like tumors, including low expression of HER2 and luminal markers
[178, 184]. These tumors have high expression of immune response genes, including
genes that are typically expressed by B-cell and T-cell lymphocytes. The presence of
lypmphocyte proteins indicates immune cell infiltration; however, the expression CXCL2
most likely occurs within the tumor cells [185]. Claudin-low tumors are also enriched for
cells that express the tumor initiating stem cell markers CD44+/CD24-/low [232]. Additionally,
these tumors have high expression of mesenchymal and stem cell markers N-cadherin and
vimentin [184]. Moreover, tumor expression of CD44+/CD24-/low was more enriched in the
claudin-low subtype following endocrine and chemotherapy treatment [233].
Only about 12-14% of breast cancers are classified as claudin-low tumors. Claudinlow tumors are predominantly triple negative, with only up 25% being hormone-receptor
positive. Patients with claudin-low tumors recurred sooner than the luminal A subtype and
have lower overall survival than either luminal A or luminal B [184, 234]. There are currently
no specific therapies to treat the claudin-low sub-type. Similar to basal-like tumors, these
tumors receive treatment based on their hormone-receptor and HER2 status.
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1.7 TRIPLE-NEGATIVE BREAST CANCER
TNBC is a clinical diagnosis given to patients with breast tumors that lack expression
of ER, PR or HER-2 amplification [177]. Up to 10- 20% of breast cancers are TN, with
patients predominantly consisting of premenopausal, African American patients. In fact,
20.8% of African American patients with breast cancer are triple-negative, versus only
10.4% of Caucasian patients [235]. TN tumors are aggressive with patients presenting at an
advanced stage at time of diagnosis, with large, high-grade tumors that have metastasized
to the lymph nodes [236]. Moreover, TNBC patients have a poor prognosis due to an
increased rate of distant metastasis within the first five years of diagnosis, peaking at 3
years, compared to patients with other subtypes who remained constant throughout. Less
than one third of women with metastatic TNBC survive 5 years [237, 238]. Similar to BLBC,
TNBC preferential metastatic sites include, lung (40%), brain (30%), liver (20%) and bone
(10%), differing from non-TNBC [239, 240]. As previously described, 70% TNBC tumors are
classified as BLBC sub-type, with the remaining tumors falling into other subtypes [241].
TNBC tumors are more likely to occur in women with BRCA1 gene mutations, with 80% of
breast cancer patients with BRCA1 mutations diagnosed as TN [227, 241, 242]. Over half
of TNBC tumors have EGFR overexpression, which is correlated with poor prognosis [243].
Additionally, TNBC tumors frequently have deregulated cell cycle machinery, including high
expression of cyclin E, low expression of cyclin D and aberrant expression/ mutations in the
tumor suppressor p53 [80, 244-246]. Also, a majority of TNBC tumors have loss of Rb, but
this is correlated with a good prognosis [247]. Overall, TNBC tumors differ both molecularly
and clinically from non-TNBC tumors (Table 6).
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Table 6. Comparison of TNBC and non-TNBC tumors
TNBC
Mean age at diagnosis (yrs.)
53
Age < 40 at diagnosis (%)
12.2
Tumor size at diagnosis (cm)
3
Lymph node mets. (%)
54.4
Grade III tumors (%)
66
Poorly differentiated (%)
71.1
Sites of distant metastasis
Lung, brain, liver, bones
(most likely to least likely)
Basal cyotkeratins (%)
71
EGFR (%)
>60
p53 mutation (%)
54-82
Mitotic index
High
Rb loss (%)
64.5
Adapted from: [237], [240], [245, 247, 248]
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non-TNBC
57.7
5.7
2.1
45.6
28.3
26.5
Bones, liver, lung, brain
6.3
2-16.5
13
Sub-type specific
6.5-22.6

The heterogeneity of TN tumors was illustrated in gene expression analysis that
generated 6 subtypes within TNBC, including basal like 1 (BL1), basal like 2 (BL2),
immunomodulatory (IM), mesenchymal (M), mesecnchymal stem-like (MSL) and luminal
androgen receptor (LAR) [177]. To determine if these subtypes could predict response to
treatment, breast cancer cell lines used in the laboratory were also subtyped. The BL1
subtype is enriched in cell cycle and cell division genes and the DNA damage ATR/BRCA
pathway genes. BL2 tumors have high expression of the EGF, WNT and IGF1R pathway
genes. Both BL1 and BL2 tumors have higher Ki-67 expression compared to the other
subtypes. Cell lines within the BL1/BL2 classification were much more sensitive to the
chemotherapeutic Cisplatin compared to other subtypes. However, not all cell lines
responded equally to the PARP inhibitors veliparib and olaparib. IM tumors are enriched for
immune response genes, including the IL-12, IL-7, B cell receptor and natural kill cell
pathways as well as the TNF and JAK/STAT signaling pathways. Genes involved in cell
motility characterize the M subtype, including the Rho pathway, as well as extracellular
matrix receptor interaction genes, including WNT, ALK and TGF-β pathways. In addition to
Rho, TGF-β and ALK pathways, MSL tumors are enriched for EGFR, PDGF and ERK1/2
pathway genes. Both M and MSL tumors have higher expression of EMT genes, including
MMP2, TWIST1 and ZEB1. Compared to M tumors, MSL tumors have lower proliferation
along with higher expression of stem cell genes. Cell lines within this subtype are more
sensitive to dasatinib, an inhibitor of the cell migration protein Src, than the LAR cell lines.
Tumors within the LAR subgroup are enriched for androgen and estrogen metabolism,
steroid biosynthesis, TCA cycle and sucrose and fatty acid metabolism genes [177]. LAR
and a subset of MSL cell lines were sensitive to the AR antagonist bicalutamide, whereas
basal-like cell lines had IC50 values greater than 500 um [177]. The identification of TNBC
tumor subtypes could potentially lead to more personalized care for these patients.
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In contrast, a recent paper that employed RNA and DNA profiling analysis on TNBC
tumors identified 4 TNBC subtypes, including Luminal-AR (LAR), Mesenchymal (MES),
basal-like immune suppressed (BLIS) and basal-like immune activated (BLIA) [249]. The
conflicting results between the Lehman et al. study and the Burstein et al. study may be due
to the method used to confirm the TN status of tumors analyzed. The LAR subtype is
characterized by increased gene expression of cyclin D1, dehydrogenase/reductase
member 2, prolactin-induced protein and androgen receptor. Possible druggable targets
against the LAR tumors include ER, PR and mucin 1 cell surface receptor. The MES
subtype shows high expression of EGFR and alcohol dehydrogenase 1B, with possible
druggable targets including neurotrophic tyrosine kinase receptor type 2, endothelin receptor
type B and interleukin 1 receptor. The BLIS subtype is characterized by increased
expression of fibroblast growth factor receptor 2 (FGFR2) and E74-like factor 5. Patients
with BLIS tumors show decreased disease-free survival compared to the other subtypes.
Overexpression of FGFR2 provides a potential target for treatment of the BLIS subtype.
Tumors in the BLIA subtype have gene amplification of CDK1, chemokine ligand 9 and
topoisomerase II alpha. In addition to topoisomerase II, possible drug targets against BLIA
are chemokine ligand 10 and proteasome subunit beta type 9. Overall, patients with BLIA
tumors have a good prognosis and have increased disease-free survival compared to the
other subtypes [249]. Further validation will most likely be required to consolidate the
findings of both TNBC subtype studies. In any case, the subtyping of TNBC will hopefully
lead to the development of more targeted therapies.
Since TN tumors do not express ER or HER2, they do not respond to current
targeted therapies, including tamoxifen and trastuzumab. As a result, TNBC patients
receive chemotherapy and surgery for treatment [248]. There is no standard of care for
TNBC patients, with patients receiving a variety of chemotherapeutics including
anthracyclines, fluropyrimidines, taxanes and platinum-based drugs (Table 7). The
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alkyating agent cyclophosphamide, which forms interstrand and intrastrand crosslinks, is
often added to anthraycline-based therapy to increase therapeutic benefit [250]. TNBC
patients can also receive platinum-based chemotherapy both as a single agent and in
combination therapy, with TNBC patients responding better to platinum based therapy
compared to non-TNBC patients [251]. TNBC tumors are more likely to have pCR
compared to ER positive tumors (22% vs 11%) to neoadjuvant chemotherapy. A study that
monitored patients treated with paclitaxel followed by treatment with 5-fluorauracil,
doxorubicin and cyclophosphamide (FAC), found that TNBC patients had a higher rate of
pCR of 45%, compared to only 6% in luminal tumors [179]. The delivery method of
combination treatments can impact treatment efficacy. For example, simultaneous
administration of doxorubicin and paclitaxel in metastatic patients increased RR to 47%
compared to 36% and 34% of doxorubicin or paclitaxel alone, respectively. Interestingly,
there was not significant benefit when drugs were administered sequentially [252].
However, TNBC patients who do not achieve pCR in response to therapy, and have
residual disease, have decreased overall survival compared with non-TNBC patients who
had residual disease. Specifically, TNBC patients have decreased PFS and overall survival
within the first 3 years of diagnosis [253]. Overall, drug combinations have greater efficacy
over single-agent treatment, but can be associated with increased toxicity, compared to
single agent therapy [193, 194]. Therefore, although TNBC patients initially respond well to
chemotherapy, their poor prognosis and increased risk of recurrence forces a search for
novel therapies.
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Table 7. Chemotherapy options for TNBC patients
Drug Family

Anthracyclines

Anti-metabolites

Taxanes

Doxorubicin

Response as single
agent in breast
cancer patients
10-50%

Epirubicin

13-48%

Etoposide

15-35%

5-fluorouracil

25-54%

Capecitabine
Gemcitabine

20-35%

Mechanism of
action
Intercalates with
DNA, inhibits
topoisomerase II
activity
Nucleoside
analogs, disrupt
RNA and DNA
synthesis

Drugs

Abraxane

12-37%
21 days: 18-68%
7 days: 33-50%
21 days: 16-62%
7 days: 22-53%
33-48%

Vinorelbine

25-50%

Cisplatin, carboplatin

9-51%

Doxetaxel

Microtubule
stabilizer by
binding to βtubulin

Inhibit
Vinca-alkaloids
microtubule
formation
Covalent binding
Platinum-based
to DNA purine
bases
Adapted from: [193], [254-261]

Paclitaxel
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Several novel targeted therapies against TNBC are in clinical trials. PARP inhibitors
are proving to be very promising against BRCA1/BRCA2 mutation derived tumors. PARP
repairs SSBs via BER, with PARP inhibition leading to a collapse of replication forks. This
causes SSBs to develop into DSBs that would require HR for repair. However, studies
found that cancer cells with BRCA1/BRCA2 genes are deficient in HR, sensitizing cells to
PARP inhibition [170, 262]. Since most BRCA-derived tumors are diagnosed as TN and TN
tumors have many of the same DNA-repair deficiencies as BRCA tumors, PARP inhibitors
became an obvious treatment strategy for TNBC. PARP inhibitors are also being evaluated
for serous ovarian cancer. There are currently six PARP inhibitors being examined in the
clinic, including olaparib, veliparib, rucaparib, BMN-673, CEP-9722 and niraparib [263]. As
a single agent, PARP inhibitors have anti-tumor activity in BRCA-mutation carriers and noncarriers (Table 8). A phase II study in BRCA-mutation carriers with refractory disease found
that olaparib monotherapy had a RR of 31.1% and 12.9% in ovarian and breast cancer
patients, respectively [264]. Several trials have combined PARP inhibitors with
chemotherapeutics, aiming to maximize DNA damage and tumor cell death (Table 8).
Ongoing phase II/III trials, including combining rucaparib with cisplatin in TNBC patients with
BRCA-mutations, will further illuminate the utility of PARP inhibitors in the clinic [263].
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Table 8. Sample of clinical trials with PARP inhibitors
Clinical trials independent on BRCA status
NCT Identifier

NCT007535451

Regimens

Olaparib:
single agent

NCT00679783

Olaparib

NCT00707707

Olaparib with
Paclitaxel

Setting
Randomized, double
blind placebo-controlled
phase II study for
maintenance of recurrent
platinum sensitive serous
ovarian cancer
Phase II study in TNBC
and serous ovarian
cancer

Phase I study in
metastatic TNBC patients

Major Findings
Well tolerated; PFS
improved of 8.4
months vs. 4.8
months

OR in 41% of BRCA
patients vs. 24% in
non-BRCA patients
(ovarian); no OR in
BC patients
Diarrhea, nausea and
neutropenia. 37%
partial response

Ref.

[265]

[266]

[267]

Clinical trials dependent on BRCA status
NCT00628251

Liposomal
doxorubicin
and olaparib

NCT0144518

Carboplatin
and olaparib

NCT00749502

Phase II study BRCApatients with relapsed
ovarian cancer
PhaseI/IIb study in
BRCA-patients with
breast and ovarian
cancer
Phase I study (24/100
with BRCA mutations)

Niraparib
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No statistical
difference in
treatment groups
Well tolerated; 50%
partial response, 1
patient pCR
Well tolerated; 40%
OR in BRCA-patients
with ovarian cancer,
50% OR in BRCApatients with BC

[268]

[269]

[270]

EGFR has become an attractive target against TNBC. Some studies have found up
to 64% of TNBC tumors having overexpression of EGFR protein; with 33% of tumors having
high EGFR gene copy number, correlating to poor outcome [271]. In vitro studies
demonstrated increased sensitivity of BLBC cells to the monoclonal antibody cetuximab
compared to luminal cells, with combination therapy of carboplatin followed by cetuximab
being synergistic [272]. A randomized phase II study examining cetuximab alone versus
cetuximab with carboplatin in TN MBC patients found that while cetuximab was well
tolerated, it showed low activity against the tumor. However, combination therapy had an
18% RR, with 27% of patients showing clinical benefit [273]. However, more clinical trials
are needed to validate the efficacy of targeting EGFR as both single-agent and combination
therapy.
The vascular endothelial growth factor (VEGF) family and their receptors (VEGFR)
are required for angiogenesis and have been linked to tumor growth and metastasis in
variety of tumors, including breast cancer [193, 274]. As single-agent therapy, bevacizumab
(Avastin), a humanized recombinant antibody against VEGF-A, had a RR of 6.7% in a
phase I/II trial in MBC patients, with 22% of patients experiencing hypertension [275].
However a phase III trial in metastatic breast cancer patients found that paclitaxel plus
bevacizumab versus paclitaxel alone increased PFS to 11.8 vs. 5.9 months and RR to
36.9% vs. 21.2%, respectively [276]. Moreover, a randomized study in TNBC patients with
primary tumors found treatment with epirubicin and cyclophosphamide followed by
docetaxel with and without the addition of bevacizumab increased pCR to 39.3% versus
27.9%, respectively [277]. Therefore, inhibition of angiogenesis can increase the response
to chemotherapy in TNBC patients.
1.8 GAP IN KNOWLEDGE
The molecular and clinical characteristics of TNBC demonstrate that TNBC patients
cannot benefit from currently approved targeted therapy. Initial sensitivity to
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chemotherapeutics has not been able to greatly improve the overall survival and prognosis
of TNBC patients. While novel treatments are in development, current studies do not
investigate how targeting the deregulated TNBC cell-cycle checkpoints could be
synthetically lethal with chemotherapeutics. In order to generate a novel treatment strategy
the following questions must be answered:
•

Would the deregulation of the cell cycle sensitize TNBC cells to cell cycle inhibitors;
would non-TNBC and non-transformed cells respond differently?

•

Can a synthetic lethal combination of cell-cycle inhibition and chemotherapeutics
specifically target TNBC cells, without inflicting harm to non-transformed cells?

•

Will combination cell cycle targeted therapy be an effective method in a pre-clinical
model?

•

What affect would combination therapy have on the cell cycle of TNBC cells
compared to non-transformed cells?

•

Is there a molecular target/pathway that can be used as a marker to predict
combination treatment response?

•

Can combination treatment augment the DNA damage inflicted by
chemotherapeutics explicitly in TNBC cells?

The following chapters of this dissertation will address these questions. The overall
hypothesis of this dissertation is that TNBC cells are sensitive to cell cycle-targeted
combination therapy, leaving non-transformed cells unharmed. The examination of
these questions, potentially leading to the generation of a novel targeted therapy treatment
strategy, could greatly improve the care of TNBC patients.
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CHAPTER 2: SEQUENTIAL ADMINSTRATION OF ROSCOVITINE FOLLOWED BY
DOXORUBICIN INDUCES SYNERGISTIC CELL DEATH IN TNBC CELLS
2.1A DEREGULATION OF THE CELL CYCLE IN BREAST CANCER
As with all tumor cells, breast cancer cells possess the ability to proliferate
continuously due to gene amplifications of cycling promoting factors, mutations in CKIs and
alterations in protein expression. About 15% of breast cancer tumors have gene
amplification at chromosome 11q13, where CCND1 is located [278]. Moreover, 50% of
breast cancers have high cyclin D1 expression at both the mRNA and protein level,
contributing to Rb inhibition [279, 280]. Also, there is a positive correlation between ER
positivity and cyclin D1 expression, with ER activity inducing cyclin D1 transcription [281,
282]. Unlike cyclin D1, cyclin E is seldom amplified in breast cancer. However, over 40% of
breast tumors have cyclin E overexpression at the protein level, contributing to CDK2
overactivation [80, 283]. Cyclin E protein overexpression is a poor prognostic marker in
breast cancer, and is associated with negative ER and PR status [80, 284]. As previously
described, cytoplasmic localization of LMW-E is oncogenic in breast cancer, and has been
shown to specifically enable ER positive breast cancer cells to bypass letrozole-induced G1
arrest [76, 285]. High expression of cyclin B1 in either the cytoplasm or the nucleus
correlated with poor overall survival in breast cancer, suggesting that any increase in cyclin
B1 expression can increase the aggressiveness of the tumor [286]. In addition to aberrant
cyclin expression, CKIs can also be deregulated in cancer. The CKI p27 has decreased
expression and irregular cytoplasmic localization in breast cancer cells. Moreover,
decreased nuclear p27 expression correlated with high tumor grade, negative ER status and
could serve as predictor of decreased disease free survival in breast cancer [287, 288].
About 20-30% of breast cancers have promoter hypermethylation, leading to epigenetic
silencing of the CKI p16INK4A gene [289]. Whereas p21 is rarely mutated in breast cancer,
the p21 transcription factor p53 is mutated in 54-82% of BLBC and TNBC [180, 290, 291].
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Activity of kinases that participate in chromosome segregation can also be augmented in
breast cancer. Aurora A kinase, required for chromosome segregation, is often
overexpressed in breast cancer due to gene amplification, leading to chromosomal
instability [292]. Importantly, microarray analysis on breast cancer tumors from patients
under the age of 55 revealed that expression of several cell cycle genes, such as cyclin E2,
cyclin B2, CDC25B, and Bub1, comprise a poor prognosis gene signature that predicts
metastasis in less than 5 years [234]. Therefore, targeting the cell cycle is a viable
treatment option for breast cancer, especially to target more aggressive tumors.
2.1B CYCLIN AND CDK KNOCKOUT MICE
Cyclin and CDK knockout mice were generated to investigate the role of each protein
during development and to examine compensatory mechanisms within the cell cycle (Table
9). For example, cyclin A1 knockout mice are viable, with only male mice suffering from
sterility. This suggests that cyclin A2 can compensate for cyclin A1, and that cyclin A1 is
only required for spermatogenesis [293]. However, cyclin A2 knockout mice are embryonic
lethal [294]. Similarly, while cyclin B1 knockout mice are embryonic lethal, cyclin B2 are
viable, indicating that cyclin B1 can compensate for cyclin B2 during development.
Knockout of other cyclins show abnormalities in specific tissues, indicating their participation
in tissue-specific development (Table 9). Cyclin A and B are required to activate CDK1, with
CDK1 knockout mice also being embryonic lethal [295]. Moreover it was found CDK1 could
bind to cyclin E in CDK2-deficient MEFs and, in the absence of all interphase CDKS, can
phosphorylate Rb to complete the cell cycle [295, 296]. Together, these studies indicate
that CDK1 activity can drive the entire mammalian cell cycle in the absence of other CDKs
[295]. However, the compensatory mechanisms observed in in vivo model systems do not
always translate to CDK inhibition studies in vitro. This may be because CDK inhibition
does not automatically make their cyclin subunits accessible to bind to other CDKs.
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Therefore, in vitro systems are often preferred for development of CDK inhibitors as
opposed to transgenic models [33].
Table 9. Phenotypes of cyclin and CDK knockout mice
Cyclin/CDK
Phenotype
Cyclin A1
Viable, no abnormalities. Only male mice sterile
Cyclin A2
Embryonic lethal at E5.5
Cyclin B1
Embryonic lethal at E10.5
Cyclin B2
Viable, no abnormalities, both genders fertile.
Viable, reduced body size, neurological abnormalities,
Cyclin D1
hypoplastic retina, mammary gland defects (inability to
lactate during pregnancy)
Viable, females sterile and males with hypoplastic testes.
Defects in B-lymphocyte proliferation, pancreatic β-cell
Cyclin D2
proliferation, hypoplastic thymus and abnormalities in
cerebellar development and adult neurogenesis
Cyclin D3
Viable. Defects in T-lymphocyte development
Reduced body size, hypoplastic cerebella, mortality 3
Cyclin D1/D2
weeks after birth
Cyclin D2/D3
Megaloblastic anemia, embryonic lethal at E17.5
Cyclin
Proliferative defects in hematopoietic cells and cardiac
D1/D2/D3
myocytes, embryonic lethal at E16.5
Cyclin E1
Viable, no abnormalities
Cyclin E2
Viable, no abnormalities, reduced male fertility
Defects in extraembryonic tissues, embryonic lethal at
Cyclin E1/E2
E11.5
CDK1
Embryonic lethal E2.5
Reduced body size, impaired neural progenitor cell
CDK2
proliferation, both genders sterile
Reduced body size, insulin deficient, diabetes caused by
CDK4
reduced pancreatic β-cells,
CDK6
Hypoplasia and defects of thymus and spleen
CDK2/4
Heart defects, embryonic lethal at E15.5
Reduced body size, hematopoietic defects, both genders
CDK2/6
sterile
CDK4/6
Severe anemia, embryonic lethal at E14.5-E18.5
Heart defects, hematopoietic defects, embryonic lethal at
CDK2/4/6
E13.5
Severe neurological defects, mortality immediately
CDK5
following birth
CDK11
Embryonic lethal at E3.5
Adapted from: [33]
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2.1C CDK INHIBITORS IN CANCER
CDK inhibitors have been developed to target the consistent deregulation of the cell
cycle in cancer. The two main types of CDK inhibitors are ATP-competitive
competitive inhibitors and
non-ATP inhibitors. ATP-competitive
competitive inhibitors bind to the CDK catalytic ATP-site,
ATP
preventing CDK activation. ATP
ATP-competitive inhibitors consist of heterocyclic families,
including naturall products (i.e. flavon
flavones and staurosporine), purines, pyrimidines,
pyrimidines indoles,
pyrazoles and thiaozoles (Table 10
10) [315]. The following section will detail ATP-competitive
ATP
CDK inhibitors that have been extensively examined clinically (Table 11).

Table 10. Clinically examined CDK inhibitors
Drug
Drug
Structure
(Company)
Family

Target
CDKs

Flavopiridol
(SanofiAventis)

Flavone

CDK1, CDK2, CDK4,
CDK6, CDK7 & CDK9

Palbociclib
(Pfizer)

Pyridopyrimidine

CDK4/CDK6

Dinaciclib
(Merck)

Pyrazolopyrimidine

CDK1, CDK2, CDK5 &
CDK9

Roscovitine
(Cyclacel)

Purine

CDK1, CDK2, CDK5,
CDK7, & CDK9

Adapted from: [315] Chemical structures adapted from Sigma
Sigma-Aldrich
Aldrich and Selleckchem
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Table 11. Clinical trials with CDK inhibitors
Trial
Results
Drug
Phase
Solid tumors: complete response/partial response in
I
5/27 patients, stable disease in 10/27 patients (C)
CLL: partial response in 40% of patients, PFS of 12
I
months (M)
II
Malignant melanoma: no clinical significance (M)
Flavopiridol
NSCLC: No OR, disease progression in 4/20
II
patients (M)
AML: With cytrabine and mitoxantrane increased
II
complete remission compared to standard of care
(C)
Advanced Rb-positive solid tumors: In a 28-day
I
cycle (3 weeks on, 1 week off), 125 mg/daily is
MTD. SD in 35% of patients (M)
Advanced Rb-positive BC: 38% of patients had SD
for over 6 months, with 19% of patients having
II
some clinical benefit. Over 50% of patients had
Palbociclib
dose reduced because of cytopenia (M)
Advanced ER-positive BC: Improved PFS from 10.2
II
vs. 20.2 months comparing letrozole vs. letrozole
plus palbociclib, respectively (C vs. M)
III
ER positive BC: on-going with letrozole (C vs. M)
10/48 patients, including (NSCLC, prostate cancer
sarcoma, melanoma, esophageal carcinoma,
I
gastrointestinal stromal tumor, adenoid cyst
carcinoma and pseudomxyoma peritonei) achieved
SD for at least four 28-day treatment cycles (M)
Advanced breast cancer: 2/7 patients had PR, no
Dinaciclib
II
benefit compared to capecitabine (TTP 2.73 vs.
4.17 months) (M)
NSCLC: TTP 1.49 vs. 1.58 months, dinaciclib vs.
II
erlotinib, respectively. Adverse effects included
neutropenia, leukopenia, vomiting and diarrhea (M)
III
CLL: dinaciclib vs. Ofatumumab, on-going (M)
Nasopharyngeal cancer: 50% of patients had tumor
I
reduction (M)
NSCLC: In combination with gemcitabine and
I
cisplatin. Patients showed PR (6/27), SD (7/27)
and disease progression (1/27). MTD 800 mg (C)
Roscovitine
Advanced solid tumors: Sequential combination
treatment sapacitabine and roscovitine induced PR
I
2 patients with breast and pancreatic cancer and
SD in 6 patients. Germline BRCA mutation
suggested as marker to response (C)
M = monotherapy, C = combination therapy
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Flavopiridol is a semisynthetic flavone analog of an Indian plant rohutkine.
Flavopiridol has shown to have activity against CDK1, CDK2, CDK4, CDK6, CDK7 and
CDK9 at nanomolar concentrations and has also been shown to decrease cyclin D1 mRNA
expression. Flavopiridol is administered intravenously [290, 330]. In vitro studies performed
on multiple myeloma cell lines found that flavopiridol induces apoptosis while reducing
mRNA and protein levels of the anit-apoptotic protein MCL-1 [331]. However, this CDK
inhibitor has shown mixed results in the clinic (Table 11). Untreated metastatic melanoma
patients enrolled in a phase II study showed no significant clinical benefit with single-agent
flavopiridol. Although flavopiridol was relatively well tolerated, over 80% patients suffered
from diarrhea [318]. Similarly, a phase II trial in NSCLC patients showed no objective
response, with some patients progressing during treatment [319]. Phase II studies in
patients with acute myeloid leukemia who were treated with flavopiridol followed by
cytarabine and mitoxantrone had increased complete remission rates compared to patients
treated with cytarabine and danurubicin [320]. Moreover, a phase I trial in patients with
solid tumors found that combination of docetaxel followed by flavopiridol induced complete
response or partial response in 5/27 patients and stable disease (SD) in 10/27 patients
[316]. These studies illustrate the clinical potential of flavopiridol in combination therapy.
Although flavopiridol has shown promising results in leukemias, its manufacturer, SanofiAventis, is no longer developing it for cancer treatment [315].
Palbociclib is a potent CDK4/CDK6 inhibitor that has promising therapeutic potential
in breast cancer [332]. While other CDK4/CDK6 inhibitors, such as LEE011 and LY283519
have been clinically examined, palbociclib is the focus here due to the success and efficacy
it has made in breast cancer (Table 11) [333]. An in vitro study that examined the response
of forty-four human breast cancer cell lines and three immortalized cell lines to palbociclib
treatment found that luminal ER positive (including HER2 amplified) cells were the most
sensitive to treatment compared to BLBC or cells that had undergone epithelial to
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mesenchymal transition. Growth inhibition was measured via cell counting, as no
cytotoxicity was detected. Moreover, sensitive cells had elevated gene expression of Rb
and cyclin D1 and decreased levels of p16. Palbociclib treatment reduced phospho-Rb
specifically in sensitive cell lines, causing a G0/G1 arrest. Additionally, palbociclib increased
the growth inhibitory affect of tamoxifen and trastuzumab treatment in ER-positive and
HER2 amplified cell lines, respectively [334]. When examined in drug resistant cell lines,
palbociclib treatment re-sensitized cells to tamoxifen and induced growth arrest and
senescence in cells resistant to endocrine therapy [334, 335]. A phase I study that enrolled
patients with Rb-positive advanced solid tumors refractory to standard treatment examined
treatment with palbociclib in a 3 weeks on, 1 week off schedule, found that 125 mg once
daily was the maximum tolerated dose (MTD) and induced SD in 13/41 [321]. A phase II
trial enrolled 37 women with advanced breast cancer with confirmed Rb-positive protein
expression also examined the dose of 125 mg/daily 3 weeks on, 1 week off schedule. Fiftyone percent had dose reductions due to cytopenia. Thirty eight percent of patients had SD
for over 6 months, with 19% of patients having some clinical benefit. However, Rb nuclear
expression, percent Ki-67, cyclin D gene amplification and p16 loss did not correlate to a
positive response, indicating that further investigation is required for predictive response
marker [322]. A randomized phase II study investigated the safety and efficacy of letrozole
versus letrozole plus palbociclib in treatment-naive postmenopausal women with advanced
ER positive (HER2 negative) breast cancer. Letrozole was administered continuously at 2.5
mg daily, while palbociclib was administered 125 mg daily for 3 weeks on, 1 week off. This
study found that combination treatment significantly improved the median PFS from 10.2
versus 20.2 months comparing the letrozole group versus the letrozole plus palbociclib,
respectively. For toxicity, 1% versus 54% of patients had neutropenia, and none versus 19%
had leucopenia with letrozole alone versus letrozole plus palbociclib, respectively. Similar to
other studies, this trial did not find any correlation between cyclin D1 and p16 status and
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response [323]. Based on the significant phase II results, phase III trials on palbociclib in
combination with letrozole are currently ongoing in ER-positive breast cancer [336].
Dinaciclib, or SCH727965, is a potent pyrazol-pyrimidine derivative that inhibits
CDK1, CDK2, CDK5 and CDK9 in the nanomolar range [330]. Dinaciclib has shown activity
against a broad range of malignancies in pre-clinical settings. In vitro studies with ovarian
cancer cells found that dinaciclib was more effective at reducing phospho-Rb (S807/811)
expression while inducing apoptosis measured by cleaved PARP1 expression at >6.25 nM
compared to 1µM flavopiridol [337]. A human ovarian cancer xenograft in a mouse model
system found that dinaciclib had a higher MTD of 60 mg/kg versus <10 mg/kg of flavopiridol
(based on 20% weight loss) [337]. Furthermore, dinaciclib induced a 50% reduction in
tumor growth at 5 mg/kg after 7 days of treatment, versus 10 mg/kg of flavopiridol.
Additionally, dinaciclib decreased pancreatic cancer cell viability and migration capacity in
vitro. Human pancreatic cancer xenograft studies revealed that dinaciclib reduced tumor
growth both as a single agent and in combination with gemcitabine [338]. Since flavopiridol,
which showed promise in leukemia, was discontinued, dinaciclib was examined in a
preclinical model against CLL cells. A 2hr exposure of a clinically achievable dose of
dinaciclib induced apoptosis in CLL cells isolated from patients, including high-risk patients
[339]. Dinaciclib has also been investigated in clinical trials (Table 11). A phase-I dose
escalation study in patients with solid tumors found the maximum administered dose to be
14 mg/m2, recommending a phase II dose of dinaciclib to be 12 mg/m2. In this study, 10/48
patients, including patients with NSCLC, prostate cancer, sarcoma and melanoma, achieved
disease stabilization for at least four 28-day treatment cycles [324]. A phase II open-label
study comparing standard of care treatment erlotinib to dinaciclib in NSCLC patients found
that time to progression (TTP) was 1.58 months for erlotinib versus 1.49 months for
dinaciclib. These patients experienced neutropenia, leukopenia and vomiting [326].
Furthermore, a phase II study in patients with advanced breast cancer found that dinaciclib
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treatment of 50 mg/m2 once every 21 days caused a partial response in 2/7 patients.
However, dinaciclib treatment had earlier TTP compared to capecitabine treatment (2.73 vs.
4.17 months), and the study concluded after 30 days ([325]. While showing limited efficacy
in solid tumors, the safety and efficacy of dinaciclib compared to ofatumumab (a monoclonal
antibody against CD20) is being investigated in a phase III trial in refractory CLL patients
(NCT01580228) [336]. Similar to other CDK inhibitors, the narrow efficacy of dinaciclib as
single-agent therapy against solid tumors could indicate that it could be more efficacious in
combination therapy.
Roscovitine, also known as selicicib or CY-202, is also a pan-CDK inhibitor that has
activity against CDK1, CDK2, CDK5, CDK7 and CDK9 at micromolar concentrations
according to in vitro kinase assays [330]. Roscovitine has been used in combination in
multiple pre-clinical models. In p53 mutant breast cancer cells roscovitine increased
accumulation in G2 and augmented ionizing radiation (IR)-induced growth inhibition.
Moreover, concomitant treatment of roscovitine (100mg/kg) and IR (7.5Gy) significantly
reduced tumor volume compared to either treatment alone in a xenograft model system.
Here, it was suggested that combination treatment reduced the ability of cells to undergo
NHEJ [340]. Combination treatment of roscovitine and IR also significantly increased
apoptosis of NSCLC cells in vitro. Moreover, combination treatment reduced expression of
NHEJ proteins Ku70 and Ku80, again suggesting that roscovitine can inhibit DNA repair
[341]. Roscovitine also synergized with IR in nasopharyngeal cancer cells by increasing
apoptosis and inducing a G2/M cell cycle arrest, while retarding tumor growth in a xenograft
model [342]. In addition to IR, roscovitine has been examined in combination with
chemotherapeutics. Our lab has found that roscovitine synergizes with doxorubicin to
induce cytotoxicity in sarcoma cell lines in vitro [343].
Roscovitine has been investigated clinically where it was administered orally (Table
11) [315]. A phase I study that examined treatment with roscovitine, gemcitabine and
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cisplatin in NSCLC patients found that the maximum tolerated dose of roscovitine was 800
mg twice daily (with 1000 mg/m2 gemcitabine and 75mg/m2 cisplatin). In this study, 6/27
patients had a partial response, 7/27 had SD and 1/27 patients had disease progression
[328]. In a phase I study of nasopharyngeal cancer, roscovitine was administered at either
400 mg or 800 mg twice daily on days 1 to 3 and 8 to 12. While patients receiving 400 mg
did not have significant toxicities, patients receiving 800 mg had liver toxicity and vomiting.
However, despite being only briefly exposed, 50% of evaluable patients showed tumor
reduction; with IHC analysis revealed increased apoptosis and necrosis and decreased
cyclin D1, MCL1 and phospho-Rb [327]. Moreover, a phase I study examined the toxicity
and efficacy of sequential administration of sapacitabine and roscovitine in patients with
advanced solid tumors [329]. Sapacitabine is a prodrug of the nucleoside analog 2′-Ccyano-2′-deoxy-1-β-D-arabino-pentofuranosylcytosine (CNDAC), that can induce SSBs that
develop into DSBs [344]. These patients received sapacitabine daily for days 1-7,
roscovitine days 8-10, followed by 11 days off. Here the MTD for roscovitine (in combination
with sapacitabine) was found to be 1200 mg, with dose limiting toxicities being reversible
neutropenia and increased transaminase levels. Of the 27 patients, two patients with either
breast or pancreatic cancer, both BRCA mutation carriers, had a partial response.
Additionally, 6 patients had SD for at least 12 weeks, including a BRCA mutation carrier
patient with ovarian cancer for over 24 weeks. It was suggested that BRCA mutations could
be a marker for response to the sapacitabine and roscovitine combination [329]. Overall,
more studies are needed to confirm the clinical efficacy of roscovitine, especially in
combination with DNA damaging agents.
2.1D HYPOTHESIS AND SPECIFIC AIMS
Despite showing encouraging results when combined with DNA-damaging agents
(and targeted therapies), little has been done to develop a combination treatment strategy in
TNBC with CDK inhibitors. While others have shown that over-activation of the oncogene
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Myc causes sensitivity to CDK inhibition in TNBC cells, this strategy again only examines
CDK inhibition in a monotherapy setting [345]. As previously described, due to defects in
cell cycle regulation, cancer cells continuously proliferate even in the presence of DNA
damage, with TNBC tumors initially responding to chemotherapeutics (Table 2).
Anthracyclines, including topoisermase II inhibitors doxorubicin and epirubicin, are used in
the standard of care of TNBC and are often used in combination therapy (Table 7) [179].
Therefore, we hypothesized that combining CDK inhibitor roscovitine with the
chemotherapeutic doxorubicin would cause increased cell death only in TNBC cells. To
address this hypothesis the following, specific aims were examined:
•

Determine the cell cycle response of HMEC, ER positive and TNBC cells to
roscovitine treatment.

•

Investigate the inhibitory effect of combination treatment of roscovitine and
doxorubicin on HMEC and TNBC cells.

•

Examine combination-induced cytotoxicity in TNBC and HMEC cells.

•

Establish combination treatment in a pre-clinical in vivo model system.

Overall, the data presented in this chapter demonstrates that roscovitine treatment induced
a significant G2/M arrest specifically in TNBC cells. Analysis using the Chou-Talalay
method revealed that only sequential administration of roscovitine followed by doxorubicin
induced synergistic cell inhibition only in TNBC cells, not in HMEC cells [346]. Moreover,
administration of roscovitine prior to doxorubicin increased apoptosis only in TNBC cells
compared to single drug treatment. Finally, a xenograft model of TNBC cells found that
combination treatment was well tolerated and significantly decreased tumor growth and
increased overall survival compared to single agent treatment.
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2.2 MATERIALS AND METHODS
2.2A CELL CULTURE
The immortalized human mammary epithelial (HMEC) cell lines 76NE6 and 76NF2V
were obtained from Dr. V. Band (University of Nebraska Medical Center) and MCF10A cells
were obtained from the American Type Cell Culture Collection (ATCC; Manassas, VA).
These cells were maintained in DCFI-1 medium in culture as described previously [347]. The
breast cancer cell lines MDA MB 157, MDA-MB-231 and HCC1806 cells were obtained from
the ATCC and maintained in complete alpha medium [347]. The breast cancer cell lines
MCF-7, ZR75-1, T47D and MDA MB 468 was obtained from the ATCC and maintained in
complete Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% fetal calf
serum (FCS). All reagents were purchased from Sigma-Aldrich (St. Louis, MO) unless
stated otherwise. All cells were kept in a humidified incubator in a 6.5% CO2 atmosphere at
37°C. All cells were tested for mycoplasmal contamination, and their identities were verified
via karyotype analysis. Breast cancer cell line hormone receptor, HER2 and p53 and Rb
status are available in Table 12.

Table 12. Breast cancer cell lines examined
Cell Line
ER
PR
HER2
MCF10A
76NE6
76NF2V
HCC1806
MDA MB 157
MDA MB 231

-

-

-

-

-

-

+
+
-

+

MDA MB 468
MCF7
+
T47D
+
ZR75-1
+
Adapted from: [347, 348]

p53 status
WT
Degraded by HPV-6
WT
Mutant
Mutant
Mutant
Mutant
WT
Heterozygous Mutant
WT
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Rb status
WT
WT
WT
Functionally
inactive
Functionally
inactive
Functionally
inactive
WT
WT
WT

2.2B DRUGS
Roscovitine, provided by Dr. Laurent Meijer (National Center for Scientific Research,
Paris France), was diluted to 10 mM in dimethyl sulfoxide (DMSO). Doxorubicin-HCl
(Bedford Laboratories, Bedford, OH) was reconstituted in a 0.9% sterile saline solution at 2
mg/mL and shielded from light. Staurosporine (Sigma-Aldrich) was diluted to 2.14 mM in
DMSO.
2.2C FLOW CYTOMETRY
Cells were seeded in 10 cm dishes at 3.5 x 105 cells per plate to examine cell-cycle
phases in response to drug treatment. Cells were then treated with roscovitine at 20 µM for
24 hours. Following treatment, cells were fixed and stained to measure their DNA content
as described previously [285]. Briefly, cells were resuspended and fixed in 1.5 mL of cold
phosphate-buffered saline (PBS) and 3.5 mL of cold ethanol overnight. Cells were then
washed with PBS, resuspended in PBS containing 10 µg/mL propidium iodide, RNase A,
Tween 20, and bovine serum albumin and incubated at 4°C overnight. Prior to measuring
their DNA content, cell samples were incubated for 1 hour at 37°C. Samples were analyzed
at The University of Texas MD Anderson Cancer Center Flow Cytometry and Cellular
Imaging Facility using a Beckman Coulter Gallios Flow Cytometer (Indianapolis, IN)
equipped with the Kaluza software program (Beckman Coulter).
2.2D HIGH-THROUGHPUT SURVIVAL ASSAY
To assess the effect of combination drug treatment on HMEC and TNBC cell lines,
cells were subjected to a high-throughput survival assay (HTSA) as described previously
(Figure 3) [349]. Briefly, for all combinations cells were seeded in 96-well plates (Table 13).
We administered the roscovitine and doxorubicin combination drug treatment
simultaneously and sequentially, in both directions (Figure 3 A, B). For concomitant drug
administration, cells were treated for 72 hours with roscovitine and doxorubicin
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simultaneously (Table 14, R+D). For sequential drug administration, cells were treated with
drug A at the 10% inhibitory concentration (IC10), IC25, and IC50 for 24 hours. Following drug
A treatment, the medium was removed from the wells, and cells were treated with drug B at
the IC10 to the IC50 for 48 hours, equaling 72 hours of total drug treatment (Table 14, D R,
RD). Following the completion of 72 hours of drug treatment, the medium in the wells was
replaced with fresh-drug free medium. Every 96-well plate contained cells that remained
untreated as controls. Controls for treatment with drug A or drug B only were also included.
The drug-free medium was changed every 48 hours for 9 days. Nine days after the removal
of drug B, the plates were subjected to a (3-(4, 5)-dimethylthiazol-2-yl)-2, 5diphenyltetrazolium bromide (MTT) assay (2.5 mg/mL; Sigma-Aldrich), incubated for 4 hours
at 37°C, and solubilized (0.04 N HCl and 1% sodium dodecyl sulfate [SDS], in isopropyl
alcohol). Absorbance was read at 590 nM using Epoch microplate spectrophotometer with
the Gen5 software program (BioTek, Winooski, VT). Isobolograms and combinational
indices were generated using the CalcuSyn software program (Biosoft, Cambridge, UK).

Table 13. Cell number/well seeded for HTSA
Cell Line
MCF10A
MDA MB 157
MDA MB 231
MDA MB 468

Cells/well
1000
3500
1500
2000

Table 14. Drug concentrations used for combination treatment
R+D
D
R
R
D
D
R
Cell Line
(µM)
(nM)
(nM)
(µM)
IC10, 25, 50
IC10-IC50
IC10, 25, 50
IC10-IC50
MCF10A
7,10,18
6-13
12,22,30
1-12
MDA
5,9,15
4-8
9.5,12,17.5
4-26
MB157
MDA MB
5,18, 25
5-18
1,3,6
2-20
231
MDA MB
10,12,15
5-9
1, 22, 25
1-16
468
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R
D
R
(µM)
IC10, 25, 50
9, 11, 13

D
(nM)
IC10-IC50
1-20

8, 22, 32

1-15

6, 18, 24

5-42

1, 10, 24

2-21

Figure 3.. Schematic illustrating the HTSA using both simultaneous (A) and
sequential (B) drug administration
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2.2E DYE-EXCLUSION ASSAY
To examine cell viability, cells were subjected to a dye-exclusion assay. Cells were
seeded at 3.5 x 105 cells per plate and treated with roscovitine for 24 hours, followed by
doxorubicin for 48 hours at IC50 concentrations (Table 14). Roscovitine and doxorubicin only
treated cells were used as single drug controls. Untreated and staurosporine-treated cells
served as negative and positive controls, respectively. Cells were harvested at indicated
times, and cell pellets were washed with cold PBS. Following centrifugation, pellets were
resuspended in PBS, and propidium iodide was added to each harvested sample at a final
concentration of 2 µg/mL prior to flow cytometric analysis using an LSR II flow cytometer
equipped with the CellQuest Pro software program (BD Bioscience).
2.2F CASPASE ACTIVITY LUCIFERASE ASSAY
A Caspase-Glo 3/7 (Promega, Madison, WI) assay was used to measure caspase
activity in HMEC and TNBC cells in response to single and combination drug treatment.
Cells were seeded in 96-well white-walled plates (Table 13). After 24 hours, cells were
treated with roscovitine and doxorubicin at the IC50 concentrations for 24 and 48 hours,
respectively (Table 14). Caspase 3/7 activity of the cells was measured after single
(roscovitine or doxorubicin) and combination (roscovitine followed by doxorubicin) treatment
according to the assay manufacturer’s protocols. The luciferase activity was deteced using a
Synergy H4 hybrid microplate reader equipped with the Gen5.1.1 software program
(BioTek). Readings of wells containing media only were subtracted from all experimental
values.
2.2G WESTERN BLOT ANALYSIS
To extract protein lysates from cells for Western blot analysis, cells were harvested
following indicated treatments. Cells were washed with cold PBS, trypsinized (0.25%), and
centrifuged. Next, cell pellets were washed with cold PBS and centrifuged again. Cell pellets
were lysed with RIPA buffer (150 mM NaCl, 10 mM Tris, pH 7.3, 0.1% SDS, 1% Triton X-
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100, 1% deoxycholate, and 5 mM ethylenediaminetetraacetic acid) containing protease
inhibitors, with occasional vortexing. Cell pellets were centrifuged at 16,000 rpm for 60
minutes, with supernatant containing protein lysates. Western blot analysis was performed
to examine protein expression in HMEC and TNBC cells as described previously [350].
Briefly, the protein lysate was subjected to electrophoresis on an SDS-polyacrylamide
electrophoresis gel and transferred to Immobilon-P membranes overnight at 4°C at 35 mV.
Blots were blocked with BLOTTO milk for 1 hour at room temperature and incubated with
primary antibody overnight at 4°C. Antibodies against PARP-1 (Cell Signaling Technology,
Beverly, MA) and actin (EMD Millipore, Billerica, MA) were used to probe for protein
expression. Blots were incubated with goat anti-rabbit or goat anti-mouse immunoglobulinhorseradish peroxidase-conjugates at a dilution of 1:5000 in BLOTTO for 1 hour (Pierce,
Rockford, IL). Blots were then washed and developed using a Renaissance
chemiluminescence system (Perkin Elmer Life Sciences, Inc., Boston, MA) as directed by
the manufacturer. Image J was used to perform densitometry analysis.
2.2H TRANSFECTION
To generate transient knockdown cells, HMEC and TNBC cells were seeded for 96well plates for survival analysis or 6-well plates for flow cytometry or Western blot analysis
according to manufacture protocols (Thermo Scientific Transfection Dhramafect siRNA
Transfection Protocol). Thermo Scientific siGENOME smart pool siRNA, including siControl
pool #1, siCDK1 and siCDK2, were resuspended according to the manufacture’s protocol at
100 µm. Cells were transfected with siRNA targeting CDK1, CDK1 or both using the
transfection reagent Dharmafect formulation 1 according to the manufacture’s protocol
(Thermo Scientific). Non-coding siControl pool #1 was used as a negative control. Cells
were harvested 48 hours post transfection or as indicated for Western blot analysis and flow
cytometry. Cells were subjected to MTT for survival analysis 9 days after removal of
doxorubicin.
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2.2I XENOGRAFT MODEL
To develop a pre-clinical model, four-week old nude mice were injected with 4.5 million MDA
MB 468 cells in a 1:2 ratio with matri gel (BD Bioscience) into mammary fat pads four and
nine of the mouse. Once the tumor reached a volume (L x W 2 /2) of 100-150 mm3, mice
were treated with vehicle + vehicle, roscovitine (50 mg/kg) 4 days on/3 days off, doxorubicin
(2mg/kg) once a week, or 4 days of roscovitine followed by one day of doxorubicin for four
cycles. All drugs were administered i.p. Roscovitine was diluted at 100 mg/ml in DMSO and
then further diluted to 10 mg/ml in a carrier solution consisting of 10% Tween 80 (Sigma
Aldrich), 20% N-N-dimethylacetamide (Acros Organics, Geel, Belgium) and 70%
polyethylene glycol 400 (Sigma-Aldrich) [351]. Tumor volume and weight were measured
twice a week. Mice were sacrificed if their total tumor burden reached 1500 mm3, tumors
became ulcerated or inhibited mouse movement or if mice loss 20% of initial body mass.
Mice were housed five per cage in sterilized micro-isolator cages (Lab Products, Seaford,
DE) furnished with corncob bedding. Mice received care in accordance with the Animal
Welfare Act, the National Institutes of Health “Guide for the Care and Use of Laboratory
Animals,” and the institutional guidelines of the MD Anderson Cancer Center.
2.2J WESTERN BLOT ANALYSIS OF TUMOR TISSUE
Following surgical resection, tumors were snap frozen in liquid nitrogen. Protein
lysates were extracted via sonication in a protease inhibitor solution as previously described
[352]. Homogenates were centrifuged at 45,000 g for 45 minutes. Supernatants were
subjected to Western blot analysis. Blots were probed with anti-PARP1 antibody (Cell
Signaling Technology, Beverly, MA).
2.2K STATISTICAL ANALYSIS
The Student t-test with a 95% confidence interval was performed to determine p
values. P values less than 0.05 were considered significant. Survival analysis was
performed using the Mantel-Cox test.
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2.3 RESULTS
2.3A ROSCOVITINE INDUCES A G2/M ARREST IN TNBC CELLS
To investigate how breast cancer subtype and G1 checkpoint status (Table 12)
would affect response to CDK inhibition, the HMEC cell line MF10A, the ER positive cell line
MCF7 and the TNBC cell line MDA MB 231 were treated with roscovitine for 24 hours
followed by cell cycle analysis via flow cytometry. p53 wildtype HMEC and ER positive cells
had 70 or 60% of cells in G1, respectively. However, over 60% of p53 mutant MDA MB 231
cells accumulated in the G2/M phase (Figure 4A). To examine the effect of CDK inhibition
on G2/M accumulation, a wide panel of HMEC (MCF10A, 76NF2V and 76NE6), ER positive
cells (MCF7, T47D and ZR75-1) and TNBC (MDA MB 157, MDA MB 231, MDA MB 468 and
HCC1806) cells were treated with roscovitine for 24 hours followed by cell cycle analysis.
Roscovitine induced a 10 percent or less increase in G2/M phase in HMEC cells MCF10A
and 76NF2V. However, roscovitine caused a significant (pvalue < 0.001) 20% increase in the p53 inactive 76NE6 cells (Figure 4A, B). Similar to
HMEC cells, roscovitine induce a 10% or less increase in G2/M of ER positive cells. In
comparison, all four TNBC cell lines exhibited a significant (p-value < 0.05) increase in the
G2/M phase in response to treatment, with MDA MB 231 cells having over a 25% increase
in cells in G2/M (Figure 4B, C). Roscovitine treatment enriched the G2/M population of the
TNBC cell lines examined to 40-60 percent, compared to the non-TNBC cells with 30
percent or less accumulating in G2/M (Figure 4C). 76NE6 cells were the exception to the
trend detected in HMEC cells, with 60% of cells accumulating in the G2/M phase following
roscovitine treatment (Figure 4C). These data suggests that the roscovitine-induced G2/M
arrest is subtype and p53 mutant status specific.

73

Figure 4. Roscovitine-induced
induced G2/M accumulation is cell
cell-type
type and p53 status specific.
specific
A, HMEC, ER-positive
positive and TNBC cells were treated with roscovitine (R) for 24 hours
followed by cell cycle analysis via flow cytometry
cytometry. Untreated
d cells served as a control (C).
(C) B,
Percent change in G2/M phase cells due to roscovitine treatment. C, Cell cycle analysis of a
panel of HMEC, ER positive and TNBC cells in response to roscovitine
roscovitine.. Percent of cells
G2/M phase plotted.. Mean ± SD.
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2.3B SEQUENTIAL ADMINSTRATION OF ROSCOVITINE FOLLOWED BY
DOXORUBICIN INDUCES SYNERGISTIC CELL INHIBITION ONLY IN TNBC CELLS
To investigate if the roscovitine-induced G2/M arrest in TNBC cells can be exploited
to develop combination therapy, we subjected TNBC and HMEC cells to HTSA. We
combined the clinically available chemotherapeutic doxorubicin with roscovitine both
concomitantly and sequentially (Figure 3A, B). CalcuSyn, which quantifies synergy using the
Cho-Talalay method, generates combination indices (CI) that determine if a combination is
antagonistic (CI >1), additive (CI = 1) or synergistic (CI<1) [346]. The CI values
demonstrated that concomitant treatment induced an antagonistic response in all cell lines
(Figure 5A, left panel). Sequential administration of doxorubicin treatment prior to
roscovitine also induced antagonism in all cell lines (Figure 5A, middle panel). Strikingly,
administration of roscovitine prior to doxorubicin induced synergism in TNBC cell lines, but
antagonism MCF10A cells (Figure 5A, right panel). Sequential administration of roscovitine
and doxorubicin had a significantly lower (p-value < 0.05) CI value in all TNBC cell lines
compared to simultaneous treatment or administration of doxorubicin prior to roscovitine
(Figure 5A). Therefore, combination treatment can specifically inhibit TNBC cells and not
HMEC cells.
Since roscovitine can inhibit multiple CDKs, we examined whether inhibition of
CDK1, CDK2 or both CDKs simultaneously was required for synergism with doxorubicin
treatment. MCF10A and MDA MB 468 cells were transiently transfected with siRNA against
either CDK or both, with non-targeting siRNA used as a control. Cell viability was assessed
on day 12 with MTT. While knockdown of CDK1 or both CDKs reduced cell viability in
MCF10A cells by 60%, there was no further reduction in viability with the addition of
doxorubicin. Knockdown of CDK2 did not decrease percent viability, however the addition of
doxorubicin again reduced viability by 60% in MCF10A cells (Figure 5B). Transient
knockdown of CDK1 or both CDKs simultaneously reduced viability by about 50% in MDA
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MB 468 cells, whereas knockdown of CDK2 caused only 20% cell inhibition. However, the
addition of doxorubicin to CDK1 or CDK1/CDK2 knockdown caused 90% cell inhibition in
MDA MB 468 cells (Figure 5B). This suggests that inhibition of CDK1 combined with
doxorubicin treatment is sufficient to induce synergistic cell inhibition in TNBC cells.
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Figure 5.. Sequential administration of roscovitine (R) and doxorubicin (D) induces
synergistic cell inhibition only in TNBC cells. A, MCF10A and TNBC cells were treated
with R and D simultaneously (R+D, left), D preceding R (D
(DR,
R, middle) or R preceding D
(R D, right). Isobolograms and CI values were generated using CalcuSyn. B, MCF10A
and MDA MB 468 cells were transfected with either non
non-targeted
targeted siRNA (siControl) or siRNA
targeting CDK1, CDK2 or both. Western blot analysis confirmed knockdown (left). Percent
Perce
viability with and without doxorubicin treatment was assessed by MTT on day 12 (right).
Mean ± SD.
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2.3C COMBINATION TREATMENT INCREASES APOPTOSIS SPECIFICALLY IN TNBC
CELLS
We used a luciferase caspase 3/7 assay to examine the apoptotic response of
HMEC and TNBC cells to single and combination treatment. No increase in caspase 3/7
activities was detected in MCF10A cells. While doxorubicin and combination treatment did
significantly increase caspase activity in TNBC cells compared to untreated cells (p-value <
0.05), there was no significant difference between the caspase activities of doxorubicin
versus combination treated TNBC cells (Figure 6). These data suggested that both single
and combination treatment induced apoptosis, but does not account for the synergistic cell
inhibition measured only in TNBC cells

Caspase 3/7 activity
(RLU normalized)

Caspase 3/7 activity
120

*

** *

80

Control
Roscovitine
Doxorubicin
R-->D
* p-value < .05
** p-value < .01
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n=3
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7
M
D
A

M
B

M
B
M
D
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Cell Line
Figure 6. Doxorubicin and combination treatment induce caspase 3/7 activity. HMEC

and TNBC cells were treated with single or combination drug treatment and
subjected to a luciferase assay to measure caspase 3/7 activity.
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Since caspase activity during drug treatment could not account for the synergistic
response of combination treatment in TNBC cells, cell death was examined in TNBC and
HMEC cells using a dye-exclusion assay in response to single and combination treatments
both during and following drug treatment. Cells were subjected to a dye-exclusion assay
with propidium iodide (PI). PI positivity is detected via flow cytometry when the cell
membrane is compromised, a characteristic of apoptosis [353]. Roscovitine-induced PI
positivity peaked at 24 hours post drug exposure (Figure 7A, left). Doxorubicin treatment
steadily reduced cell viability over time; with MDA MB 157 cells showing over 30% PI
positivity on day 12 (Figure 7A, right). When the drug was present, combination treatment
induced 15% PI positivity in MCF10A cells, but induced 45% and 30% PI positivity in MDA
MB 157 and MDA MB 468 cells, respectively (Figure 7, right). Moreover, only TNBC cells
continued to exhibit decreased cell viability, or PI positivity, after release from treatment.
MDA MB 157 cells had over 50% PI positivity 72 hours after being released from treatment,
while MDA MB 468 cells had over 25% PI positivity 120 hours after being released from
treatment (Figure 7A). These data demonstrate that the combination treatment inhibited
TNBC cell recovery, causing the cells to continue to die after treatment and to a greater
extent than HMEC cells.
Western blot analysis was performed to detect PARP-1 cleavage, a marker of
apoptosis. Densitometry analysis was used to measure the ratio of cleaved PARP-1 to full
length PARP-1. Staurosporine treatment, used as a positive control, induced PARP-1
cleavage in HMEC and TNBC cells (Figure 7B). MCF10A cells did not induce PARP-1
cleavage in response to treatment above basal levels. TNBC cells expressed cleaved
PARP-1 both during and after release from combination treatment. MDA MB 157 cells had
the highest ratio of PARP-1 cleavage at 48 hours into combination treatment, and
maintained cleaved PARP-1 expression until 72 hours post release (Figure 7B). MDA MB
468 cells had the highest ratio of PARP cleavage 24 hours into combination treatment, and
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also had a sustained apoptotic signal until 72 hours post release (Figure 7B). The
persistence of cleaved PARP-1 expression, similar to the continuous PI positivity, indicates
that TNBC cells continued to undergo apoptosis after treatment. These data demonstrate
that combination treatment inhibits cell recovery, leading to a persistent apoptotic signal only
in TNBC cells.
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Figure 7.. Combination treatment induces prolonged apoptosis only in TNBC cells. A,
HMEC and TNBC cells were treated with roscovitine (R) for 24 hours, doxorubicin (D) for 48
hours,, or roscovitine preceding doxorubicin (RD) at IC50 concentrations.. Staurosporine
(S) treatment was used as a positive control. Cells were harvested at indicated times and
subjected to a dye-exclusion
exclusion assay using propidium iod
iodide
ide (PI). B, HMEC and TNBC cells
were treated with R, D or R preceding D and harvested at indicated times. Western blot
analysis was used to detect full
full-length and cleaved PARP1. Full PARP-1 and cleaved
PARP-1 bands were quantified with Image J (ratio = cl
cleaved/full PARP-1).
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To determine if inhibition of CDK1, CDK2 or both is required for inducing apoptosis
with doxorubicin, MCF10A and MDA MB 468 cells were transiently transfected with siRNA.
Samples were harvested immediately after treatment and 48 hours post treatment. Cleaved
PARP-1 expression was detected in all conditions in MCF10A cells immediately after
treatment; however, the addition of doxorubicin to CDK knockdown did not increase cleaved
PARP-1 expression. Indeed, simultaneous CDK1 and CDK2 knockdown plus doxorubicin
had the least PARP cleavage in MCF10A cells (Figure 8A). In contrast, knockdown of
CDK1, CDK2 or both increased PARP-1 cleavage in MDA MB 468 cells compared to
siControl transfected cells. Moreover, the addition of doxorubicin to CDK knockdown
increased cleaved PARP-1 expression (Figure 8C). Forty-eight hours post treatment,
MCF10A knockdown and combination treated cells showed complete recovery, expressing
only full-length PARP (Figure 8B). However, MDA MB 468 cells had persistent cleaved
PARP1 expression in both transient knockdown cells and in cells that had CDK knockdown
with doxorubicin 48 hours post treatment (Figure 8D). These findings reveal that TNBC cells
cannot recover from potent CDK inhibition or CDK inhibition combined with doxorubicin,
leading to an enduring apoptotic signal.
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Figure 8. TNBC cells cannot recover from CDK inhibition plus doxorubicin. (A, B)
MCF10A and (C, D) MDA MB 468 cells were transfect
transfected
d with siRNA with or without
doxorubicin treatment. Cells were harvest
harvested directly after treatment (A, C)) and 48 hours
post treatment (B, D).
). Western blot analysis was used to detect PARP1. Full PARP and
cleaved PARP bands were quantified with Image J (ratio = cleaved/full PARP).
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2.3D ROSCOVITINE-DOXORUBICIN COMBINATION INHIBITS TUMOR GROWTH AND
INCREASES SURVIVAL
To examine combination treatment in a pre-clinical model, MDA MB 468 cells were
used to generate human xenograft tumors in nude mice. There were four treatment arms:
vehicle, roscovitine (50 mg/kg) for 4 days on 3 days off, doxorubicin (2mg/kg) once a week
and roscovitine (4 days) followed by 1 day of doxorubicin, 3 days off, all given for 4 cycles.
Mice began receiving treatment when tumors reached a volume of 100-150 mm3.
Combination treated tumors did not increase in volume while on treatment, with tumors
averaging at 125 mm3 on day 26. Combination treated tumors were significantly smaller (pvalue <0.01) than vehicle treated tumors that averaged 330mm3 on day 26. Moreover,
combination treated tumors were significantly smaller (p-value <0.05) than both roscovitine
and doxorubicin treated tumors at the end of treatment (Figure 9 A, B). Following drug
treatment, combination treated tumors remained significantly reduced compared to the other
three treatment arms (Figure 9A). Notably, no measurable difference was observed
between vehicle and roscovitine treated mice; supporting clinical findings that roscovitine is
inefficient as a single agent.
None of the combination treated mice suffered from increased toxicity or tumor
burden during the 60-day experiment. As such, combination therapy significantly increased
overall survival (p-value < 0.05) compared to vehicle, roscovitine and doxorubicin treated
mice (Figure 9C). It is imperative to ensure that novel combination therapies do not cause
increased toxicity. Overall toxicity was assessed by weight loss during and following
treatment. Based on weight loss, combination therapy did not increase toxicity (Figure 9D).
Roscovitine treatment also did not cause weight loss toxicity (Figure 9D). However, 80% of
doxorubicin treated mice had to be sacrificed due to >20% weight loss, again revealing the
limitations of doxorubicin as monotherapy (Figure 9D, Table 15).
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Western blot analysis of PARP-1 on tumors resected on day 26 found that
combination therapy significantly increased apoptosis (p-value <0.05) compared to
doxorubicin treated tumors. Also, p21 expression was not detected in any of the tumors
(Figure 9E). Overall, this data suggests that roscovitine-doxorubicin combination therapy is
both well tolerated and efficacious against TNBC, supporting future clinical studies.
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Figure 9. Combination treatment reduces tumor growth and increases overall
survival without increasing toxicity. Mice were treated with vehicle, roscovitine (50
mg/kg 4 days on, 3 days off), doxorubicin (2mg/kg once a week), or roscovitine followed by
doxorubicin for 4 cycles. A, Tumor volume (L x W2 / 2) was measured twice a week. B,
Representative tumors shown of the four treatment arms were resected at the end of
treatment on day 26. Statistical analysis based on tumor volume. C, Kaplan-meier curve
was generated to examine mouse overall survival. Survival analysis was performed using
the Mantel-Cox test. D, Mouse weight was measured twice a week. Percent change from
weight at start of treatment is shown at times indicated. E, Western blot analysis examining
PARP-1 in protein lysates from tumors resected on day 26.
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Table 15. Cause of euthanasia/death
Euthanasia due to tumor
burden
(%)
Vehicle
100
Roscovitine
100
Doxorubicin
20
Roscovitine  Doxorubicin
0
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Euthanasia due to weight
loss/deteriorated health
(%)
0
0
80
0

2.4 CONCLUSIONS
Roscovitine treatment causes a G2/M arrest exclusively in TNBC cells that can be
exploited to augment the doxorubicin-induced apoptotic response. The G2/M arrest
detected only in TNBC cells suggests that the molecular characteristics that differentiate
TNBC cells from non-TNBC cells can be exploited to target the cell cycle. Roscovitine also
induced a G2/M arrest in HMEC 76NE6 cells, which share the TNBC cell characteristic of
p53 inactivity. This similarity could be indicative of a marker for response, which will be
thoroughly investigated in Chapter 3.
Combination treatment caused a sustained cell death signal specifically in TNBC
cells. However, neither single or combination treatment caused a significant amount of
apoptosis in HMEC cells. The prolonged combination-induced apoptotic response in TNBC
cells inhibited cell recovery. Although roscovitine is a pan-CDK inhibitor, transient
knockdown of CDK1 and CDK2 revealed that inhibition of CDK1 is sufficient to induce
synergism with doxorubicin in TNBC cells. Moreover, the addition of doxorubicin to CDK
knockdown cells also caused an increased apoptotic signal only in TNBC cells. These data
validate the hypothesis that it is possible to induce synergistic cell death in TNBC cells while
leaving non-malignant cells unharmed.
In vivo pre-clinical studies must be performed to translate a novel therapy to the
clinic. Although both roscovitine and doxorubicin have been clinically examined, welltolerated single agents can have increased toxicities when combined. For example, 27% of
patients had cardiac dysfunction when treated with trastuzumab and an anthracycline [221].
However, our xenograft studies illustrate that combination treatment had increased efficacy
over single agents without causing increased toxicity. The drugs were again administered
sequentially. Other cancer models have corroborated the finding that the sequence of drug
administration affects combination efficacy and toxicity. For example, a colorectal cancer
pre-clinical model that examined the combination of the topoisomerase I inhibitor irinotecan
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with 5-FU administered simultaneously and in both sequences found that when each drug
was given at 50% MTD, irinotecan followed by 5-Fu caused the most growth inhibition
without additional toxicity. However, when the drugs were given at 75%, the same
sequence was 100% lethal [354]. These findings, along with our own studies, demonstrate
that combination sequence and dosage is crucial for maximizing efficacy while limiting
adverse effects, and will need to be closely monitored in the clinic.
The specificity of drug administration required for synergism also emphasizes that
the effectiveness of combination treatment is pathway driven. The concept of synthetic
lethality was born from genetic studies performed in drosophila that found that loss of one
gene was tolerated due to overcompensation in another pathway. However, when genes
from both pathways were inhibited, synthetic lethality occured [355]. This concept is now
being applied to cancer therapy in order to maximize therapeutic benefit and limit toxicities
[356]. PARP inhibitors, for instance, are synthetically lethal to cancer cells with BRCA
mutations because these cells heavily rely on BER to compensate for impaired HR [170,
262]. Studies performed in non-mammalian systems have also yielded potential synthetic
lethal therapies. Drug screenings done in yeast, a readily genetically modified system, found
that yeast with mutations in DNA HR proteins were especially sensitive to cisplatin [357].
These findings illustrate the benefit of using DNA damage agents in cancer cells with altered
or impaired DNA repair pathways to establish a synthetic lethality.
The roscovitine-doxorubicin combination can be considered synthetic lethal in TNBC
cells because it targets two major deregulated pathways in tumorgenesis, cell cycle
regulation and DNA damage response. Sporadic TNBC tumors are often characterized as
having a “BRCAness” phenotype, or have BRCA1/BRCA2 dysfunction or downregulation,
which is associated with deregulated HR and sensitivity to anthracycline-and platinumbased chemotherapies [242, 358-361]. While the cell lines used in this study are BRCA
wildtype, roscovitine has been shown to impair HR, one of the pathways that would be
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required to repair doxorubicin-induced DNA damage [362]. Cancer cells often upregulate
DNA repair pathways to survive assault from DNA-damaging agents used in therapy [356].
Therefore, by potentially inhibiting DNA repair with roscovitine while targeting anthracyclinesensitive TNBC cells with doxorubicin, we have generated a synthetic lethal combination.
The proceeding chapter will further elucidate the possible mechanism of TNBC sensitivity to
roscovitine-doxorubicin combination treatment.
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CHAPTER 3: ROSCOVITINE-DOXORUBICIN SYNTHETIC LETHALITY REQUIRES P53
PATHWAY ABLATION
3.1A EFFECT OF CHECKPOINT DEREGULATION ON THERAPEUTIC RESPONSE
Mutation or deregulation of checkpoint proteins Rb and p53 has been shown to affect
prognosis and response of cancer cells to therapy. Rb pathway deregulation can occur
through multiple mechanisms, including Rb gene mutations, cyclin D1
amplification/overexpression, CDK4 overexpression or point mutations, gene deletions or
epigenetic silencing of CKIs p16 and p14 (Table 2). Rb deregulation is often associated
with poor prognosis [363]. Loss of Rb heterozygosity was measured in 72% and 62% of the
more aggressive BLBC and Luminal B breast cancer subtypes, respectively [364].
However, the effect of deregulation of the Rb pathway on prognosis and therapeutic
response is subtype-specific. In patients with ER-positive tumors, the Rb-loss gene
signature correlated with decreased relapse free survival [363]. Notably, ablation of the Rb
pathway can reduce sensitivity to endocrine therapy and is associated with tamoxifen
resistance [365]. However, for patients with ER-negative tumors, the Rb-loss signature was
associated with improved relapse-free survival [363]. Disruption of the Rb pathway also
correlated to increased sensitivity to cisplatin and ionizing radiation in cell culture and in
xenograft models [365]. In accordance with these findings, an Rb-loss signature was
associated with increased pCR in both ER-positive and ER-negative breast cancer patients
who received neoadjuvant 5-FU/doxorubicin/cytoxan and taxane/doxorubicin chemotherapy
regiments [366]. The paradox of Rb-loss being attributed to more aggressive tumors, but
leading to increased sensitivity to DNA damaging agents, may be because cells that lack a
G1 checkpoint are more sensitive to chemotherapy [367, 368].
The effect of p53 mutations on prognosis and treatment response is less
straightforward. Similar to Rb, p53 is subject to a variety of gene mutations in cancer
including, missense or point mutations, gene amplification of the p53 inhibitor MDM2, GOF
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mutations and inhibition from viral oncogenic proteins (Table 2) [90]. The impact of
compromised p53 function on treatment response may be dependent on the type of
mutation present [369]. Examination of 60 cell lines, including breast, prostate, lung, colon,
kidney, ovarian cancer, leukemia and melanoma cell lines, against 123 anti-cancer agents
found that p53 mutant cell lines tended to be more resistant to the growth inhibitory effects
of most compounds, including DNA cross-linking agents, antimetabolites and topoisomerase
I and II inhibitors, compared to p53 wildtype cell lines. However, response to antimitotic
agents was independent of p53 status, indicating that the effect of p53 mutations on
treatment may also be dependent upon the agent used [370]. IHC analysis of p53
expression in tumors from NSCLC patients after receiving treatment found that aberrant
overexpression of p53 correlated to cisplatin resistance and reduced pathological response
[371]. However, disruption of p53 function via transfection of viral oncoprotein HPV-E6 or
expression of a dominant negative p53 mutant increased sensitivity of ER-positive breast
cancer cells MCF7 to cisplatin treatment in vitro. Here, it was hypothesized that G1
checkpoint deregulation and/or reduced NER contributed to increased cisplatin-sensitivity in
MCF7 p53 mutant breast cells [372]. Clinical studies found that mutations in the zinc
binding L2 and L3 domains of p53 (codons 163-195 and 236-251, respectively), which
interact with DNA, were associated with decreased survival and de novo resistance to
doxorubicin monotherapy in breast cancer patients [373, 374]. Moreover, meta-analysis of
2,319 breast cancer patients found that when using a relative hazard ratio (RH), in which
RH>1 indicates poor prognosis, node-negative and node-positive patients who had p53
gene alterations had an RH of 1.7 and 2.6, respectively. The RH >1 in both sets of patients
associated p53 mutations with more aggressive breast tumors [375]. Also, microarray
analysis of p53 wildtype and p53 mutant breast cancer tumors identified a 32-gene p53
signature. The study found that 89% of ER-negative tumors and 79% of grade III tumors
were classified into the p53-mutant cluster. Moreover the p53 gene-signature correlated
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with decreased disease free survival both in ER-positive breast cancer patients who
received adjuvant tamoxifen treatment and in ER-negative patients. Similarly, the gene
signature predicted that patients from the Sorlie, et al. study that received doxorubicin or 5FU and mitomycin and had tumors with p53-mutant like gene expression had a 35%
probability of 5-year survival compared to a 90% probability for patients with p53-wildtype
like expression [176, 376]. However, there was a significant correlation with premenopausal
breast cancer patients who had p53 overexpression (IHC) and response to treatment with
cyclophosphamide/methotrexate/5-FU [377]. Therefore, although there are some
inconsistencies in the literature on the effect of p53 dysfunction, p53 mutations are generally
correlated with more aggressive tumors that are refractory to treatment.
3.1B CYCLIN DEPENDENT KINASES PARTICIPATE IN DNA DSB REPAIR
Several DSB DNA repair proteins are substrates for CDKs. CDK phosphorylation
can affect function and complex formation of DNA repair proteins. Notably, CDK activity can
serve as a molecular switch between faithful DNA repair and more error-prone pathways
(Table 16).
Table 16. CDKs participate in DNA DSB repair
Substrate
CDK
Function
(Site)
Unknown, however, yeast studies indicate a
53BP1
role in checkpoint activation through Chk1
(Unknown)
CDK1

Unknown
(CDK1 or
CDK2)

CtIP
(T847)
BRCA2
(S3291)
CtIP
(S327)

Ref.
[378, 379]

Required for DNA end resection

[113]

Inhibits binding to Rad51

[380]

Required for CtIP/BRCA1/MRN complex
formation. Could serve as a switch between
HR and MMEJ
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[114, 381,
382]

As previously described, the MRN complex identifies DSBs for repair. The ATM
substrate p53 binding protein 1 (p53BP1) also accumulates at the site of damage to
facilitate recruitment of downstream repair proteins, such as BRCA1, and is required for
accurate intra-S phase and G2/M checkpoint activation [378, 383]. The CDK1-cyclin B
complex has been shown to phosphorylate 53BP1 both in vitro and in vivo in proliferating
mammalian cells. Moreover, treatment with roscovitine inhibited CDK1 phosphorylation of
53BP1 [379]. While the functional role of CDK1 phosphorylation of 53BP1 is currently
unknown in mammalian cells, yeast protein Cdc2 (CDK1 homologue) phosphorylates the
53BP1 orthologue Crb2 at T215 following DNA damage, leading to checkpoint activation
through Chk1 regulation [384, 385]. Cdc2 phosphorylation stimulates binding of the DNA
repair protein Cut5 (orthologue to human TopB1), which promotes Crb2 accumulation at the
DNA damage site and is required for Chk1 activation [385]. Further investigation is needed
to confirm the role of 53BP1 in activating Chk1 upon DNA damage in mammalian cells.
Following initial recognition of the damage site, to undergo HR, DNA end resection is
required at the damage site to generate single strands (Figure 2). Yeast studies
demonstrated that CDK1 phosphorylates the endonuclease Sae2 at Ser267, which is
required for DNA end resection [112, 386]. Moreover, mutating the Ser267 site on Sae2 to
prevent CDK phosphorylation resulted in hypersensitivity to the topoisomerase I inhibitor
camptothecin, indicating that CDK activity is necessary for repair of DSBs [386]. The human
orthologue of Sae2 is CtIP, which is recruited to DNA DSBs only during S and G2 for end
resection [387]. CDK1 also phosphorylates CtIP at Thr847. Treatment of U2OS cells with
roscovitine inhibited phosphorylation at the Thr847 site. Furthermore, U2OS cells with a
T847A mutation, which prevents CDK1 phosphorylation, were hypersensitive to
camptothecin. U2OS mutant cells that mimicked CtIP constitutive activation with a T847E
mutation were resistant to camptothecin treatment. Quantification of γ-H2AX revealed that
camptothecin caused similar amounts of DNA damage in CtIP mutants; however, T847A
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mutants had a significant reduction of RPA recruitment, which is downstream in the DNA
end resection pathway (Figure 2) [113]. The observation that CDK1 activity was required for
recruitment of downstream repair proteins, such as RPA, was corroborated in studies that
found that roscovitine treatment reduced the ability of sarcoma cells to recruit RPA when
exposed to ionizing radiation despite the formation of γ-H2AX foci [362]. Therefore, CDK
activity is imperative for end resection and the recruitment of downstream repair proteins
during HR.
CDK phosphorylation of CtIP is also important for DNA repair complex formation.
CtIP has an additional CDK phosphorylation site at Ser327, which is required for its
interaction with BRCA1 and MRN [381, 388]. The CtIP/MRN/BRCA1 complex occurs during
S and G2, with roscovitine treatment abrogating the IR-induced interaction between BRCA1
and MRN [381]. Moreover, CDK phosphorylation of CtIP at Ser327 may serve as a switch
between more accurate pathways of DNA repair (e.g. HR) and a recently discovered
process called microhomology-mediated end joining (MMEJ). MMEJ occurs during G1 of
the cell cycle phase and can repair DSBs in an error-prone manner that can contribute to
genomic instability [114]. MMEJ repairs DNA DSBs differently from NHEJ in that it involves
end resection followed by ligation of complimentary ends of DNA, resulting in nucleotide
deletions [382]. An avian B-cell line DT40 model system demonstrated that while HR is
dependent upon CDK phosphorylation at Ser327, MMEJ is not. However, CtIP may still
provide the endonuclease activity required for MMEJ. This suggests that inhibition of CDK
activity can lead to a more error-prone method of DNA repair of DSBs, with CDK
phosphorylation of CtIP serving as a switch between HR and MMEJ [114].
Paradoxically, CDK phosphorylation of the HR protein BRCA2 can inhibit its activity
[380]. BRAC2 facilitates loading of Rad51 onto the single strand filaments during HR
(Figure 2) [117]. BRCA2 has a CDK phosphorylation site at Ser3291 at its C-terminus.
CDK phosphorylation at Ser3291 prevents BRCA2 binding to Rad51 and is low during S-
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phase, but increases as cells enter mitosis during normal cell cycle progression. Due to the
increase in phosphorylation of BRCA2 specifically in nocodazole treated cells, which arrests
cells in mitosis, the CDK1-cyclin B complex is most likely responsible for BRCA2
phosphorylation. However, both CDK1-cyclin A and CDK1-cyclin B complexes could
phosphorylate BRCA2 in in vitro kinase assays. Exposure to IR reduced CDK kinase
activity and phosphorylation of BRCA2. Therefore, CDK phosphorylation impairs the
BRCA2-Rad51 interaction unless DNA DSBs are detected [380].
Overall, CDK activity has an important role in the recruitment and regulation of repair
proteins required for DNA DSBs. While necessary for checkpoint activation, complex
formation and DNA end resection, CDK activity must eventually be reduced in order for HR
to occur. Importantly, CDK activity ensures a more accurate mode of DSB repair. The
absence of CDK activity can lead to a reliance on MMEJ for DSB repair, which can cause
gene deletions and tumor-promoting chromosome rearrangements [114, 389]. Thus,
inhibiting CDKs could potentially compromise DNA repair, sensitizing tumor cells to DNAdamaging agents.
3.1C HYPOTHESIS AND SPECIFIC AIMS
Although the effect of G1 checkpoint deregulation on endocrine therapy and
chemotherapy has been examined, it is unknown what effect Rb and p53 pathway ablation
will have on combination treatment response. Moreover, CDK inhibition consistently
compromises HR, possibly forcing cells to rely on more error-prone DDR pathways and
increasing genomic instability. Therefore, we hypothesized that G1 checkpoint ablation is
required for roscovitine-doxorubicin-induced synergism in TNBC cells. This hypothesis was
addressed with the following specific aims:
•

Examine the effect of combination treatment on the cell cycle in HMEC and TNBC
cells.
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•

Investigate the effect of combination treatment on G1 checkpoint pathways in HMEC
and TNBC cells.

•

Determine how ablation of Rb and p53 pathways affects response to combination
treatment.

•

Elucidate the mechanism that predisposes TNBC cells to roscovitine-doxorubicin
combination sensitivity.

•

Examine the effect of combination treatment on DNA damage response and repair in
HMEC and TNBC cells.
The data presented in this chapter shows that TNBC cells maintain a G2/M arrest in

response to doxorubicin and sequential roscovitine-doxorubicin treatment, while HMEC
cells are able to activate their G1 checkpoint in response to treatment. Furthermore,
ablation of the p53 pathway, and not the Rb, is crucial to roscovitine-doxorubicin induced
synergism. Detection of DNA repair foci demonstrate that combination treatment increases
DNA damage explicitly in TNBC cells, while simultaneously reducing the ability of these
cells to recruit downstream HR repair proteins despite being arrested in the G2/M cell cycle
phase.
3.2 METHODS AND MATERIALS
3.2B CELL CULTURE
For medium ingredients and cell line origin of 76NE6, 76NF2V, MCF10A, MDA MB
157, MDA MB 231 and MDA MB 468 please see chapter 2.2A. The colorectal cancer cells
HCT116 p53 wildtype (p53+/+) and p53 knockout (p53-/-) were obtained from Dr. Junjie Chen
and maintained in DMEM supplemented with 10% FCS. HEK-293T cells for lentiviral
packaging were maintained in DMEM supplemented with 10% FCS.
3.2C DRUGS
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For origin and dilution of roscovitine and doxorubicin please see chapter 2.2B.
Etoposide (Sigma-Aldrich) was diluted in DMSO to 10 mM and used at 5 µM.
3.2D FLOW CYTOMETRY
Cells were seeded in 10 cm dishes at 3.5 x 105 cells per plate to examine cell-cycle
phases in response to single and combination drug treatment. After 24 hours, cells were
treated with roscovitine for 24 hours, doxorubicin for 48 hours or roscovitine followed by
doxorubicin at IC50 concentrations (Table 14). Cells were harvested after treatment and 24
hours-post treatment as indicated. For methods of cell harvesting and sample analysis
please see chapter 2.3C.
3.2E HIGH-THROUGHPUT SURVIVAL ASSAY
For procedures on HTSA, including method of drug administration, harvesting with
MTT and cell inhibition analysis, please see chapter 2.2D. Number of cells seeded and IC
concentrations of roscovitine and doxorubicin are found in Tables 17 and 18, respectively.

Table 17. Cell number/well seeded for HTSA
Cell Line
76NE6
76NF2V
HCT116 (p53+/+ and p53-/-)

Cells/well
150
1000
750

Table 18. Drug concentrations used for combination treatment (R
D)
R
D
Cell Line
(µM)
(nM)
(IC10, 25, 50)
(IC10-IC50)
76NE6
3, 6, 9
1-14
76NF2V
15, 20, 22
1-14
HCT116 (p53+/+ and p53-/-)
6, 12, 20
5-35

3.2F WESTERN BLOT ANALYSIS
For methods on protein lysate extraction, western blot analysis or protein detection,
please see chapter 2.2G. Antibodies against PARP-1, CDK1, total Rb and phospho-Rb
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(Ser807/811) (Cell Signaling Technology, Beverly, MA), CDK2 (Santa Cruz, Dallas, TX), p27
(BD Biosciences, San Jose, CA), p53, p21, and actin (EMD Millipore, Billerica, MA) were
used to probe for protein expression.
3.2G GENERATION OF STABLE KNOCKDOWN
To generate Rb stable knockdown in 76NF2V cells, HEK-293T cells were
transfected with lentiviral packaging vectors pMDG.2 and pCMV deltaR8.2 (produced by the
Didier Trono laboratory (Lausanne, Switzerland) and made available through the Addgene
repository) and lentiviral vector containing shRNA against Rb or scramble sequence
(University of Texas MD Anderson Cancer Center ShRNA and ORFeome Core Facility)
using LipoD293 transfection reagent (SignaGen, Rockville, MD) according to manufacturer’s
protocols. Virus-containing medium was filtered through 0.45 µM filters and directly added to
target cells in the presence of 8 µg/ml polybrene (Millipore). 76NF2V cells were selected in
2 µg/ml puromycin (InvivoGen, San Diego, CA) and maintained at half selection
concentration. Knockdown of Rb was confirmed via Western blot analysis.
3.2H TRANSFECTION
For the protocol used to transfect siRNA against CDK1, CDK2 or both CDKs in
HMEC and TNBC cells, please see chapter 2.2H
3.2I RT-qPCR
To measure transcription of p21, cells were subjected to roscovitine for 24 hours,
doxorubicin for 48 hours or both drugs sequentially at IC50 concentrations, with untreated
cells serving as a negative control (Table 14). Twenty-four hours of etoposide at 5 µM
treatment served as a positive control. Following drug treatment, cells were harvested and
RNA was extracted using the Qiagen RNeasy Mini Kit according to manufacturer’s protocols
(Venlo, Netherlands). Cell extracts were DNAase treated (Qiagen). Following RNA
extraction, cDNA was synthesized using a High Capacity cDNA Reverse Transcription Kit
(AB Biosystems, Foster City, CA) according to manufacturer’s protocols. Gene transcription
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of p21 was measured using SYBR Green Jumpstart Taq Ready Mix (Sigma-Aldrich) on a
7500 Fast Real-Time PCR System equipped with 7500 software version 2.3 (AB
Biosystems). Forward primer used for p21 was (5’-3’): ACTCTCAGGGTCGAAAACGG and
reverse primer was (5’-3’): CCTCGCGCTTCCAGGACTG (Sigma-Aldrich). Relative mRNA
was normalized to GAPDH.

3.2J NEUTRAL COMET ASSAY
A neutral comet assay was performed according to Trevigen (Gaithersburg, MD)
protocols to measure DNA double-strand breaks (DSBs) in HMEC and TNBC cells in
response to single and combination drug treatment. Briefly, following treatment with single
or combination drug treatment, cells were harvested from 10 cm dishes, combined with lowmelting agarose, and spread onto CometSlides (Trevigen). After allowing the cells to
adhere to the slides, cells were lysed with Trevigen lysis solution. The slides were then
placed in an electrophoresis chamber with neutral electrophoresis buffer. A current of 21 V
was used for 21 minutes. After drying, samples were stained with SYBR Green I and
allowed to dry at room temperature in the dark. Images of nuclei were captured using an
Eclipse 90i microscope equipped with the NIS-Elements Br 3.10 software program (Nikon,
Tokyo, Japan). The tail moment was measured using the CometScore software program
(TriTek, Sumerduck, VA).
3.3K IMMUNOFLUORESCENCE TO DETECT DNA REPAIR FOCI
For γ-H2AX and Rad 51 immunofluorescence, HMEC, TNBC and HCT116 p53+/+
and p53-/- cells were seeded on 8-well chamber slides (Thermoscientific, Rochester, NY)
and treated with roscovitine for 24 hours, doxorubicin for 48 hours or both drugs sequentially
all at IC50 concentrations (Table 14). Cells were fixed in 4% paraformaldehyde for 20
minutes followed by permeabilization with a 0.3% triton solution (20mM Hepes, 50mM NaCl,
3mM MgCl2, 300mM sucrose and TritonX-100) for 20 minutes. Cells were blocked in PBS
with 10% BSA and 2% horse serum for one hour. Antibodies were diluted 1:500 and 1:1000

101

for anti-γ-H2AX (EMD Millipore) and anti-Rad51 (generously provided by Dr. Junjie Chen),
respectively, and incubated at 4°C overnight. Secondary goat anti-mouse or goat anti-rabbit
antibodies (Alexa Fluor 594 and 488, respectively, EMD Millipore) were diluted at 1:750 and
incubated at room temperature at 1 hour. Nuclei were stained with DAPI (Life Technology,
Grand Island, NY) at 1µg/ml for 5 minutes at room temperature. Cells were mounted with
Dako fluorescent mounting medium (Carpentaria, CA). Images for quantification were
captured using the Olympus FV1000 Laser Confocal Microscope at 60X magnification
(Tokyo, Japan). Images for corresponding figures were captured using Eclipse 90i
microscope equipped with the NIS-Elements Br 3.10 software program at 100X
magnification. At least 100 cells were counted per sample per trial. Cells with ≥5 foci of γH2AX were considered positive. Cells with ≥1 foci of Rad51 were considered positive.
3.2L STATISTICAL ANALYSIS
The Student t-test with a 95% confidence interval was performed to determine p
values. P values less than 0.05 were considered significant. Mean ± SD.
3.3 RESULTS
3.3A SINGLE AND COMBINATION DRUG TREATMENT MAINTAIN A G2/M ARREST
ONLY IN TNBC CELLS
To determine the effect of single and combination treatment on the cell cycle, TNBC
and HMEC cells were treated with roscovitine (24 hours), doxorubicin (48 hours), or
sequential roscovitine-doxorubicin (cumulative 72 hours) at IC50 concentrations followed by
cell-cycle-phase FACS analysis. As seen in Figure 10, single and combination treatment
had little effect on the cell-cycle-phase profile of MCF10A cells, with over 70% cells
continuing to remain in G1. However, doxorubicin treatment induced over 20% polyploidy in
the TNBC cell line MDA MB 231, an effect that was maintained during combination
treatment (Figure 10A). Notably, following a 24-hour release from doxorubicin and
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combination treatment, 45% and 30% of MDA MB 231 cells had polyploid nuclei,
respectively. Doxorubicin reduced G1 phase cells in MDA MB 157 cells by 10% compared
to control. This G1 phase reduction was maintained in combination treatment, with nearly
30% cells entering polyploidy (Figure 10B). Fifty-percent of MDA MB 468 cells accumulated
in G2/M in response to doxorubicin and combination based treatment (Figure 10B). Unlike
HMEC cells that accumulated in G1, accumulation of TNBC cells in G2/M and/or induction of
polyploidy in response to combination treatment suggests that TNBC cells do not have an
intact G1 cell cycle checkpoint.
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Figure 10. Single and combination drug treatment induces a G2/M arrest and
polyploidy only in TNBC cells. A, MCF10A and MDA MB 231 cells were treated with
roscovitine, doxorubicin or roscovitine followed by doxorubicin and subjected to cell cycle
analysis via flow cytometry. G
Graphs, generated using Kaluza,, are representative of three
trials. B, HMEC and TNBC
BC cells were treated with single and combination treatment
followed by flow cytometry. Three trials were performed per cell line.
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3.3B KNOCKDOWN OF CDK1 IS SUFFICIENT TO AUGMENT G2/M ARREST WITH
DOXORUBICIN
To determine if inhibition of CDK1, CDK2 or both is required for the G2/M arrest and
induction of polyploidy in TNBC cells, we transiently transfected HMEC and TNBC cells with
siRNA with and without the addition of doxorubicin (IC50 concentration) followed by cell cycle
analysis. Western blot analysis of CDK1 and CDK2 confirmed knockdown (Figure 11A).
Cell cycle analysis revealed that MCF10A cells only had about a 10% increase in G2/M
upon CDK knockdown, with the addition of doxorubicin either reverting cells to a G1
accumulation (70-80%) or causing no change (Figure 11B). In TNBC cells, knockdown of
CDK1 or CDK1/CDK2 lead to a G2/M accumulation that was augmented with the addition of
doxorubicin. Indeed, 80% of MDA MB 468 cells accumulated in the G2/M cell cycle phase
when knockdown of CDK1 was combined with doxorubicin treatment, demonstrating a 20%
or 40% increase in G2/M cells compared to knockdown or doxorubicin treatment alone,
respectively. There was no additional gain in the G2/M phase when both CDKs were
knocked down in the presence of doxorubicin compared to CDK1 knockdown plus
doxorubicin in TNBC cells (Figure 11B). Therefore, while HMEC cells arrest in G1 in
response to CDK inhibition and/or doxorubicin treatment, TNBC cells (with p53 mutations
and Rb pathway inactivation) may lack the ability to arrest in G1, forcing them to accumulate
in G2/M.
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Figure 11. Knockdown of CDK1 is sufficient to induce a G2/M arrest in the presence of
doxorubicin. A, HMEC and TNBC cells were transiently transfected with siRNA
siRN against
CDK1, CDK2 or both. Non-targeting
targeting siControl was used as a negative control. Western blot
analysis confirmed knockdown. B, Following knockdown with and without doxorubicin
treatment, HMEC and TNBC cells were subjected to cell cycle analysis via flow cytometry.
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3.3C SINGLE AND COMBINATION DRUG TREATMENT INDUCE G1 CHECKPOINT
ARREST ONLY IN HMEC CELLS
Activation of G1 checkpoint proteins was examined in both HMEC and TNBC cells
through Western blot analysis and RT-qPCR. MCF10A cells showed reduced expression of
phospho-Rb in response to doxorubicin and combination treatment, suggesting Rb is
actively inhibiting transcription factor E2F and inducing G1 checkpoint activation.
Doxorubicin and combination treatment also increased p27 expression in MCF10A cells
(Figure 12A). Additionally, MCF10A cells had p53 pathway activation as measured by p21
expression. MCF10A cells had a modest increase in both p21 protein expression and
transcription in response to treatment, with combination treatment inducing a 3-fold increase
in p21 transcription (Figure 12A, B). Etoposide treatment induced over a 15-fold increase in
p21 transcription, exemplifying the ability of HMEC cells to induce p53 activity upon DNA
damage.
In contrast, drug treatment increased phospho-Rb expression in TNBC MDA MB 157
cells, indicating Rb inhibition (Figure 12A). Furthermore, MDA MB 157 cells showed no
change in in p21 protein expression, with combination treatment inducing only a 1.8-fold
change in p21 gene expression (Figure 12A, B). Etoposide treatment caused a less than 5fold change in p21 expression, illustrating the diminished capacity of MDA MB 157 cells to
induce p53 pathway activation upon DNA damage compared to HMEC cells (Figure 12B).
Western blot data suggests that increased expression and activation of G1 checkpoint
proteins upon single and combination drug treatment leads to the G1 accumulation
measured in HMEC cells.
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Figure 12. Single and combination treatment activates the G1 checkpoint only in
HMEC cells. A, MCF10A and MDA MB 157 cells were subjected to roscovitine for 24 hours
(R), doxorubicin for 48 hours (D) and sequential combination treatment (R
D) and
harvested as indicated followed by Western blot analysis to detect expression of G1
checkpoint proteins. All drugs were administered at IC50 concentrations. B, Densitometry
D
analysis of phospho-Rb, total
otal Rb
Rb, p21 and p27 using Image J per cell line. All proteins were
normalized to β-actin.
actin. C, Cells were subjected to single and combination treatment followed
by RNA extraction and qRT-PCR
PCR analysis to measure p21 transcription. Etoposide
treatment was used as a positive control for p53 activation.
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3.3D G1 CHECKPOINT ABLATION CORRELATES TO ROSCOVITINE-DOXOURBICIN
SYNERGISTIC RESPONSE IN HMEC CELLS
To examine the effect of G1 checkpoint deregulation in HMEC cells, the immortalized
isogenic cell lines 76NF2V and 76NE6 cells were subjected to synergistic combination drug
treatment. The viral oncoprotein HPV16-E6 binds and degrades p53 in 76NE6 cells (Table
12) [390]. 76NF2V cells were immortalized with a mutant HPV-16E6 gene (F2V), that is
unable to degrade p53, but still immortalizes cells [391]. Sequential administration of
roscovitine and doxorubicin caused an additive response in p53 wildtype 76NF2V cells
(Figure 13A). However, combination treatment induced synergism in the p53 inactive
76NE6 cells (Figure 13A). These findings suggest that G1 checkpoint deregulation, via p53
degradation or other mechanisms, correlates to response to roscovitine-doxorubicin
combination treatment.
To determine how G1 checkpoint regulation affects cell cycle response of HMEC
cells to single and combination treatment, 76NF2V and 76NE6 cells were subjected to flow
cytometry. Twice as many untreated control 76NE6 cells are in the G2/M phase compared
to untreated 76NF2V cells, with 76NE6 cells demonstrating polyploid nuclei. Although
doxorubicin induced a G1 accumulation in both cell lines, the percent of 76NE6 cells in G1
decreased by 10% 24-hours post doxorubicin treatment. However, 76NF2V cells continued
to have over 75% of cells accumulate G1 24-hours post doxorubicin treatment (Figure 13B).
The faster recovery of 76NE6 cells from G1 phase arrest compared to 76NF2V cells
suggests that 76NE6 cells are more prone to re-enter the cell cycle following DNA damage.
Notably, both cells lines accumulated in almost equal amounts in the G2/M phase due to
combination treatment. However, 76NE6 cells had twice as many cells with polyploid nuclei
both during and post release from combination treatment compared to 76NF2V cells (Figure
13B). Similar to TNBC cells, the detection of polyploid nuclei in untreated and combination
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treated 76NE6 cells suggests that G1 checkpoint deregulation can lead to abnormal DNA
content.
To measure expression of G1 checkpoint proteins, 76NF2V and 76NE6 cells were
subjected to single and combination treatment followed by Western blot analysis.
Roscovitine and combination treatment reduced phospho-Rb expression in 76NF2V cells,
with expression returning 24 hours post combination treatment (Figure 13C). The decrease
in phospho-Rb caused by single and combination treatment suggests that Rb is inhibiting
E2F transcription factors and promoting G1 checkpoint activation. While doxorubicin
treatment increased p27 expression, both roscovitine and combination treatment increased
p21 expression in 76NF2V cells (Figure 13C). In contrast, roscovitine and combination
treatment did not reduce phospho-Rb in 76NE6 cells; however, doxorubicin and 24-hours
post release of combination treatment did cause a modest decrease in phospho-Rb
expression. Neither single nor combination drug treatment induced p21 expression in
76NE6 cells (Figure 13C). It is expected that 76NE6 cells will be unable to induce p21
expression since p53, the transcription factor for p21, is degraded in these cells. Therefore,
Western blot and cell cycle analysis revealed that 76NE6 cells have a reduced capacity to
activate their G1-checkpoint.
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Figure 13. Roscovitine-doxorubicin
doxorubicin induced sy
synergism
nergism correlates to reduced G1G1
checkpoint activation. A, 76NF2V and 76NE6 cells were subjected to HTSA where
roscovitine and doxorubicin were administered sequentially. Isobolograms and CI values
generated with CalcuSyn. B, HME
HMEC cells were treated with roscovitine (R) for 24 hours,
doxorubicin (D) for 48 hours and combination treatment (RD) followed by flow cytometry.
Cells were also harvested 24 hours post release from treatment
treatment. C, Following single and
combination drug treatment, Western blot analys
analysis
is was used to detect G1 checkpoint
proteins in HMEC cells.
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3.3E KNOCKDOWN OF RB IS INSUFFICIENT TO INDUCE SYNERGISM IN HMEC
CELLS.
Since doxorubicin and combination drug treatment reduced phospho-Rb expression
in both MCF10A and 76NF2V cells, but remained elevated in MDA MB 157 cells, Rb was
stably knocked down using lentiviral infection in 76NF2V cells to examine the effect of Rb
inactivation on combination-induced synergy (Figure 12A and 13C). Western blot analysis
was used to confirm knockdown (Figure 14A). When subjected to HTSA followed by
CalcuSyn analysis, roscovitine-doxorubicin combination treatment induced additivity or
antagonism in non-targeted shScramble or shRb cells, respectively (Figure 14C). Moreover,
cell cycle analysis of knockdown cells revealed that ablation of the Rb pathway did not
cause 76NF2V cells to accumulate more in the G2/M phase compared to shScramble cells
(Figure 14B). Therefore, Rb inactivation is not sufficient to cause roscovitine-doxorubicininduced synergism in HMEC cells.
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Figure 14. Knockdown of Rb is insufficient to cause HMEC cells to respond
synergistically to combination treatment. A, Lentiviral infection was used to generate
generat
76NF2V cells stably expressing non-targeting shRNA (shScramble) or shRNA against Rb
(shRB). Western blot analysis was used to confirm knockdown. B, shScrabmble and shRB
cells were treated with single (R or D) and combination treatment (RD) followed by cell
cycle analysis. C, 76NF2V shScramble and shRb cells we
were subjected to sequential
roscovitine-doxorubicin
doxorubicin combination treatment. Isobolograms and CI values were generated
using CalcuSyn.
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3.3F KNOCKOUT OF THE P53 PATHWAY CAUSES SENSITIVITY TO ROSCOVITINEDOXORUBICIN-INDUCED SYNERGISM IN TUMOR CELLS
Thus far, only TNBC and HMEC cells with G1 checkpoint deregulation responded
synergistically to roscovitine-doxorubicin treatment (Figure 5A, 13A). However, knockdown
of Rb was insufficient to induce synergism in HMEC cells (Figure 14C). Therefore, the direct
effect of p53 pathway abolishment in tumors cells was examined in the isogenic colon
cancer cells HCT116 p53+/+ and HCT116 p53-/-. Western blot analysis confirmed the
presence or absence of p53 expression in p53 wildtype and knockout cells, respectively
(Figure 15A). When subjected to HTSA and CalcuSyn analysis, p53 wildtype cells
responded antagonistically with a CI value of 1.23 to combination treatment. However,
knockout of p53 induced synergism in HCT116 cells (Figure 15B). Consequently,
abolishment of the p53 pathway is sufficient to sensitize tumor cells to the synthetic lethal
roscovitine-doxorubicin combination.
Western blot analysis was employed to examine expression of G1 checkpoint
proteins. Sequential roscovitine-doxorubicin treatment reduced phospho-Rb expression in
p53 wildtype cells. Moreover, both single and combination drug treatment caused increased
expression of p27 and p21 in p53 wildtype cells (Figure 15C). Although both roscovitine and
combination treatment caused a reduction in phospho-Rb expression in p53 knockout cells,
drug treatment did not increase p27 or p21 expression in these cells (Figure 15C). The
inability of HCT116 p53-/- cells to induce p21 expression indicates a compromised G1
checkpoint in these knockout cells.
Cell cycle analysis was performed to examine the effect of combination treatment on
p53 wildtype and knockout cells. Although polyploidy was detected in both p53 wildtype and
knockout untreated cells, p53 knockout untreated cells had twice as many polyploid nuclei,
indicating that knockout of the p53 gene can lead to a propensity for irregular DNA content
(Figure 15D). Combination treatment and 24-hours post treatment increased G2/M
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accumulation and polyploidy in both p53 wildtype and knockout cells. However,
combination-treated p53 knockout cells had twice the amount of Sub-G1 cells (20%)
compared to p53 wildtype cells both during and following treatment (Figure 15D). Sub-G1 is
indicative of cell death, suggesting that lack of p53 expression correlates to increased cell
death in response to roscovitine-doxorubicin treatment in tumor cells. Detecting increased
Sub-G1 in HCT116 p53-/- cells due to combination treatment is in accordance with the
synergism that was measured using HTSA and CalcuSyn (Figure 15A, D).
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Figure 15. Abolishment of p53 pathway in tumor cells causes synergistic response to
roscovitine-doxorubicin
doxorubicin combination treatment. A, Western blot analysis confirmed
expression and knockout of p53 in HCT116 p53+/+ and HCT116 p53-/- cells, respectively.
MCF10A cells served as a positive control for p53 expression. B, p53 wildtype and knockout
cells were subjected to HTSA with sequential roscovitine
roscovitine-doxorubicin
doxorubicin treatment followed by
CalcuSyn analysis. C, Western blot analysis was use
used
d to detect expression of G1
checkpoint proteins. D, p53 wildtype and knockout cells were subjected to flow cytometry
following combination treatment and 24
24-hours post release.
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3.3G ROSCOVITINE-DOXORUBICIN TREATMENT INCREASED DNA DSBs
SPECIFICALLY IN TNBC CELLS
CDK1 activity is required for recruitment of HR proteins, which repairs DNA DSBs
during late S, G2 and M cell cycle phases (Table 16) [112]. Also, pretreatment with
roscovitine inhibits recruitment of HR protein RPA34 to damage sites [362]. Thus, we
performed a neutral comet assay to quantify DNA DSBs in response to single and
combination drug treatment. The tail moment, or the amount of DNA in the distance
traveled, measures the extent of DNA DSBs. As expected, treatment with doxorubicin
induced DNA DSBs, indicated by an increased tail moment, in both HMEC and TNBC cell
lines (Figure 16). However, administering roscovitine prior to doxorubicin caused a
significant (p value < 0.05) increase in the amount of DNA DSBs only in TNBC cells (Figure
16). Combination treatment did not cause an increase in DNA DSBs in MCF10A cells
(Figure 16). This indicates that treating TNBC cells with roscovitine prior to doxorubicin can
enhance the DNA damage inflicted by doxorubicin.
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Figure 16. Administering roscovitine prior to doxorubicin increases DNA DSBs
explicitly in TNBC cells.. HMEC and TNBC cells were treated with roscovitine (R),
doxorubicin (D) or combination drug treatment (RD) and subjected to the neutral
neu
comet
assay. Images were captured at 10x. Tail moment was measured using Comet Score.
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3.3H COMBINATION TREATMENT INCREASES DNA DSBs WHILE REDUCING
RECRUITMENT OF DOWNSTREAM HR PROTEINS
Due to the increase in DNA DSBs we measured in TNBC cells, γ-H2AX foci, a
marker of DNA DSBs, was examined in response to single and combination treatment.
Doxorubicin treatment induced γ-H2AX foci in about 60% of MCF10A cells and both TNBC
cell lines (Figure 17A, B, C). However, treatment with roscovitine prior to doxorubicin
significantly increased (p-value < 0.05) the percentage of γ-H2AX positive cells by 20%
explicitly in TNBC cells (Figure 17B,C). Combination treatment did not cause an increase in
DNA damage in MCF10A cells (Figure 17A, C). Indeed, combination treated MDA MB 157
cells had significantly 20% more (p-value < 0.05) γ-H2AX positive cells than combination
treated MCF10A cells (Figure 17C). The increase in γ-H2AX foci only in TNBC cells
confirms that combination treatment causes more DNA DSBs than doxorubicin treatment
alone.
As previously shown, combination treatment causes accumulation of TNBC cells in
the G2/M cell cycle phase, where cells rely on HR for DSB repair (Figure 10) [105]. The HR
protein Rad51 binds to the excised single strands to facilitate strand invasion (Figure 2).
Quantification of γ-H2AX positive cells with Rad51 foci was used to examine the recruitment
of downstream HR proteins. Untreated control HMEC and TNBC cells had limited DNA
damage, but had over 60% or over 80% cells with Rad51 positivity when γ-H2AX was
present, respectively (Figure 17A, B, D). Roscovitine treatment reduced the recruitment of
Rad51 in both MCF10A and MDA MB 157 cells. Moreover, combination treatment
significantly (p-value < 0.05) reduced the formation of Rad51 foci by 20% compared to
doxorubicin treatment in TNBC cells, even though over 80% of these cells had γ-H2AX
positivity (Figure 17B, D). Combination and doxorubicin only treated MCF10A cells were
able to recruit Rad51 foci at a similar percentage of 35% (Figure 17A, D). However, over

119

70% of these cells are in G1, and thus do not rely on HR for DSB repair (Figure 10A, B).
These findings are consistent with previous studies demonstrating that roscovitine
decreased RPA34 foci in response to irradiation despite formation of γ-H2AX foci [362].
Therefore, treatment with roscovitine prior to doxorubicin impaired TNBC cell DNA damage
response to DNA DSBs, regardless of increased DNA damage and cell cycle phase.
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Figure 17. Roscovitine-doxorubicin
doxorubicin treatment increases DNA DSBs while reducing
recruitment of downstream HR proteins in TNBC cells. A and B, MCF10A and MDA MB
231 cells were treated with single and combination drug treatment followed by
immunofluorescence to detect γ-H2AX
H2AX and Rad51 foci. C, Percent of cells with γ-H2AX were
quantified in HMEC and TNBC cells
cells. Cells with ≥5
5 foci were considered positive. D, Percent
of γ-H2AX-positive
positive cells with Rad51 positivity. Cells with ≥1
1 foci were considered positive.
One hundred cells per sample were counted per trial (n ≥ 3).

121

3.3I ABSENCE OF P53 ALLOWS COMBINATION TREAMENT TO INCREASE DNA
DSBs
HCT116 p53+/+ and HCT116 p53-/- were used to determine the effect of p53 pathway
abolishment on DNA damage and repair. Presence or absence of p53 had little effect on
doxorubicin-induced DNA damage, with 41% and 46% of p53 wildtype and p53 knockout
cells having γ-H2AX positivity, respectively (Figure 18A, B, C). However, combination
treatment significantly increased (p-value < 0.01) γ-H2AX positive cells to 60% only in p53
knockout cells compared to doxorubicin treated cells. Combination treatment did not
augment γ-H2AX positivity in p53 wildtype cells. Moreover, combination treated p53
knockout cells had significantly 20% more (p-value < 0.01) γ-H2AX positive cells compared
to combination treated p53 wildtype cells (Figure 18C). As such, absence of p53 causes
tumor cells to have increased DNA damage in response to combination treatment.
The effect of deletion of p53 on DNA DSB repair through the HR pathway was
measured through the recruitment of Rad51 foci in γ-H2AX positive cells. Upon doxorubicin
treatment, p53 wildtype and p53 knockout cells recruited Rad51 to γ-H2AX sites in 63% and
59% of cells, respectively (Figure 18A, B, D). Combination treatment had no effect on
Rad51 recruitment in p53 wildtype cells. However, p53 knockout cells had a significant
decrease (p-value < 0.05) in the percent of γ-H2AX positive cells with Rad51 foci compared
to doxorubicin treated cells (Figure 18A, B, D). Despite having more G2/M cells, p53
knockout cells had almost 20% less recruitment of Rad51 foci than p53 wildtype cells during
combination treatment (Figure 15D, Figure 18A, B, D). Therefore, deletion of p53 reduces
the ability of tumor cells to recruit downstream HR proteins during roscovitine-doxorubicin
combination treatment.
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Figure 18. Abolishment of p53 pathway causes combination treatment to increase
DNA DSBs. A, B HCT116 p53+/+ and HCT116 p53-/- cells were subjected to single and
combination drug treatment followed by immunofluorescence to detect γ-H2AX and Rad51
foci. C, Percent of γ-H2AX positive cells were quantified. Cells with ≥5 foci were considered
positive. D, Percent of γ-H2AX positive cells with Rad51 foci quantified. Cells with ≥1 foci
were considered positive. At least one hundred cells per sample were counted per trial
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3.4 CONCLUSIONS
Roscovitine-doxorubicin combination treatment is synthetic lethal explicitly in tumor
and HMEC cells with an abrogated p53 pathway. The role of p53 inactivity in sensitizing
cells to combination treatment was addressed using isogenic HMEC and tumor cells with
and without p53 activity. Here, loss of p53 at the protein or genomic level, and concordant
lack of p21 expression, lead combination treatment to be synthetically lethal. Cells with p53
activity were consistently less sensitive to combination treatment. Moreover, loss of Rb did
not sensitize HMEC cells to combination treatment. Therefore, G1 checkpoint deregulation
via p53 inactivity is required for roscovitine-doxorubicin-induced synergism in TNBC cells.
Loss or mutated p53 is associated with increased accumulation in the G2/M cell
cycle phase and polyploid nuclei in untreated, single and combination treated cells. HMEC
and tumors cells with an intact p53 pathway are more prone to arrest or accumulate in the
G1 cell cycle phase in response to treatment. Whereas knockdown of CDK1 is sufficient to
cause accumulation of cells in G2/M arrest in the presence of doxorubicin in TNBC cells,
p53 wildtype HMEC cells continued to accumulate in the G1 phase during these conditions.
Moreover, ablation of the Rb pathway did not increase G2/M phase accumulation in HMEC
cells. These findings demonstrate that p53 pathway abrogation allows TNBC cells to
bypass the G1 checkpoint, causing increased G2/M accumulation and potentially irregular
DNA content in response to combination therapy.
The role of p53 is not limited to the G1 checkpoint, as p21 also inhibits CDK activity
during G2 and M phases (Figure 1). DNA damage can cause p53 to arrest cells in G1 or
G2 [84]. Irradiation of HCT116 p53-/- cells demonstrated that p53 is required for G2 arrest
maintenance, with knockout cells entering mitosis and failing cytokinesis [392]. Therefore,
the observation of polyploid nuclei in untreated and treated p53 mutant TNBC cells may also
be due to a compromised G2 checkpoint that allows cells to progress through mitosis
regardless of damaged DNA.
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Combination treatment caused increased DNA DSBs in TNBC cells while reducing
the recruitment of downstream HR proteins. Arresting TNBC cells in the G2/M cell cycle
phase via CDK inhibition primes them for DNA damage assault. Cells rely on HR to repair
DNA DSBs during late S, G2 and M phases of the cell cycle. Inhibition of CDK1 impairs
DNA end resection and recruitment of HR proteins, potentially forcing cells to rely on more
error-prone methods (i.e. MMEJ) for repair or leaving breaks unrepaired. Thus, by inducing
a G2/M accumulation via CDK inhibition followed by doxorubicin treatment, TNBC cells are
being subjected to DNA damage while having a compromised HR pathway. Moreover, p53
pathway abolishment enabled combination treatment to increase DNA DSBs while inhibiting
recruitment of HR proteins in tumor cells. The conclusion that TNBC and other tumor cells
that are accumulated in the G2/M phase have increased sensitivity to doxorubicin treatment
is consistent with previous studies that found doxorubicin induced more cytotoxicity in
mouse-derived leukemia p53-mutant cells when they were synchronized to S and G2/M
[393]. In the present study, non-transformed cells with an intact p53 pathway are protected
from the most damaging effects of doxorubicin because they arrest in G1 phase. p53
wildtype tumor cells were also protected from additional DNA damage. Therefore, upon
combination treatment, TNBC cells undergo increased DNA damage with compromised
DNA DSB repair pathways; HMEC cells remain relatively unharmed.
The concept of chemoprotecting normal tissues from cytotoxic drugs by inducing a
reversible cell cycle arrest is called cyclotherapy [394]. This concept is especially promising
for targeting p53 mutant tumors. Current studies have utilized p53 activators antinomycin D
and nutlin-3, a MDM2 inhibitor, to activate p53 and arrest normal cells, shielding them from
S and M phase toxins [395]. For example, treatment with nutlin-3 protected p53 competent
tumor cells U2OS and HCT116 p53+/+ and non-transformed human keratinocytes from
gemcitabine treatment. However, pre-treatment with nutlin-3 did not arrest HCT116 p53-/-,
allowing gemcitabine to remain cytotoxic in these cells [396].
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Both single and combination treatment induced G1 arrest that correlated to p53
activity, as measured by p21 expression, in p53-competent HMEC and tumor cells.
Activation of p53 protected these cells from doxorubicin-associated cyto-toxicities. The
shielding of non-transformed cells via p53 activation supports the finding that doxorubicin
treatment was more toxic in vivo than combination treatment (Figure 9C,D and Table 15).
Also, administering roscovitine first is also advantageous because it further sensitized TNBC
cells to doxorubicin treatment. The requirement of abrogated p53 activity to cause
combination-induced synergism enables specific targeting of p53-mutant TNBC cells while
simultaneously limiting the damage inflicted on non-transformed cells.
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CHAPTER 4 DISCUSSION AND FUTURE DIRECTIONS
4.1 MAJOR FINDINGS
TNBC is an aggressive disease associated with decreased overall survival in which
tumors are molecularly and clinically distinct from non-TNBC tumors. Since patients with
TNBC tumors cannot benefit from clinically available targeted therapies, there is an urgent
need to develop novel treatment strategies that target the specific biology of TNBC tumors.
Due to a majority of TNBC tumors carrying mutations in the cell cycle machinery, including
p53, Rb and cyclin E, it was hypothesized that TNBC cells are sensitive to cell cycle
targeted combination therapy, leaving non-transformed cells unharmed. The data
presented in this dissertation addressed the questions posed in the first chapter.
1. Would the deregulation of the cell cycle sensitize TNBC cells to cell cycle
inhibitors; would non-TNBC and non-transformed cells react differently?
Treatment with roscovitine induced a significant G2/M arrest in TNBC cells (all p53mutant) and in the HMEC cell line 76NE6 cells, which does not express p53. Roscovitine
treatment did not induce a major G2/M arrest in HMEC and ER-positive cells with intact (or
heterozygous) p53 pathways. Therefore, sensitivity to cell cycle inhibitors is sub-type and
p53-mutant specific.
2. Can a synthetic lethal combination of cell-cycle inhibition and chemotherapeutics
specifically target TNBC cells, without inflicting harm to non-transformed cells?
Sequential administration of roscovitine and doxorubicin treatment was synthetic
lethal specifically in TNBC cells, but was antagonistic in HMEC cells. Notably, simultaneous
drug administration or treating with doxorubicin prior to roscovitine was antagonistic in TNBC
cells. Combination treatment prolonged and increased apoptosis only in TNBC cells
compared to single drug treatments.
3. Will combination cell cycle targeted therapy be an effective method in a pre-clinical
model?
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Combination treatment was both efficacious and well tolerated in mice with human
TNBC xenografts. Since combination treatment inhibited tumor growth without increasing
toxicity, no combination treated mice were euthanized, resulting in a significant increase in
overall survival. Despite being well tolerated, roscovitine had very limited efficacy, causing
all mice to be euthanized due to excessive tumor burden. Mice treated with doxorubicin
suffered from excessive tumor burden and deteriorated health, illustrating its inadequacy as
a single agent.
4. What affect would combination therapy have on the cell cycle of TNBC cells
compared to non-transformed cells?
Both single and combination treatment maintained a G2/M arrest and/or induced
polyploid nuclei specifically in TNBC cells. In contrast, HMEC cells accumulated in the G1
phase in response to treatment. Moreover, knockdown of CDK1 was sufficient to augment
the percent of G2/M accumulation in the presence of doxorubicin only in TNBC cells.
5. Is there a molecular target/pathway that can be used as a marker to predict
combination treatment response?
TNBC cells with p53 mutations had a diminished capacity to induce p21 transcription
compared to p53 wildtype HMEC cells. Knockdown of Rb was insufficient to cause a
synergistic response in HMEC cells. However, combination treatment was synthetic lethal in
p53-compromised HEMC and tumors cells, whereas the paired isogenic p53 wildtype cells
were additive or antagonistic to treatment. Moreover, the cell cycle profile of HMEC and
tumor cells lacking p53 activity closely mimicked the cell cycle profile of TNBC cells; the
isogenic p53 wildtype cells had less G2/M accumulation. Thus, p53 inactivation serves as a
putative predictor of synergistic response to roscovitine-doxorubicin combination treatment.
6. Can combination treatment augment the DNA damage inflicted by
chemotherapeutics explicitly in TNBC cells?
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Administration of roscovitine prior to doxorubicin caused increased DNA DSBs while
reducing the recruitment of the downstream HR protein Rad 51 in TNBC cells. Combination
treatment did not subject HMEC cells to increased DNA damage. Moreover, combination
treatment increased DNA damage and reduced recruitment of HR proteins in p53-null tumor
cells compared to isogenic p53-wildtype cells. Therefore, ablation of the p53 pathway in
TNBC cells can further sensitize cells to combination treatment-associated DNA damage.
4.2 LIMITATIONS
The present study focused on increasing the innate sensitivity of TNBC cells to
anthracycline-based therapy. However, TNBC tumors are also sensitive to platinum-based
chemotherapies, such as cisplatin. Since platinum-based therapies also induce DNA
damage by binding to DNA purine bases, it is reasonable to hypothesize that roscovitine
treatment could synergize with cisplatin. Additionally, because anthracyclines are
associated with cardiotoxicity, it would be beneficial to determine how well tolerated
roscovitine and platinum-based chemotherapy combination treatment is.
4.3 FUTURE DIRECTIONS
The roscovitine-doxorubicin combination is a novel treatment strategy that can
specifically target p53-mutated TNBC tumors. However, TNBC is a heterogeneous disease
and identifying the population of patients that will benefit the most from combination
treatment, while preventing unnecessary treatment of non-responder patients, is necessary
for effectively implementing this therapy. The TNBC cell lines used in this study, including
MDA MB 157, MDA MB 231 and MDA MB 468 have a range of p53 mutations. MDA MB
157 cells have a 26 base pair deletion in codon 261, MDA MB 231 cells have a missense
mutation in codon 280 and MDA MB 468 cells have a missense mutation in 273, all of which
occur in the DNA binding domain of p53 [348]. However, p53 is deregulated through
multiple mechanisms, including missense mutations, deletions, GOF mutations, MDM2
overexpression and deletions in p14 (a negative regulator of MDM2). The effect of p53
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status on treatment response has been inconsistent. As previously described, p53
mutations in the zinc binding domain conferred resistance to doxorubicin treatment [373].
Moreover, Bourdon et al. found that the p53 gene has an alternative internal promoter that
can transcribe 9 splice variants with differing functions. For example, variant p53β can
heighten p53 target gene expression, whereas variant ∆133p53 acts as a dominantnegative and inhibits p53 full-length activity. These isoforms were differentially expressed
between normal versus tumor tissue [397]. These splice variants potentially contribute to
the discrepancies between p53 status and treatment response [348, 397]. The effects of
these splice variants and other p53 mutations have not been directly investigated in the
present study. Since HCT116 p53-/- cells were synergistic to combination treatment, it can
be hypothesized that MDM2 signaling for p53 degradation would induce synergism in tumor
cells. However, it is undetermined whether MDM2 overexpression or p14 gene deletions
are sufficient to sensitize tumor cells to combination treatment. Therefore, further
investigation is required to examine the effect of differing p53 mutations and pathway
deregulations on combination treatment response. As a result, it is likely that patient tumors
will have to be sequenced to distinguish responders from non-responders.
Roscovitine-doxorubicin treatment was well tolerated in an in vivo model system.
However, a phase I study examining the MTD and efficacy of dinaciclib in combination with
the anthracycline epirubicin found that this treatment was very toxic, ending the trial before
efficacy could be determined. Dose-limiting toxicities included neutropenia, syncope and
vomiting (NCT01624441). To increase the efficacy of combination treatment while reducing
toxicity, the drugs could be paired with a nanocarrier delivery system. Coupling roscovitine
or doxorubicin with nanotechnology drug deliverance system will limit dispersal of the drug
to only at the site of action, protecting other organs and tissues from cytotoxicity [398]. For
example, anti-HER2 immunoliposomes containing doxorubicin were targeted to HER2
overexpressing tumors, increasing the therapeutic benefit of doxorubicin while reducing
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toxicity in a xenograft mouse model [399]. Roscovitine could be directly delivered to the
tumor site if it was bound to a ligand-mediated active binding nanoparticle. EGFR, which is
overexpressed in a majority of TNBC tumors, is a cell surface receptor that provides a
putative target to deliver roscovitine to the tumor site. Indeed, EGFR-targeted polymer
nanocarriers delivered paclitaxel and ionidamine to multi-drug resistant EGFRoverexpressing tumor cells, increasing drug cytotoxicity [400]. Developing EGFR-targeted
nanocarriers to deliver to roscovitine directly to the tumor site could increase the therapeutic
benefit of CDK inhibition while reducing toxicities. Moreover, liposomal-doxorubicin, which
accumulates at tumor sites due to leaky vasculature, is clinically available to treat breast
cancer [401]. Thus, it would be clinically beneficial to consider incorporating roscovitinedoxorubicin combination treatment with nanoparticle delivery system.
Investigating the application of this combination treatment in other types of cancers
was beyond the scope of the present study. However, p53 is mutated in over 50% of
cancers. Previous studies in our laboratory found that roscovitine-doxorubicin combination
treatment induce synergism in sarcoma cells [343]. Additionally, this study found that
combination treatment was synergistic in the colorectal cancer cell line HCT116 p53-/-.
Furthermore, pretreatment with roscovitine could enhance the cytotoxicity in the broad range
of malignancies that doxorubicin is currently used to treat, including bladder, head and neck,
liver, lung, ovarian cancer and sarcomas [254]. As such, the therapeutic benefit of this
novel combination treatment strategy may extend beyond TNBC. Future studies should
assess the efficacy of roscovitine-doxorubicin combination treatment in other cancers with
p53 pathway deregulation.
4.4 SIGNIFICANCE
TNBC patients have no therapeutic options beyond chemotherapy and surgery. Due
to the aggressive nature of TNBC and decreased overall survival of these patients, there is
a pressing need to develop innovative treatment strategies that target the molecular and
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biological characteristics attributed to TNBC cells. Here, sequential administration of
roscovitine prior to doxorubicin is synthetic lethal explicitly in TNBC cells, with nontransformed cells remaining unharmed. Demonstrating promise in a pre-clinical in vivo
model, this combination strategy can greatly impact the treatment and care of TNBC
patients. Since the success of this combination treatment requires p53 pathway abrogation,
mutated p53 status provides a putative predictor of response. Overall, roscovitinedoxorubicin combination could potentially become a powerful tool for clinicians to treat
TNBC.
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